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ABSTRACT:
In addition to cancer cells, solid tumors consist of a variety of cell types and tissues defining a complex
microenvironment that influences disease progression and response to therapy. To fully characterize and
probe the tumor microenvironment, new tools are needed to quantitatively assess microanatomical and
physiological changes during tumor growth and treatment. Particularly important, is the metabolic
microenvironment defined in tumors by hypoxia (low p02) and acidity (low pH). These parameters have been
shown to influence response to radiation therapy and chemotherapy. However, very little is known about
spatio-temporal changes in P0 2 and pH during tumor progression and therapy. By modifying the technique of
intravital multiphoton microscopy (MPM) to perform phosphorescence quenching microscopy, I developed a
non-invasive method to quantify oxygen tension (p02) in living tissue at high three-dimensional resolution. To
probe functional changes in the metabolic microenvironment, I measured in vivo P0 2 during tumor growth
and antiangiogenic (vascular targeted) treatment in preclinical tumor models.
Nanotechnology is rapidly emerging as an important source of biocompatible tools that may shape the future
of medical practice. Fluorescent semiconductor nanocrystals (NCs), also known as quantum dots, are a
powerful tool for biological imaging, cellular targeting and molecular sensing. I adapted novel fluorescence
resonance energy transfer (FRET) -based nanocrystal (NC) biosensors for use with MPM to qualitatively
measure in vivo extracellular pH in tumors at high-resolution.
While intravital multiphoton microscopy demonstrates utility and adaptability in the study of cancer and
response to therapy, the requisite high numerical aperture and exogenous contrast agents result in a limited
capacity to investigate substantial tissue volumes or probe dynamic changes repeatedly over prolonged
periods. By applying optical frequency domain imaging (OFDI) as an intravital microscopic tool, the technical
limitations of multiphoton microscopy can be circumvented providing unprecedented access to previously
unexplored, critically important aspects of tumor biology. Using entirely intrinsic mechanisms of contrast
within murine tumor models, OFDI is able to simultaneously, rapidly, and repeatedly probe the
microvasculature, lymphatic vessels, and tissue microstructure and composition over large volumes. Using
OFDI-based techniques, measurements of tumor angiogenesis, lymphangiogenesis, tissue viability and both
vascular and cellular responses to therapy were demonstrated, thereby highlighting the potential of OFDI to
facilitate the exploration of pathophysiological processes and the evaluation of treatment strategies.
Thesis Supervisor: Rakesh K. Jain, Ph.D.
Andrew Werk Cook Professor of Tumor Biology, HMS, MGH
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I. Original Contributions
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The microenvironment of solid tumors is complex and heterogeneous consisting of a
variety of cell types. The interactions between the components of the tumor
microenvironment and pathophysiology are not well understood. This Thesis focuses on
studying the metabolic microenvironment and microvasculature, both critical
determinants of disease progression and response to therapy. The overall goal is to
develop new minimally invasive tools to perform multiparametric analysis of the tumor
microenvironment during both tumor growth and response to therapy.
Oxygen is a key player in the metabolic microenvironment of tumors, which is typically
characterized by hypoxia. Techniques exist to measure in vivo oxygen tension (p02),
however each method has its intrinsic limitations. No single technique exists to perform
high-resolution spatio-temporal quantification of P02 in the context of the tumor
microenvironment. In this Thesis I develop a method to quantitatively measure oxygen
tension by applying the principles of phosphorescence quenching to multiphoton
microscopy (MP-PQM; Chapter 3). I demonstrate that MP-PQM is able to measure
oxygen in the interstitial space with a resolution as low as 1pm3 using phosphorescent
palladium-porphyrins, previously believed to be unattainable due to transport
characteristics of the porphyrin oxygen sensors. The two-photon excitation properties of
Pd-porphyrin is fully characterized for the first time including the effects of
phosphorescence saturation, an important consideration using mode-locked pulsed
laser sources, and the theoretical in vivo resolution. Finally, I show that the Krogh tissue
cylinder model for oxygen diffusion in skeletal muscle may not be applicable in real-
world capillary networks due to the anisotropic arrangement of the muscle fibers.
In the tumor microenvironment, oxygen has been shown to be heterogeneous and
many models have been postulated to explain the tumor oxygenation due to the
vascular geometry. However, few direct measurements of tumor PO2 exist with spatial
correlation to the tumor vasculature. Secondly, the effect of targeted anti-cancer
therapies, such as antiangiogenic agents, on the tumor PO2 is not well known. Here, I
develop a method to map oxygen tension onto the tumor vasculature with high three-
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dimensional resolution and deep penetration (~400pm) using MP-PQM (Chapter 4).
With this technique, I illustrate the differences in oxygen consumption and spatio-
temporal profiles in PO2 across a variety of tumor types. Further, I introduce a model to
predict tumor oxygenation and tissue PO2 profiles using a simple metric describing the
microvasculature and associated tissue volumes. The results exhibit good agreement
with in vivo oxygen measurements using MP-PQM. Finally, the metabolic tumor
microenvironment is probed with MP-PQM during either VEGF-R2 blockade or
trastuzumab (Herceptin) treatment. Both are treatment protocols translatable to clinical
treatments. The results suggest that antiangiogenic therapies should be titrated for a
limited dose response to transiently increase P02 and therefore the efficacy of radiation
therapy and many chemotherapeutics.
A related metabolic parameter to P02 is the pH of the tumor microenvironment, which
is often found to be acidic. The pH gradients found in tumors across the cancer cell
membranes have protective effects against many chemotherapeutics, reducing their
cytotoxicity. More understanding is needed about how this parameter changes during
tumor progression and therapy so that therapeutic regimens with better prognostic
outcome can be designed. To this end, I introduce a novel F6rster resonance energy
transfer (FRET)-based semiconductor nanocrystal (NC; also known as quantum dots)
biosensor, developed in collaboration with investigators from the Bawendi and Nocera
labs at MIT, for in vivo measurements of pH in tumors (Chapter 5). I show that
nanocrystals act as a two-photon antenna, conferring the ideal photophysical properties
of the NC to acceptor dyes under excitation in the nonlinear regime with MPM. Through
multiple evolutions of NC construct design, a biocompatible pH sensor with limited non-
specific interactions is developed and shown to qualitatively measure pH. Finally, the
NC-biosensor is demonstrated to perform ratiometric pH measurements during
hyperglycemia in the tumor microenvironment and correlate the results with the local
tumor vasculature using multiphoton fluorescence ratiometric imaging. Further, I
present sensing schemes and evidence of NC-biosensors for other analytes important in
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tumor biology as well as the potential for targeting these constructs to the tumor
microenvironment(Chapter 7).
While the metabolic microenvironment plays a critical role in tumor progression and
therapeutic response, other components of the tumor microenvironment also influence
the same parameters. Methods exist to assess each component individually although
many are invasive or require administration of exogenous contrast agents. A non-
invasive multiparametric imaging method is needed to characterize the tumor
microenvironment. In collaboration with investigators in the Wellman Labs, we show
that optical frequency domain imaging (OFDI) is capable of simultaneously imaging the
tumor vasculature, lymphatics, tissue viability and tumor microanatomy with high-
resolution over significant tissue volumes (Chapter 6). Through the development of
novel techniques, instrumentation and algorithms, we demonstrate the unique
capabilities of OFDI to quantitatively image in vivo the microenvironment of model
tumors rapidly and persistently over time without requiring exogenous contrast agents.
We also show that OFDI can study the multiparametric response to both vascular- and
cellular-targeted therapies. The abilities of OFDI for studying tumor biology are
impressive and I introduce additional concepts that may potentially permit non-invasive
measurement of blood flow velocity, vascular permeability, macromolecular transport,
cellular metabolism, edema and spontaneous tumorigenesis (Chapter 7).
The technologies introduced and developed in this Thesis are hopefully only the
beginning of a new era in non-invasive multiparametric analysis of the tumor
microenvironment. Many unanswered questions about in vivo cancer biology and
response to treatment remain and additional tools are always needed to find solutions
and pose new more directed questions. Each new step in advancing our understanding
of the tumor microenvironment may help develop new methods and drugs for treating
cancer translatable to the clinic.
Chapter 2
II. Introduction and Specific Aims
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II.1 Introduction and Motivation:
Solid tumors are complex and heterogeneous tissues consisting of a variety of cell types.
The tumor microenvironment can be ascribed to all components outside of the tumor
cells themselves. This is a broad definition encompassing the vasculature, stromal cells,
extracellular matrix, host tissues and metabolic parameters. All of these biological
components have been shown to play a critical role in both tumor progression and
treatment'. In vivo heterotypic interactions between the tumor microenvironment and
the cancer cells themselves are multifaceted and not well understood. New minimally
invasive tools are needed to perform multiparametric analysis of the tumor
microenvironment to elucidate these underlying mechanisms.
This Thesis will focus on the development of quantitative in vivo imaging tools that
probe the tumor microenvironment. In particular, this work focuses on studying the
metabolic microenvironment and microvasculature, both important determinants of
disease progression and therapeutic response. In this Chapter, I define the metabolic
microenvironment and its important implications on tumor growth, metastasis, and
therapy. I also describe the anatomical and molecular characteristics of the blood and
lymphatic vasculature of solid tumors including consequences of antiangiogenic
therapy. The advances and limitations of current techniques for studying both the
tumor vasculature and metabolic microenvironment are also described. Finally, I give a
brief background of the technologies employed in this Thesis: multiphoton microscopy,
fluorescent semiconductor nanocrystals and optical coherence tomography. This
Chapter concludes with the specific aims and hypotheses driving the work presented in
the following Chapters.
11.2 Metabolic Microenvironment
Hypoxia and low pH are hallmarks of the tumor microenvironment. These physiologic
parameters are important determinants of tumor growth, gene expression 2, metastatic
potential3 , metabolism, prognosis4 -6, and response to therapy''8 . Additionally, these
CHAPTER 2
physiological parameters vary with tumor location in the host and within the same
tumor from one day to the next9-12 . Furthermore, oxygen consumption and increased
metabolic waste by cancer and endothelial cells coupled with poor perfusion by
abnormal tumor vasculature contribute to the hypoxic and acidic environment of the
tumor. Oxygen sensitizes a tissue to radiation'4 ; therefore, the hypoxic tumor
microenvironment effectively shields cancer cells from radiotherapy. Additionally, many
chemotherapeutics, such as paclitaxel, are pH sensitive and demonstrate reduced
cytotoxic efficacy at the acidic pH's found in solid tumors8,15. Thus, further
understanding of the dynamic relationship between P02 and pH in the tumor
microenvironment during disease progression and treatment is critical to improve
response to therapy.
Energy metabolism in tumors is complex and experimental studies have provided
contradictory results. In vitro studies have demonstrated that the rate of oxygen
consumption is dependent on both P02 and glucose1'6" 7. The Warburg hypothesis
proposes that cancer cell oxidative metabolism is grossly disturbed instead relying on
glycolysis18 . However, this concept has been challenged because many cancers
demonstrate high levels of oxygen consumption19-21. Further, it has long been known
that many tumor types demonstrate high levels of respiration (oxidative metabolism)
relative to aerobic or anaerobic glycolysis . High levels of glycolysis increases the
concentration of lactic acid in tissue and thus was believed to be the sole source of
acidic pH. However, resultant tumor acidity has also been attributed to increased
carbon dioxide (CO2) due to oxidative respiration. Interestingly, an in vivo study
simultaneously measuring P02 and pH demonstrated no correlation between the two
metabolic indicators24, suggesting that tumor cell metabolism is uncoupled utilizing
whatever substrates (oxygen and/or glucose) are available.
11.3 Vasculature of the Tumor Microenvironment
Two types of vasculature, blood and lymphatic, play critical roles in cancer progression
and response to treatment. In solid tumors both are abnormal structurally and
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functionally contributing to pathophysiology. Intravital microscopy methods have
permitted in situ visualization of both vascular networks in the tumor
microenvironment2s-31. Additional techniques have provided insights into in vivo
function (or dysfunction) of the tumor microvasculature and their impact on transport,
metastasis and treatment 3 3. It should be noted that cancer is a complex disease and
the characteristics of the vascular networks, like the metabolic microenvironment is
heterogeneous across tumor types and even within a single tumor.
1.3a BLOOD AND LYMPHATIC VASCULATURE: STRUCTURE AND FUNCTION
Tumor vascular networks are morphologically irregular consisting of dilated and
tortuous vessels with ill-defined routes of transport typified by blind ends and loops29,39-
41. Flow through the blood vessels is intermittent and heterogeneous with many regions
of stasis or flow reversa 4 2-46. Both the abnormal structure and high hematocrit in
tumors influence the variable resistance to fluid flow in the tumor vasculature47'48.
Additionally, heterogeneous expression of vascular cell surface markers reduces
leukocyte-endothelial cell interactions in the tumor vasculature49. The vascular wall in
tumors is also found to be immature in cellular makeup leading to high permeability due
to the presence of fenestrations in the endothelium, absence of supporting cells,
irregular endothelial cell placement, and mosaic structures with interspersed cancer
cellsSO53. Finally, solid stress from the surrounding cancer cells over-burdens the vessel
structural capacity leading to compression of many vessels in the microenvironments4-s7
The striking characteristic of intratumoral lymphatics is that they do not exist in a
functional form38'58'59. The walls of lymphatic vessels are not designed for high pressures
and in fact are found in a collapsed state in many normal tissues. Compression from the
surrounding cancer cells in a solid tumor inhibits any lymphatic transport. Reduction of
the tumor cell burden through cellular-targeted therapy can relieve some of the stress
permitting patent lymphatic vessels in the tumor microenvironment57. Conversely, the
lymphatics at the tumor margin are found to be dilated in many tumors suggesting
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lymphatic metastasis must occur by these routes6o-62 . These lymphatic vessels may be
pre-existing or recruited through lymphangiogenesis63.
Structural and functional malformations in both blood and lymphatic tumor-associated
vessels promote significant interstitial fluid pressures (IFP) in solid tumors64-66. The
combination of increased vascular permeability and lack of functional lymphatics, which
reduce tissue fluid volume, leads to increased IFP. Further, both the oncotic and
hydrostatic pressure gradients across the tumor vessel wall are severely decreased due
to the leakage of macromolecules (protein) and equilibrium between mean vascular
pressure and IFP, respectively 67. These effects in addition to inefficient transport within
the vascular networks are physicochemical barriers to drug delivery to the tumor
microenvironment 34,68
II.3b TUMOR ANGIOGENESIS
The formation of new vessels to supply a growing tumor is a critical step in disease
progression. The requirement of vascular recruitment for tumor growth has been
known for some time 1-71. The limitations of oxygen diffusion in metabolically active
tumors place constraints on continued cell proliferation unless new vessels are
recruited. This process, termed angiogenesis, typically occurs through sprouting or
intussusception from adjacent normal vessels. Vasculogenesis can also contribute to
tumor vessel formation from recruitment of endothelial cell precursors to newly
forming vessels73 . These processes actively occur in embryogenesis and many normal
tissues including during wound healing49'7 4.
Angiogenesis has proved a predictive indicator of tumor progression and response to
therapy in clinical disease 36,75,76. The degree of angiogenesis in the primary tumor has
been shown to be linked to metastases77. In breast cancer in particular, it has been
demonstrated that angiogenesis plays a central role in the progression of disease both
locally and in metastases 78. Clinicopathologic studies have also shown that angiogenesis,
as determined by microvascular density (MVD), correlate strongly with both the
aggressive nature of primary disease and metastatic potential in breast cancer79 -81
30
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Angiogenesis in tumors is hypothesized to be caused by an imbalance between pro- and
anti-angiogenic factors2 . The "angiogenic switch", when the imbalance shifts to pro-
angiogenic factors, is widely understood to be a critical step in tumorigenesis83. The
angiogenic phenotype is not ascribed to all cells within the tumor, but is often found in a
subpopulation that influences vessel formation for the whole tumor. A variety of
soluble factors have been implicated in promoting angiogenesis, but none more so than
the vascular endothelial growth factor (VEGF) family of proteinS84. VEGF has been shown
to be upregulated in both tumor cells and tumor-associated stromal cells51,85. Increasing
VEGF expression leads to increased angiogenesis and tumor growth in animal
models8'',8. Levels of VEGF expression have been positively correlated with poor clinical
prognosis in a variety of cancers80'88' 89. Other factors such as basic fibroblast growth
factor and platelet derived growth factor have been implicated in angiogenesis as
well90' 91. These angiogenic pathways may be more important in some cancers or as
alternative routes of angiogenesis during vascular targeted therapies. Besides directly
supporting angiogenesis through growth factors, these cells often induce down-
regulation of antiangiogenic factors such as thrombospodin through heterotypic
interactions between the cancer cells and stroma92
Lymphangiogenesis is also regulated by the VEGF family of proteins. One isomer of
vascular endothelial growth factor (VEGF-C) has been implicated in peripheral lymphatic
hyperplasia in solid tumors93. Upregulation of VEGF-C has been shown to increase
metastases in animal models37 . Expression of VEGF-C and its receptor VEGF-R3 have
been associated with the presence of distance metastases and poor prognosis in a
number of clinical cancers94-96.
II.3c IMAGING ANGIOGENESIS IN THE TUMOR MICROENVIRONMENT
A number of methods exist to image, blood and lymphatic vessels in the tumor
microenvironment. Histological techniques permit molecular phenotyping of tissue, but
must be performed ex vivo. Further, complications exist in drawing conclusions from
histological samples for both angiogenesis and lymphangiogenesis. Microvascular
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density (MVD) is typically the metric used to characterize tumor angiogenesis. However,
the link between this parameter and what occurs in vivo is questioned in the
literature97. In histology of lymphatic vessels, the commonly used molecular marker of
lymphatic endothelial cells (LYVE-1) has been shown non-specific as it can be expressed
on other cells types98. Non-invasive imaging methods such as magnetic resonance
imaging99, micro-computed tomographyl'o and positron emission tomography01 have
progressed significantly in their ability to assess angiogenesis and vascular functionio2
However, the minimum resolution of these techniques is in the 50-100pm range.
Further, the results of the various techniques used with MRI have proved to be indirect
measures of angiogenesis and vascular function with much debate in the literature on
qualitative meaning03 ,104.
Figure 1I-1 Intravital optical microscopy of murine window chamber models. (a) Dorsal skinfold chamber
model (DSC). (b) Cranial window model (CW). (c) Mammary fat pad chamber. (d) Normal vascular
networks in the dorsal skin of a SCID mouse taken in a DSC (a). Both capillary networks and larger arteries
and anterioles are seen paired with veins. (e) Vasculature in a murine brain from a CW (b). The large
venous sinuses are visible as well as the convolute cortical capillaries. (f) Vasculature in the mammary fat
pad of a female SCID mouse bearing a MFP chamber (c). Upon closer inspection the optical distortion
effects of the adipocytes can be seen. The lower right of the image also contains a mammary duct
containing fluorescent contrast. All images are mosaic colorized depth projection from MPM angiograpy.
Mouse model animations courtesy of L.L. Munn. Scale bars - 500pm.
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Intravital microscopy has proved a useful tool in understanding both angiogenesis and
lyphangiogenesis in the tumor microenvironment 05. This term is ascribed to a variety of
optical techniques that employ non- or minimally invasive methods to image in vivo
vascular networks. The resolution of intravital microscopy ranges from less than one
micron for multiphoton microscopy (MPM) to 10 microns for wide-field epifluoresence
or transillumination microscopy. With modified techniques, functional parameters can
also be quantified or assessed with intravital microscopy. Many of these methods will be
discussed in greater detail below.
Coupling intravital microscopy with animal models generally requires special tissue
preparations to provide access to the tumor. In situ preparations using tumors grown
subcutaneously in regions of thin epidermis such as the murine ear, tail or foot can be
used although light penetration is limited. Acute preparations such as extiorization of
the abdominal mesentery'06 or surgical exposure of subcutaneous tumors through a
skin flap provide direct access, but also disturb the microenvironment and have limited
repeatability. Chronic window chamber preparations provide relatively long-term non-
invasive access to the tumor vasculature microenvironment2 (Figure 1l-1). In this Thesis,
nearly all imaging was performed in murine tumor models bearing dorsal skinfold
chambers (DSC), mammary fat pad chambers (MFP), and cranial windows (CW).
II.4 The Role of Oxygen in Solid Tumors
Hypoxia, or low oxygen in the tumor microenvironment has been known for some time
to be an important indicator of progression and response to therapy. However, only in
the last two decades have the various techniques to measure oxygen become readily
available in both the laboratory and clinic. This has permitted clinicians to study the
prognostic significance of tumor oxygenation and laboratory investigators to study the
sources and potential implications in the tumor microenvironment. Three areas of focus
have arisen from these studies. The first is the tumor cell selection and genetic
alterations influenced by hypoxia107. The second involves the pathophysiological
origination of these oxygen fluctuations and their implication in disease progression and
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treatment"'-"'. Lastly, the complex effect of certain treatments on the tumor
oxygenation and the role this may play in rationally scheduling combined therapies is a
major focus of translational researchio,82,112-116. Regarding oxygen tension in the tumor
microenvironment, this thesis will focus on the latter two avenues.
1.4a MOLECULAR EFFECTS OF TUMOR OXYGENATION
The major molecular target identified in modulating cancer cell response to hypoxia is
hypoxia inducible factor a (HIF-la). This protein is constitutively expressed, but typically
undergoes degradation in normoxic environments. When not degraded, HIF-la acts as a
transcription factor regulating many cellular responses to hypoxia such as growth
factors2 , angiogenesis" , metabolism (increasing glycolosis and decreasing pH) 18 ,
apoptotic pathways1"9 and metastatic potentia120. The regulatory pathways controlled
by HIF-1 pathway are very complex and their effects on tumor growth can be
contradictory. Typically the effects of HIF-lc are enhanced by oncogenes or mutations
in tumor suppressors that may interrupt some of the pathways that inhibit tumor
growth'.
Expression of HIF-1a has served as a prognostic marker for unfavorable outcome
in many cancers 1-123 Therefore, HIF-1 would appear to be a good target of therapy in
tumors. Unfortunately direct inhibitors of HIF-1c are still under investigation and the
result of inhibition is difficult to realize due to its complex regulation in the cell124,2 .
Investigations have therefore also focused on other regulatory downstream or upstream
elements in the HIF pathway126 ,127. The majority of studies have focused on three major
targets of HIF-la. The first is a glucose transporter involved in glycolysis - GLUT1.
Increased expression of this gene in tumors has been indicative of increased or
deregulated glycolysis12 8. The second is CAIX, a carbonic anhydrase that regulates cell
pH and is an isozyme found only associated with cancer 2 9. Finally, HIF-1a has been
shown to directly upregulate vascular endothelial growth factor (VEGF) and other
107,117
angiogenic promoters ' In neoplasia, the VEGF family of proteins is correlated with
angiogenesis, vessel permeability, tumor growth and clinical outcome49. Using both
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GLUTI and CAIX as molecular markers, hypoxic regions of the tumor can be specifically
determined in some cancer models1 , however results in clinical cancers are mixed13.
Similarly, in vivo VEGF expression has been shown to be regulated by oxygen gradients
rather than absolute levels of hypoxia3 2 ,1 3
II.4b CLINICAL MEASUREMENTS OF TUMOR OXYGENATION
Hypoxia has been demonstrated to be a negative prognostic indicator for both disease
progression and therapeutic response in a variety of tumors in the clinical setting. Using
polarographic electrode methods, oxygen tension was measured in metastatic
squamous cell carcinoma patients prior to radiotherapy. Tumors with complete
response exhibited mean P02 around 21mmHg, while non-responding tumors had
hypoxic mean values around 5mmHg 4. Studies using Eppendorf needle measurements
in cervical cancer patients found the level of hypoxia (< 10mmHg) to predict survival for
advanced disease135. However, this prognostic significance has never been observed
with histological assessment of hypoxia136. This is likely due to the fact that only viable
cells can be stained with the bioreductive markers for hypoxia eliminating any necrotic
regions from the hypoxic determination. This discrepancy between P0 2 electrode and
histological measurements has been demonstrated in animal models137 . Hypoxia has
been shown to be a significant prognostic indicator of disease progression regardless of
stage in head and neck cancers13. Interestingly, direct measurements of hypoxia have
not been demonstrated as a significant indicator of disease progression139 . However,
indirect measurements of genes, such as HIF and CA-IX, have shown strong correlation
with disease progression in many different types of breast cancer14 4'141.
Brain cancers have proved challenging to directly study tumor oxygenation given their
anatomical location. However, some limited studies have been carried out using both
polarographic and histological methods. While the histological grade of glioma patients
was prognostic of survival, intra-operatively measured median tumor oxygenation was
not142 . Further confounding results, hypoxic fractions determined by EF5 did prove a
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negative indicator of survival, but did not correlate with direct measurements of
p 2137,143,144
The challenge in quantifying oxygenation in the clinical setting, such as brain tumors,
has lead to the development of additional non-invasive imaging methods. These have
been briefly mentioned in the previous section. Technologies such as (18)F-FMISO
positron emission tomography1 45 and BOLD-MR1146 prove promising for clinical
evaluation of tumor oxygenation147. However, non-invasive clinical imaging modalities
have only, thus far, proven prognostic in animal models 148. Therefore, most studies
focusing on the direct measurement of oxygen in the tumor microenvironment and its
pathophysiological significance have been performed in preclinical models.
I1.4c DIRECT MEASUREMENTS OF P02 IN THE TUMOR MICROENVIRONMENT
The sources of hypoxia in tumors are three-fold. One is chronic due to the
heterogeneous, abnormal and tortuous tumor vascular networks creating regions of
tissue >70[tm from a vessel' 49. Due to limitations on the diffusion of oxygen, large
regions of avascular tumor tissue are often found to be hypoxic. The second is acute
hypoxia due to transient fluctuations in vascular perfusion150 . Finally, hypoxia due to
decreased hematocrit, or oxygen carrying capacity, due to anemic paraneoplastic
syndromes 51 or shunting in the tumor vascular network15 2. The multiple determinants
of tumor oxygenation suggest a very complex relationship between the vasculature,
tumor cells, and metabolic microenvironment.
Using non-invasive optical measurements of P02 such as PQM, many studies have
provided direct assessment of oxygenation in multiple tumor types and preclinical
models. Much of this work has focused PO2 in the intravascular compartment in tumors.
Multiple studies have demonstrated that mean intravascular oxygen tension is lower
than that found in normal tissue i3-16. Specifically, across tumors, vascular P0 2 has been
found to both correlate with perfusion157 and not 24 ,150 .The effect of hyperoxia on tumor
vascular oxygenation has likewise produced conflicting results in the literature. Dewhirst
et al found that the PO2 increase with carbogen (95% 02 and 5% CO2) inhalation in rats
36
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was only transient 153, while others found a constant level up to 15mmHg higheriss,1s8
Surprisingly, the transient increase in P02 was found not to be accompanied by
vasomotor activity in the tumor vasculature. Increased PO2 induced by hyperoxia has
also been shown to be stable in subcutaneous tumors by fiber optic oxygen probes159.
Importantly, anesthetics have also been found to perturb tumor oxygenation; indicating
an important consideration when performing P02 measurements. Ketamine/xylazine
mixtures have been found to decrease mean tumor oxygen tension by 10-15mmHg
compared to awake animals'55. Pentobarbital anesthesia has been shown to induce
160changes in blood gases likely due to fluctuations in the depth of anesthesia over time
By far the best anesthetic appears to be isoflurane which induces a transient (~20min)
decrease in PO2 before stabilizing 57159.
While some of these studies have been performed in subcutaneously implanted tumors
many have utilized the optically accessible window chamber models for rats 61 and
mice64. These have permitted unique access to quantify macroscale spatio-temporal
properties of tumor models. The difference in intravascular oxygen tension across
different regions of the microenvironment has been observed to decrease towards the
tumor center156. Normal vessels adjacent to the tumor were found to be ~70mmHg,
while those in the tumor margin were ~25mmHg and near the core close to 12mmHg.
Further, these same investigators have shown decreasing longitudinal gradients in
vascular PO2 exist from the fascial surface of the chamber (skin capillary bed) to the
tumor surface 2,13. However, a significant difference between the two surfaces was not
found in mean P02, but only in the 10 th and 25th percentiles of the oxygen distributions,
i.e. number of hypoxic measurements. These effects may be an artifact of the model as
other investigators have not observed such steep gradients between surfaces24
Evidence of this is suggested by the fact that the microvascular density (MVD) is
significantly different between the two regions. Nonetheless, decreasing oxygen tension
towards the core of a tumor would not be unexpected. Even many decades ago,
164histology of human lung tumors revealed a viable margin and necrotic core
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Increasing hypoxia has been further confirmed in the lab as evidenced from in vitro
tumor spheroid experiments165.
Less commonly reported in the literature are interstitial measurements of P0 2
correlated with the microvasculature. A debate exists regarding the tumor compartment
probed by PO2 measurements with PQM. The large anionic charge and binding to
albumin of the water soluble phosphor have lead some to suggest that P02
measurements are dominated by the intravascular space1. Others highlight the
permeable and leaky tumor vasculature as a source of oxygen sensor evtravasation into
the interstitium. Even in normal tissue, interstitial measurements of PO2 have been
successfully performed166' 167. This is likely due to the exchange of albumin between the
vascular and interstitial spaces168.
Noninvasive measurements of tumor oxygenation in the interstitial space have been
performed in colorectal adenocarcinoma xenotransplants in the dorsal skinfold chamber
of SCID mice. A number of interesting findings have resulted from these studies. The P02
in well vascularized regions was found to be equivalent to that in normal tissue and drop
only a maximum of 5mmHg away from a vessel in the region 5 . In less vascularized
regions (vessel spaces > 200pm) heterogeneous shapes in the interstitial oxygen profiled
were found as well as hypoxic and anoxic P0 2 at distances 70-80ptm and 150-200p m
away from the vessel wall, respectively24,1s . Further, no correlation was found between
blood velocity or vessel diameter. In fact, intravascular measurements revealed
perfused vessels with hypoxic PO2 values (<5mmHg). Investigators following the mean
tumor P02 during growth found the values decreasing with time 24 . Given the depth
limitations (~50tm) of the PQM due to tissue absorption and scattering of the excitation
light, this may be due to the hypoxic tumor surface effect observed by othersi6 3 . Many
of the results found using PQM have been confirmed in other studies in the chamber
models employing oxygen microelectrodes. These studies demonstrated the differential
of P02 across regions of the vascular network 5 6 and also realized an inverse correlation
of P02 with vascular distanceso
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Recent studies have focused on temporal fluctuations in tumor P02 and their impact on
hypoxia. Microelectode measurements in the tumor interstitium have demonstrated
instability in median PO2 due to alterations in red blood cell (RBC) flux even at distances
around the diffusion limit of oxygen in the model (140tm) 150. On a macroscopic scale,
up to 50% of the presumed intravascular PO2 has been shown to dynamically change
>5mmHg over 10s of minutes169. The pathophysiologic source of these perturbations are
likely traced to changes in vascular flow 45 and provide evidence of episodic hypoxia170.
Acute hypoxia induced by such fluctuations may have a profound effect on the selection
of malignant cell populations171 ,17 2. Such changes due to transient hypoxia have been
173shown to increase lymphatic metastases in mice
II.4d MODELING TUMOR OXYGENATION
Coupling characteristics of the tumor vascular network with direct oxygen
measurements has permitted the application of mathematic models to describe the
metabolic microenvironment of the tumor. The simplest model employs cylindrical
geometry, originally proposed by Krogh174. Applied in a semi one-dimensional geometry
to intravascular P02 measurements in the tumor, the Krogh cylinder model suggests
hypoxia at distances >140pm from a vessel and in the tumor center 56 . Of course this is
dependent on both the blood velocity in the source vessels and tissue oxygen
consumption (002). Interestingly, the rate of oxygen delivery to the tumor is not
independent of oxygen consumption. Early in vivo experiments demonstrated that
tumor tissue oxygen consumption varied with changes in blood oxygen concentration
and perfusion 5.
More advanced models have taken into account vascular geometry in both two- and
three-dimensional networks. Generally, the heterogeneous structure of the tumor
vasculature is a significant factor in reducing the thresholds (oxygen consumption and
176distances to nearest vessel) required to reach hypoxia . Similar diffusion based models
using exogenous staining of in vivo hypoxia and MVD reveal hypoxic regions even in the
presence of vessels, although the oxygen tension within these vessels is very low154 .
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Other models have included additional metabolic factors related to oxygen. Combining
the diffusion-reaction relationships of oxygen with glucose transport reveals that
reducing oxygen consumption or decreasing the intervessel distance can eliminate
hypoxia in tumor vascular networks177. More complex models that account for
metabolic changes dependent on the local concentration of oxygen reveal gradients in
glycolytic factors.178 The gradients imply that regions of hypoxia can alter the
metabolism of entire macroscopic regions of the tumor. Many of these models have
focused on the formation of chronic hypoxia. However, meathematical simulations have
suggested that the same structural and functional vascular parameters that define
chronic hypoxia also characterize acute hypoxic events, particularly vascular geometry
(distance to nearest vessel)179.
II.4e P02 IN THE CONTEXT OF ANTI-CANCER THERAPY
Beyond the challenges of delivering drugs to tumors34, cancer therapies can both be
influenced by and affect tumor oxygenation. It is well known that oxygen is a sensitizer
for radiation therapy 1 4. However, the efficacy of many chemotherapeutics are subject to
the level of oxygen in the tumor microenvironment. The activity of bioreductive drugs
and alkylating agents are increased in hypoxic environments1'0"8 . Increased
bioreduction in low oxygen is the basis of hypoxic histological stains such as
pimonidazole and EF-5. In fact, many investigators have proposed clever drug designs to
take advantage of hypoxia creating pro-drugs that are activated through
182,183bioreduction ',. Other agents demonstrate reduced cytotoxicity in low oxygenated
tumors, particularly those, like radiation, that create free radicals to damage
110,114tissue '4. Many cytotoxic agents rely on proliferating cells to induce cellular damage.
Tumor cells have been shown to decrease metabolic rates and become senescent in
hypoxic environments2, thus evading some chemotherapeutics 85 . Further, hypoxia can
select for therapeutic resistance and more malignant phenotypes107,172.
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II.5 Methods for Quantitative Oxygen Sensing In Vivo:
There are a number of methods that permit in vivo measurement of oxygen. However,
some are indirect measurements of oxygen concentration, while others are invasive or
require histological examination. It is important to note whether a method measures
oxygen tension (p02), which is related to the oxygen concentration ([02]) through the
specific solubility in a given medium, or a related, but independent measure such as
oxygen saturation (S02) or a molecular marker responsive to a given range. Many of the
methodologies presented here have been reviewed in detail by others86'-88 .
II.5a POLAROGRAPHIC METHODS:
Polarographic microelectrodes have long been considered the "gold-standard" in
biological measurements of oxygen. These microelectrodes, often termed Clark-type
microelectrodes, quantify dissolved oxygen through modulation in the electrical current
due to reduction of molecular oxygen to water at the platinum cathode'89. Due to the
electrochemical reaction, oxygen electrodes consume oxygen within the small
catchment volume surrounding the cathode. Further, the electrodes require
maintenance of equilibrium, a stable immediate microenvironment, for accurate
measurements. This is often obtained by allowing stabilization after application and
utilizing a recessed and coated electrode 190. Advancements in electrode design have
minimized their catchment volume (~' 1 pm) and significantly reduced oxygen
consumption188 . However, biological application of the electrode is an invasive
procedure requiring mechanoreceptors for proper application, perturbs the local
microenvironment due to the occlusion of tissue and is not typically repeatable. Further,
microelectrodes are less sensitive at low PO2 values (<10mmHg)191. A comprehensive
study across a number of laboratory sites examining both clinical and pre-clinical
measurements of PO2 using Eppendorf electrodes demonstrated significantly variability
even in the same tumor models192. However, given the sensitivity, minimal probed
volume and significant resolution (0.01-1 pM [021), the microelectrode is often used as a
reference in the development of other techniques87.
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II.5a HEMOGLOBIN SATURATION SPECTROPHOTOMETRY:
The optical absorbance of hemoglobin changes with the binding of oxygen. Using at
least two wavelengths of light it is possible to determine the fraction of oxyhemoglobin
and therefore the oxygen saturation193 '194 . This method has been applied both in optical
microscopy in pre-clinical models and near-infrared spectroscopy of humans19s. Because
the signal depends on hemoglobin concentration, the oxygen saturation values
correspond only to the intravascular component of the tissue. Current studies are mixed
on the ability to differentiate the contribution of myoglobin from hemoglobin, which
would provide oxygen saturation of the muscular compartment as well196"1 97. While
these methods are optically-based and non-invasive, the relation of oxygen saturation
to P02 is complex. To convert measurements to quantitative oxygen concentrations,
knowledge of the oxy-hemoglobin dissociation curve and local carbon dioxide and pH
required. Further, even in microscopic implementations, the volume sampled is larger
than polarographic methods 87.
I.5b HISTOLOGY - MOLECULAR AND CHEMICAL MARKERS OF OXYGENATION STATUS
Given both the radiobiological significance of oxygen14 and the potentially prognostic
indicator of oxygen levels in tumors2, concerted efforts have been made to develop
histological techniques for assessing oxygen content. While these methods are invasive,
either performed on biopsies or post-mortem, they do provide insight into hypoxic
fractions and molecular profiling. The most common histological markers of hypoxia are
the nitroimidazoles: pimonidazole 98 and EF5199. Under hypoxic conditions, these
compounds are metabolized by cells in vivo leading to reactive anionic species that form
adducts with intracellular macromolecules. Identification is performed by using
antibodies against these adducts. Both compounds have been utilized in the clinical
setting to assess tumor hypoxia 143,200 , and have also demonstrated staining in normal
tissues with physiological hypoxia201. Because adduct formation is dependent on cellular
metabolism, necrotic regions must be excluded from histological assessment. This fact
may also explain the discrepancy with other methods where low PO2 measurements are
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not always correlated with staining137. Recently, 18F-fluoromisonidazole compounds
have been used for non-invasive imaging of tumor hypoxia in the clinical setting using
positron emission tomography 202,203.
In the past decade, additional endogenous molecular markers of hypoxia have been
investigated as immunohistochemical markers. These include the hypoxia inducible
factor 1 (HIF-1) and its target genes CA9 (of the carbonic anhydrase family) and the
membrane glucose transporter GLUT-1 204,20s. However, these molecules are also
regulated by factors other than hypoxia making them indiscriminate markers oxygen
status1
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Figure 11-2 Quenching of phosphorescence by molecular oxygen. The Jablonski diagram illustrates the
electronic energy levels of a luminescent molecule. Single photon absorption is shown for two excited
singlet electronic states (violet and blue). Phosphorescent molecules undergo intersystem crossing to the
triplet state. The excited electron in the triplet state shares the same spin orientation as the ground state
preventing simple relaxation to the ground singlet state. This "forbidden" transition increases the lifetime
of the photosensitized molecule so that relaxation and photon emission occur over a longer time scale.
For a group of excited molecules, this emission is termed phosphorescence to differentiate its longer
lifetime (milliseconds to days) and origin from the triplet state from fluorescence (nanoseconds).
Molecular oxygen, which is paramagnetic and already in a triplet state, can "quench" phosphorescence by
promoting intersystem crossing through collisional non-radiative decay.
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II.5c PHOSPHORESCENCE QUENCHING METHODS
The effect of oxygen on the quantum yield of luminescence has been known for quite
some time 20. Further, it was rapidly realized that these changes in luminescence
intensity could be used to quantify the amount of oxygen present207 . For a population of
luminescent molecules, the quantum yield and therefore intensity is directly
proportional to the lifetime of the excited state prior to relaxation to the ground state
and release of a photon. Paramagnetic molecular oxygen can quench most luminescent
molecules by inducing intersystem crossing from the singlet excited state to a dark state
that is either long lived eventually experiencing non-radiative decay to the ground state
or chemically modified 208. A subset of luminescent molecules undergo spontaneous
intersystem crossing to the triplet state after excitation experiencing a longer radiative
rate of decay, phosphorescence, due to the spin-forbidden transition to the ground
state. Molecular oxygen can quench the long lived phosphorescence (microseconds to
days) through collisions with the excited triplet state molecule inducing non-radiative
decay (Figure 11-2).
For most luminescent quenching reactions, collisional quenching by molecular oxygen is
well described by the Stern-Volmer relationship208 , shown in Eq. (11.1)
= = 1 + kqTo[0 2] = 1 + Ksv[o2]I T
The ratio of the emission intensity in the absence, I0, and presence, I, of oxygen is
related to the concentration of oxygen through the Stern-Volmer constant, Ksv, where
kqis a diffusion limited second order rate constant209.
kq = 4rirRDN A/10 3  (|.2)
Here, D is the sum of the diffusion constants for the phosphorescent sensor and oxygen,
R is the radius of interaction and r is the quenching efficiency, usually 1. The Stern-
Volmer relationship can easily be derived by considering the luminescent quantum
efficiency of the sensor in the absence and presence of oxygen,
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10 p
kp + knr (11.3)
I oc CD = k
kp + knr + kq[O2 ] ([1.4)
where k, and knr are first order decay rates for emissive and non-radiative processes,
respectively. By taking the ratio of 1 to I and substituting for the definition of the
lifetime in the absence of quencher, to = 1/(k, + kny), the Stern-Volmer relationship
[Eq. (11.1) 1 is obtained for a dynamic quenching process. A similar result is obtained if
the ratio of the luminescent lifetimes is used instead. The Stern-Volmer relationship is
non-linear for some compounds depending on the oxygen concentration' 1 .
Probes for oxygen sensing by quenched luminescence utilized constructs based on
palladium(II) or platinum(II) porphyrin moieties, ruthenium (l1) compounds, or osmium
(11)186. The quenched fluorescence of ruthenium(II) is utilized in many fiber optic sensors
such as the OxyLiteTM system 212 and the FOXYTM system 213. Fiber optic sensors have
been applied in both industrial and biological settings. However, similar to the
polarographic electrodes, inserting a fiber optic probe into tissue perturbs the
environment. Osmium probes are in development214; however the long wavelength
emission (> 700nm) makes their use difficult.
By far the most commonly used optical oxygen sensors are the metalloporphyrins. Their
long lifetime (10-100s pis) and large quenching constant, kg, makes them very sensitive
to low oxygen states1'8'188,21s. Palladium metalloporphyrins are widely used for
biological sensing and many water soluble and biocompatible forms have been
developed 215-219. The platinum metalloporphyrins have shorter lifetimes220, unless
bound in a polymer21, making them less useful as soluble probes. The soluble palladium
porphyrins have been applied in a variety of experimental imaging setups including
fluorescence lifetime microscopy24,155,167,222,223 and frequency domain lifetime
instruments22 4
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II.5d OTHER METHODS FOR MEASURING OXYGEN
In addition to the optical methods for determining oxygen status, other relatively non-
invasive methods exist and have been applied in both animal models and the clinical
setting. The relative merits and limitations have been reviewed in detail
elsewhere 187,22. A number of methods have been developed utilizing nuclear magnetic
resonance (NMR) techniques. The spin relaxation rate of 19F nuclei in perfluorocarbons
directly injected into the site of interest is sensitive to the oxygen tension. In
magnetic resonance spectroscopy, endogenous molecular metabolites that are related
to oxygen status of the tissue can be non-invasively quantified . Further, specific pulse
sequences in magnetic resonance imaging are sensitive to paramagnetic
deoxyhemoglobin in the blood (BOLD-MRI) allowing non-invasive assessment of vascular
oxygenation 228. All of these nuclear magnetic resonance techniques are beholden to the
minimum resolution of the instrumentation (~ 100 m3) and measure oxygen status (or
related parameters) over minutes. A related technique to NMR is electron paramagnetic
resonance (EPR), which measures the broadening of the hydrogen electron spin spectral
linewidths of an administered spin probe 229 . The width of these lines is related to the
collision rate of molecular oxygen with the spin probe. EPR oxymetry is less sensitive to
low P02 tissue values than phosphorescent methods187 . However, the technique has
rapidly progressed towards clinical applications230 .
I.6 The Role of pH in Solid Tumors
Similar to oxygenation, solid tumor pH plays a significant role in tumor progression and
response to therapy. It is well known that the tumor microenvironment is typically
found to be acidic8 ,231-234 . The extracellular pH (pHe) in tumors ranges from ~6.3-7, while
by comparison in normal tissue pH is maintained by homeostatic mechanism around
neutral (7.3-7.4)231,23s. In discussing tumor pH, it is important to distinguish between the
extracellular and intracellular compartments. The in vivo intracellular pH (pHi) of cancer
cells is often found to be alkaline relative to normal tissue (7.12 - 7.65 versus 6.99 -
7.20)235. There are three major areas of research regarding the pH of the tumor
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microenvironment. The first is the origination of low microenvironment pH and the
associated transcellular gradient. The second is the effect of pH on tumor progression
including direct effects on cellular genes. Finally, the implications of tumor pH on
therapy have been a major focus in the cancer field for decades.
1.6a ETIOLOGY OF LOW PH IN THE METABOLIC MICROENVIRONMENT OF TUMORS
The cause of acidic pH and the transmembrane gradient in tumors has been long
debated. Hypoxia has been shown to increase glycolysis a process known as the Pasteur
effect 236 . The regulation of glycolysis by hypoxia is directed through the HIF-1
pathway237. However, many tumors do not exhibit the Pasteur effect suggesting acidosis
is caused by other mechanisms. The Warburg hypothesis postulates that acidosis is due
to a metabolic disturbance of cancer cells promoting glycolysis even in aerobic
environments18,20,'s. Highlighting the complex nature of tumor metabolism, it has been
demonstrated that inhibiting glycolysis does not prevent acidification of pHe118 . In fact,
carbon dioxide in addition to lactate has been identified as a significant source of tumor
acidity23 ,232. Instead it is likely that tumors metabolize whatever substances are present
utilizing multiple metabolic reactions including glutaminolysis and the pentose
phosphate pathway. Demonstratably, administration of glucose does increase glycolysis
and lower pH in the tumor microenvironment 231,239,240. Of course not all of the pH
changes are due to glycolytic metabolism as a bolus of glucose also enacts
hemodynamic effects241 '242 . Of particular interest in tumors is how both the
transmembrane and interstitial vascular pH gradients are established.
It has been well established that a pH drop exists across the cellular membrane of
cancer cells in tumors23s,243-246. It is now understood that this gradient exists due to
active transport processes occurring in tumor cells. The Na*/H* exchanger (NEHI) and
H*/lactate cotransporter (monocarboxylate transporter, MCT) acidify the tumor
microenvironment by forcing protons into the extracellular space247 248. Intracellular
alkalinization drives both cancer cell proliferation and glycolysis249. Further supporting
this mechanism is the fact that proton pump inhibitors abolish the transmembrane pH
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gradient 250. These mechanisms protect the cancer cells from the clastogenicity of the
acidic microenvironment 251 ,252 and have profound implications for therapy.
In addition to transmembrane gradients, tumors display decreasing pH from the
vascular wall inward and across the tumor as a whole. In many experimentally studies
tumors, vascular gradients have been measured24 70 234 2 s3 2 s4. The pH drop along these
gradients ranges from 0.1-0.5 units. Gradients have also been found to exist at the
periphery of solid tumors255. These gradients are possibly formed by two different
mechanisms. Poor perfusion and transport of metabolic products from the tumor due to
the tortuous and inefficient vasculature decrease tumor P02 within the interstitium 256.
Second, hydrogen ion diffusion along concentration gradients to the tumor periphery
creates a pH drop across the tumor255. The transport of hydrogen ions is likely carried
with buffers allowing such gradients to be modeled25 7. It should be noted that while
interstitial pH gradients do exist in tumors, they are in no way universal. pHe has been
found to be heterogeneous within a tumor 258, across tumor types259 and even in
patients with similar cancers24.
H.6b EFFECT OF TUMOR PH ON PROGRESSION
The pH of the tumor microenvironment has been shown to promote aggressive
phenotypes. Tumors with increased glycolysis and lactate production demonstrate
increased metastasis in both animal models 257,2o-262 and patients263,264. These results
have led investigators to propose the acid-mediated tumor invasion hypothesis255 ,265
The proposed mechanism for invasion is multistep. The endogenous mechanisms of the
cancer cells decrease pHe which induces normal cell death through p53-mediated
apopotosis2,267 . By upregulating both VEGF 133,268 and interleukin-8269, low pH promotes
angiogenesis increasing tumorigenicity. The acidic microenvironment also indirectly
promotes degradation of the extracellular matrix270272 Finally, low pH reduces immune
screening of the tumor in the microenvironment27 3. Interestingly, a recent study treating
preclinical animal models with sodium bicarbonate, which raised pHe, showed a
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reduction in spontaneous metastasis24. The activity of the Na*/H* exchanger has been
associated with metastatic phenotype248
II.6c IMPLICATIONS OF TUMOR PH ON THERAPY
Analogous to PO2, the pH of the tumor microenvironment exhibits a spectrum of effects
on different cancer treatments. The main culprit in controlling the cytotoxicity of certain
therapeutics is the transmembrane gradient. The interstitial gradients also affect
treatment, but more by spatial heterogeneities in the response of groups of cells to
therapeutic agents. Chemotherapeutics that are weak bases like anthracyclines, Vinka
alkaloids and misonidazole are unable to penetrate the cell membrane to induce
844,275damages,2  . Increasing in vivo pHe through the administration of bicarbonate has
demonstrated increased cytotoxicity of these agents27 6. Conversely, the transmembrane
pH gradient increases the cytotoxicity of weak acids2 77. Drugs that utilize the existing
gradient by modifying pHi are under active investigation ,278 . Interestingly, low pH has
also been shown to confer resistance to radiation therapy 27 9-28 .
A unique approach to treating solid tumors has employed hyperthermia. Coupling
hyperthermia with hyperglycemia, which reduces pHe eliminates or reverses the
transmembrane pH gradient 279,282,283. Presumably, this occurs through a lowering of pHi
and blockage of the hydrogen ion transporters284 . However, in light of recent
understanding regarding the effect of low pH on the malignant phenotype, combined
hyperthermia and hyperglycemia may not be advisable.
I.7 In Vivo Methods for Quantitative pH Sensing in Tumors
A variety of techniques exist for measuring hydrogen ion concentration (pH) in cells and
tumors. Similar to quantification of oxygen, these methods vary in their level of
invasiveness. Some also permit collection of additional parameters to assess pH in
association with other physiological or anatomical features. In discussing the
quantification of pH, it is important to note what in vivo compartment is contributing to
the measured value. The procedures employed can either measure only pHe or pHi,
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although use of multiple probes or applications can simultaneous detect both. Another
difference between techniques that can influence measured values is the spatial
resolution and depth limits of the pH measurements.
II. 7a INVASIVE TECHNIQUES: MICROELECTRODES AND MORE
One of the older methods for in vivo quantification of pH is the application of
microelectrodes sensitive to hydrogen ions (H*). Analogous to the polarographic method
for P02 sensing, pH microelectrodes are invasive and measure pH in the catchment
volume, which varies depending on the probe. Much has also been made about
potential artifacts in the pH values due to disturbance of the tissue acid/base balance
through insertion and consumption235 . Measurements with microelectrodes have been
performed both in patients234 and animal models8 ,25 4,285. These investigators found
intratumor pH gradients ranging in pH drops from 0.1 - 0.5 across the tumor. The
implantable Guillino micropore chamber has also been employed to measure pH and
other metabolites in the tumor microenvironment232. However, the technique lacks any
spatially localized information. Finally, recent work has focused on the development of
fiber optic probes that do not consume hydrogen ions 286 -288. These measurement tools
employ changes in the emission or excitation of pH sensitive dyes placed in permeable
membranes at the tip of the probe. While such probes may not consume the anylate,
they do mechanically disturb the tumor microenvironment.
II.7b NUCLEAR MAGNETIC RESONANCE IMAGING AND SPECTROSCOPY
Intrinsic nuclei and those introduced by exogenous probes are sensitive to the pH of the
local environment. The spin relaxation of the stable isotope of inorganic phosphorous
(31P) is sensitive to the local pH289. Changes in pH induce a chemical shift in the 31P
resonance that can be calibrated for using the Henderson-Hasselbach equation. The
endogenous signal from 31P arises from the intracellular compartment allowing for
differentiation from extracellular pH in tumors243 . In tumor xenografts, the technique
has demonstrated that pH decreases during tumor growth290. The amount of
endogenous 31p is small limiting the signal to noise of pH measurements. Exogenous
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probes labeled with 31P provide greater signal to noise ratios and highlight the
extracellular compartment 24 ,291. The in vivo spatial resolution of 3P magnetic
resonance spectroscopy (MRS) is around 4mm 3292.
Similar to 31P nuclear magnetic resonance measurements, the most common stable
isotope of fluorine ('9F) is also sensitive to pH. Fluorinated exogenous probes have been
developed for 19F MRS that permit simultaneous measurement of both pHi and pHe
quantifying the transmembrane gradient2 46 ,293 . Probes employing the 1H hydrogen
nucleus have been found to be the most sensitive to pH. Intrinsic 'H resonances cannot
be employed due to interference from other endogenous metabolites and water 235 . Due
to higher sensitivity, 'H MRS uses shorter times (20 minutes) and smaller voxel sizes
(~2mm 3) 294 . The use of 'H MRS also allows for correlation of vascular parameters with
MRI 29 and with other metabolites like choline and lactate296. Gadolinium complexes
that are pH-sensitive have also been developed for use at the higher spatial imaging
resolution of MRI (~100pm) 245. Other imaging techniques, such as positron emission
tomography, have also demonstrated potential for noninvasive measurements of pH297
II.7c OPTICAL IMAGING OFPH
Numerous fluorescent dye molecules exist that have absorption or emission properties
that are sensitive to local pH. The two most common dyes used in vivo are BCECF (2',7'-
bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein) 298 and SNARF-5F) 299, which are based
on fluorescein derivatives. BCECF is often employed as a excitation ratiometric dye given
that its absorption spectrum changes with pH3oo, 301. The pKa of the dye is in the relevant
physiological range ~6.98. SNARF-5F is also used as a ratiometric dye, though typically
through the ration of its emission. However, the dye is both excitation and emission
sensitive with a pKa near neutral (7.3 - 7.4)299. Both dyes are available as cell permeable
compounds for measurement of pHi.
pH sensitive dyes have been used to measure tumor pHe using fluorescence ratiometric
imaging (FRIM) in a number of studies. Early studies in tumor tissue demonstrated that
FRIM measurements correlated well with pH as determined by microelectrodes302. The
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use of FRIM allows relatively high-resolution measurements of pH compared to other
techniques and correlation with the tumor vasculature. These studies have shown that
the pH is spatially modulated with respect to the vasculature. pH correlates strongly
both with distance from the vessel wall and vascular density24,231,253. However, no
correlation of pH with blood flow or local oxygenation was demonstrated in tumors24
While FRIM is the most common application of these dyes, their fluorescent lifetime is
also sensitive to pH303 and has been utilized to measure pH304. These optical techniques
may provide descent spatial resolution, however axial resolution and depth penetration
(~50ptm) is limited.
II.8 Antiangiogenic Therapy and "Normalization" of the Tumor
Microenvironment
II.8a ANTIANGIOGENIC AGENTS AND THEIR TARGETS
Anti-angiogenic therapy, a vascular targeted agent that blocks the formation and
maintenance of new vessels, was originally conceived as a way to starve a tumor of its
blood supply 30 ,306 . Angiostatin, a 38kDa plasminogen fragment produced naturally
including by some tumors, was discovered by Judah Folkman and shown to reduced
metastases307 and induce tumor dormancy30 . The same group also identified another
endogenous inhibitor of angiogenesis produced from a fragment of Collagen XVIII
termed endostatin309 . While these peptide fragments have demonstrated success in
animal models, clinical trials with endogenous antiangiogenic compounds have only
recently begun310 31
Instead major focus has been on targeting the vascular endothelial growth pathway.
Work in animal models has demonstrated that blockade of VEGF-Receptor 2 (VEGF-R2)
inhibits angiogenesis and delay tumor growth312 . A humanized antibody to soluble
VEGF, bevacizumab (Avastin), has been approved by the Federal Drug Administration for
treatment of colorectal cancer and advanced lung cancer 313 . Recent work has expanded
the field of antiangiogenic therapy to include broad spectrum and small molecule
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tyrosine kinase inhibitors that target multiple VEGF and other growth factor
receptors314,31s. However, in the last decade, results in both the laboratory and clinic
have suggested a more complex role for antiangiogenic agents in cancer therapy.
H.8b NORMALIZATION HYPOTHESIS
The concept of using antiangiogenic therapy to alter disease progression by starving the
tumor of its blood supply has been challenged by both laboratory and clinical results.
Phase I and 11 clinical trials using the contemporary anti-angiogenic agent bevacizumab
have reported varied results with either no evidence of improvement in progression of
disease or only a partial response in some patients"" 4 , 4 ,ne'n 7. Even in relatively well
controlled xenograft animal models, antiangiogenic therapy has produced mixed results.
Early studies administering a single antiangiogenic agent demonstrated initial tumor
growth arrest and vascular regression only to be followed by a second stage of
angiogenesis and tumor relapse49,312,318-320. These results combined with variable clinical
effects have led to the idea that antiangiogenic therapy needs to be rationally scheduled
and may work better in combination with other therapies11,,321. Particularly important
is the dynamic effects antiangiogenic agents have on the metabolic microenvironment
of solid tumors.
It is well known that oxygen sensitizes a tissue to radiation14; therefore one would
expect anti angiogenic agents and radiation to be antagonizing factors. Surprisingly, a
variety of antiangiogenic agents including angiostatin32 2 and blockage of the vascular
endothelial growth factor pathwayn3 324,325 have demonstrated increased therapeutic
efficacy when combined with radiation therapy in animal models. A recent study
employing a xenograft model of glioblastoma and using in vivo microscopy has
demonstrated a vascular "normalization window" during which radiation increased the
tumor growth delay compared to administration before or after 6.
Immunohistochemical analysis also showed decreased hypoxia during the window.
Further, measurements of tumor microenvironmental P02 during antiangiogenic
318,327,328therapy have revealed a period of increased mean oxygen tension '
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The acidic microenvironment is also susceptible to changes induced by antiangiogenic
therapy. Certain antiangiogenic agents have been shown to reduce the cancer cell
transmembrane gradient 329. This gradient, coupled with poor transport properties of
the tumor vasculature present significant barriers to chemotherapeutics330 . Reducing
the intracellular pH and thus the gradient with the acidic microenvironment enhances
the cytotoxic effects of many weak-acid drugs33 1. Animal studies have shown improved
efficacy of cytotoxic therapy when administered with antiangiogenic therapy 3
Clinical trials have provided even further support to a beneficial effect of antiangiogenic
therapy in combination with other treatments. Anti-VEGF treatments have
demonstrated synergistic results when combined with standard chemotherapeutics in
colorectal" 6 and potentially other clinical cancers'1 . A number of mechanisms have
been proposed for the improved response of radiation therapy and chemotherapeutics
in combination with antiangiogenics334 including augmented anti-vascular effects335 ,
increased tumor cell repopulation, and vascular "normalization".
As first presented by my thesis advisor Dr. Rakesh Jain, the "normalization" hypothesis
proposes that the immature and inefficient blood vessels of the tumor are selectively
pruned through antiangiogenic therapy by initiating apoptosis of excess endothelial
cells, decreasing vessel diameter, vascular density and permeability' 3 .These microscopic
changes leave the remaining vasculature with a "normal-like" appearance and may
enhance function. The "normalization" of tumor vasculature by antiangiogenic therapy
has profound implications on combined treatment. The less tortuous and lower
resistance vessels may be able to better transport therapeutic agents to the tumor and
remove metabolic waste increasing tumor pH. Additionally, higher tissue perfusion in
the tumor could mean increased P0 2, enhancing the effects of radiation therapy.
However, other therapeutic agents or radiation treatments must be applied when the
vasculature is optimally "normalized" to have the greatest effect. If therapy scheduling
or dosing is suboptimal, there could be antagonism between cytotoxic and
antiangiogenic therapies or decreased delivery of other therapeutic agents.
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I.8c TRASTUZUMAB AS AN ANTIANGIOGENIC AGENT
Other targeted anti-cancer therapies may also down-regulate angiogenic molecules
through indirect mechanisms. Recently, in an in vivo xenograft model of breast cancer,
trastuzumab (Herceptin) was shown to "normalize" and induce regression of tumor
vasculature and decrease a number of angiogenic factors336. Trastuzumab, a monoclonal
antibody against HER2/neu, is currently used for the treatment of advanced metastatic
breast cancer. As a whole, the clinical results of breast cancer treatment using
trastuzumab have been mixed. Only a subset of HER2/neu over-expressing breast
cancer patients have responded to treatment with others showing no effect with either
monotherapy or in combination with therapeutic agents337,338. Administration of
trastuzumab to HER2-positive breast cancer cell lines in vitro has been promising,
demonstrating decreased growth rate339 and increased radiosensitivity340 . In addition to
promoting vascular normalization, inhibiting HER2/neu may enhance combinatorial
therapies through other pathways.
HER2/neu is a proto-oncogene product that was shown to be amplified or over-
expressed in 10 to 34% of breast cancers and has been associated with poor prognosis
and resistance to chemotherapy in both primary and metastatic disease341 . The
amplification of the gene encoding HER2/neu, c-erbB-2, or activation of the receptor by
heregulin leads to increased HIF-1X 342 and VEGF 343 expression. At the cellular level, the
molecular pathways modulated by HIF-1a increase glycolosis, alter genetic expression,
enhance metastatic potential and induce radiation resistance2" 18. In the clinic, increased
angiogenesis and hypoxia have been demonstrated for HER2-positive primary tumors344
The increased hypoxia in HER2/neu over-expressing breast cancer suggests that its
presence may induce resistance to radiotherapy. It has recently been shown that
HER2/neu amplification protects breast cancer cells against radiotherapy by enhancing
the activity of NF-KB, a protein stress factor that blocks apoptosis in response to
oxidative stress induced by ionizing radiation340. Therefore, targeting the HER2/neu
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receptor with trastuzumab may enhance radiotherapy by potentially diminishing the
hypoxic cell population that may be resistant.
a. b.
Figure 11-3 Principles of multiphoton excitation. (a) Single photon and (b) two-photon excitation from the
ground state of a molecular fluorophore. (c) Hourglass shape of fluorescent emission during single photon
excitation of fluorescein. (d) Under two-photon excitation of the same sample using the same objective
lens, fluorescence is only observed to occur from the focal volume (red arrow).
1I.9 Intravital Multiphoton Microscopy
In the past 15 years, a novel form of optical microscopy utilizing ultrafast lasers and high
numerical aperture lasers has become a critical tool in the study of in vivo biological
properties. This technique, multiphoton microscopy, provides non-invasive optical
imaging with significant depth penetration at high three-dimensional resolution2 s34 s,346
The intrinsic properties of multiphoton excitation allow MPLSM to image fluorescently
labeled structures in tissue with a three-dimensional resolution of ~1 micron up to
depths of 450-600 microns, depending upon the tissue type.
II.9a PRINCIPLES OF MULTIPHOTON MICROSCOPY
The principle of multiphoton absorption in molecules, specifically two-photon was
originally devised by Maria Goeppert-Mayer in 1931347. Ordinarily, fluorescent
molecules are promoted to their excited molecular state with absorption of a single
photon of light of an approximate energy equivalent to the separation between the
ground and excited states (Figure 1l-3a). In two or multiphoton excitation, two or more
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photons of light are simultaneously absorbed by a molecule to reach the excited state
(Figure II-3b). Once excited, the process of fluorescent emission is independent of the
excitation mode 346 . The excitation probability of molecules by a non-linear process
through multiphoton absorption was found to be extremely small at ordinary light
intensities. It was not until the advent of high power light sources such as the maser and
laser that two-photon absorption and excitation of fluorescence could be
experimentally observed348. However, at the light intensities utilized to perform non-
linear excitation of fluorescence, damage to biological tissue would be significant. In the
early 1990s, the introduction of the ultrafast pulsed laser near-infrared laser sources
revolutionized the application of multiphoton excitation to fluorescence microscopy.
By adapting the technique of confocal microscopy, which employed a galvanometer
scanning mechanism to spatially image a sample, Denk et al were able to perform two-
photon imaging of biological samples using an ultrafast laser source345 . In confocal
microscopy, pinhole detection is required in order to reject fluorescent emission from
out of plane excitation for optical sectioning349. This constraint coupled with visible
excitation wavelengths limits both the signal to noise and depth penetration of confocal
microscopy in biological samples. In MPM, fluorescent emission exhibits a quadratic
dependence on incident intensity significantly reducing the probability of excitation
outside the focal volume (Figure 1l-3c,d).
i c P.5)
Therefore, fluorescence only occurs from the focal volume defined by the optics and the
emission can be detected in non-descanned fashion without a pinhole. Since excitation
occurs only in the focal volume, any potentially damaging processes like photobleaching
or thermal effects are limited spatially 350,35 1. This is unlike single photon excitation,
which occurs throughout the sample even though fluorescent emission may only be
collected from one depth focus. Further, the use of near-infrared excitation light (700-
1020nm) populates a region of the electromagnetic spectrum at which absorption in
biological materials by water, hemoglobin, adipose tissue and other chromophores is at
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a minimum 349 . This permits deeper imaging in biological samples than confocal
microscopy. However, it should be noted that optical resolution scales with wavelength.
Therefore radial resolution is slightly higher in confocal microscopy than MPM. In most
literature, including this Thesis, the term "multiphoton" microscopy or excitation nearly
always refers to two-photon excitation. Three-photon and higher orders of excitation
have been observed in certain biological molecules like serotonin 35 2 and DNA labels, like
DAP13 3, that absorb in the ultraviolet range. While these processes exist, they are often
not applied in vivo.
II.9b MULTIPHOTON MICROSCOPY IN CANCER BIOLOGY
Intravital imaging of tumors was first introduced by the Steele Laboratory in
collaboration with the So Lab at MIT 29. Application of MPM to transgenic mouse models
demonstrated quantitative imaging of endogenous molecular reporters, tumor
vasculature and blood flow 2s. Second harmonic generation, a nonlinear optical process
that occurs due to a different photophysical process than multiphoton excitation, can
also be performed in tumors using MPM instrumentation. Coupling MPM and second
harmonic imaging permits imaging of type I collagen in the context of the tumor
microenvironment 35 4. Dynamic changes in the extracellular matrix due to compounds
that induce degradation 355 ,356 or as a result of cellular interaction with the collagen
fibers3 7 can be observed in tumors. Modifications in the technique of MPM allow the
study of molecular transport in the tumor microenvironment through either
fluorescence correlation3 8 or fluorescence recovery after photobleaching3s9,36o
techniques.
The simple theory behind multiphoton microscopy allows for implementation in a
variety of experimental designs. The compounds that are used for imaging can be quite
versatile, permitting the use of some that respond to tissue physiology. This allows for
simultaneous imaging and physiological monitoring of tissue. In the study of neoplasia,
MPM provides many possibilities for studying pathophysiology.
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Figure 11-4 Fluorescent semiconductor nanocrystals: properties and in vivo imaging. (a) NC absorption
unaffected by pH at physioloigical extremes. (b) NCs possess broad two-photon excitation cross-sections.
Inset: Quadratic dependence of NC excitation with ultrafast NIR lasers. (c) In vivo angiography in a murine
tumor model with red NCs. Scale bar - 100prm (d) NC-immunoconstructs (or ang) labeling integrin- $1 in a
VEGF-GFP mouse. Stromal cells (green). SHG from collagen (blue). Scale bar - 150pm.
II.10 Luminescent Semiconductor Nanocrystals
Nanotechnology is rapidly emerging as an important source of biocompatible tools that
may shape the future of medical practice. Fluorescent semiconductor nanocrystals
(NC) 361, also known as quantum dots, can provide the basic scaffolding for constructing
such tools. The intrinsic properties of NCs including high quantum yield, photostability,
tunable narrow emission peak, and broad excitation, has made them increasingly
attractive for biological imaging ,363. The photophysical properties of NCs are relatively
insensitive to the local microenvironment (Figure 1l-4a). The ability to modify surface
CHAPTER 2
coatings of NCs without affecting the photophysical characteristics of the NC core
permits control of the way NCs interact with and respond to their environment. NCs are
increasingly used in biological research as fluorescent tracers in microscopy364,36s (Figure
1l-4c), imaging molecular targets366 , cell tracking363,367, and sensing36 . Further, NCs have
proven reliable fluorescent markers for in vivo multiphoton microscopy because of an
unparalleled two-photon excitation cross-section36 9,370 (Figure 11-4b). Recently, NCs have
been exploited to study drug delivery and tumor pathophysiology366 ,367,370(Figure 1l-4d).
Fluorescent nanocrystals consist of a spherical inorganic core (2-10 nm diameter)
typically made of CdSe obtained by colloidal synthesis. The core is the source of the
optical signal which is defined by its size. Excitons - excited electrons bound to the
positively charged holes remaining in the valence band of a semiconductor material -
undergo quantum confinement when the size of the NC core approaches the distance
between the electron and hole3713 72. As the dimensions of the NC core become
increasingly smaller than the exciton, the band gap of the material increases. Increasing
band gaps lead to higher energy photons, thus smaller NCs emit at shorter wavelengths
3. The existence of higher molecular-like states in quantum confinement confers the
broad absorption spectra observed with NCs374. An additional inorganic coating, usually
ZnS, creates a protective shell that reduces non-fluorescing relaxation pathways of the
exciton, thus increasing quantum yield. These core-shell NCs also are more robust to
chemical degradation and photobleaching37 ,376. Other core materials (InP and InAs) not
utilizing heavy metals, which are biologically toxic, are under investigation .
However, in vivo toxicity has not been observed in murine studies even with repeated
exposure over extended periods 364,379-382.
For biological applications, inorganic NCs need to be solubolized and passivated to
minimize interactions with biological molecules. Chapter 5 will address this issue in
detail for the development of an ideal NC biosensor that penetrates tumor tissue
without binding. Surface coatings that contain polyethylene glycol (PEG) chains
generally have improved retention times in circulation after intravenous injection362,383-
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387. However, the terminal charge of the PEGs is critical in refining interactions and
transport in tissue, particularly the tumor microenvironment3s-391 . The biocompatible
surface coating is the major contributor to the hydrodynamic radius of the NC an
important consideration when considering delivery and transport in the tumor
microenvironment68 ,392-394. The biocompatible surface coating also serves as a scaffold
for conjugating molecules for targeting and, as will be discussed, sensing.
II.11 Fluorescence Resonance Energy Transfer and Sensing
Conventional ratiometric sensors for pH exhibit either different emissive or absorptive
properties subject to the hydrogen ion concentration. Therefore, two states exist in
these pH indicators, which if resolvable make them internally calibrated sensors. Both
BCECF and SNARF are examples of two-state ratiometric sensors299,300 . While these
probes are reliable in single photon excitation epifuorescence microscopy, the ability to
resolve the two states is impossible in multiphoton microscopy. The innovation of a
ratiometric sensor based on fluorescence resonance energy transfer (FRET) between an
NC coupled with a pH sensitive dye resolves these issues (Error! Reference source not
found.). The construct should assume the excitation properties of the NC, which exhibits
a large two-photon absorption cross-section with a broad excitation range 319,370. This
scheme permits the selection of almost any analyte sensitive dye molecule as excitation
will occur through the NC.
I1.11 a PRINCIPLES OF FRET
The process of FRET involves the non-radiative transfer of energy from a fluorescent
donor molecule to an acceptor. The process was first described in 1948 by Theodor
F6rster 395, hence FRET is sometimes referred to as F6rster resonance energy transfer.
Energy transfer typically occurs from a lower wavelength emitting donor over a short
distance (20-60A) and is due to a dipole-dipole interaction of the donor and acceptor
molecules208. The rate of energy transfer (kT) is inversely proportional to the sixth
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power of the donor-acceptor separation distance (r') and directly related to the
spectral overlap of the donor emission and acceptor absorption U).
K2 9000(In 10)kr~r) = kD? 17G28 nsNn4
Here kD is the radiative emission rate of the donor in free solution defined by the
emission lifetime (-D) and quantum yield (<Dp).
kD = (PD1.2
TD
K 2 describes the orientation of the dipoles, which in the case of randomly oriented
dipoles is considered to be 2349. This has proved successful in other FRET-based NC-3
protein sensors396. N is Avogadro's number and n is the index of refraction of the
aqueous medium (1.4). The overlap integral is defined by the normalized fluorescence
emission spectrum of the donor (FD(A)) in nm or cm and the excitation wavelength
dependent extinction coefficient of the acceptor(EA(A)) in units of M'cm-1.
= FD(A)eA(A) 4d (II.3)
The resonance energy transfer relationship is typically not defined as in Eq. (11.1), but
instead it is written in terms of the Forster distance (RO). This is the distance at which
the FRET rate is equivalent to the donor fluorescent emission rate: TD-1.
S(9000(ln 10)Ro0 = K 2 8 7s5N n* 4-
The energy transfer efficiency (E) is fraction of photons absorbed by the donor that are
transferred to the acceptor. This can be defined by the rates of these two processes
assuming that loss occurs only through radiative and non-radiative decay by the donor.
E= kT Ro
6
kT + TD- Ro0 + r6 (11.5)
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The FRET efficiency is typically determined by measuring the fluorescence lifetime of the
donor in the presence and absence of bound acceptor.
E 1 TDAE = 1 -- (11.6)
TD
If a number of acceptor molecules are present that can interact equally with the donor,
then the transfer efficiency increases with each additional acceptor. In the case of FRET
using NCs, more than one donor molecule is often attached to the NC due to its larger
size (6-12nm). In this case transfer efficiency is defined as follows396,
mR0 6
E = mR0o + r6  (11.7)
where m is the number of bound acceptor molecules.
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Figure 11-5 FRET-based sensing using semiconductor nanocrystals. (a). In the absence of analyte most
emission occurs from the NC. When analyte binds, the extinction coefficient of the sensitive dye shifts -
altering the FRET efficiency. (b). In the case of the pH biosensor, the efficiency increases with increasing
pH: decreasing NC fluorescence and increasing dye emission. In a two-photon absorption of the NC is
shown.
II.11lb EXAMPLES OF FR ET USING FLUORESCENT NANOCRYSTALS
Besides the configuration presented in Figure 11-5a, fluorescent nanocrystal sensors have
been proposed and demonstrated in a variety of schemes. The most common NCs
utilized in FRET arrangements are based on Cadmium-Selenide cores (CdSe). The work
presented in this thesis focuses entirely on this type of NC. CdSe NC energy transfer
relationships were first observed between NCs of different diameters in solids397. The
63
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broad absorption spectrum of NCs and relatively short fluorescent lifetime of many
organic fluorophores typically prevents the use of NCs as FRET acceptors in other
situations398 . A study using water soluble NCs bound to maltose binding proteins with
different organic fluorophores attached demonstrated through a series of experiments
many of the photophysical and FRET properties of NCs as energy transfer donors396
Figure II-6 FRET-based NC biosensor for pH in the physiological range found in tumors. (a) NC biosensor
without excitation of the NC at pH 6-9. (b) Under ultraviolet illumination the difference in fluorescent
emission is striking. Photos courtesy of Dr. R. Somers.
The use of NCs in FRET-based chemical and biological sensors has been thoroughly
reviewed elsewhere 398. Biological processes that modify the FRET distance between NCs
and a fluorophore have been used to detect DNA replication399, DNA cleavage400 and the
interaction between in vitro protein complexes401. Displacement of a quencher attached
to an NC by a molecule of interest has been used to sense both maltose 368 and TNT 2.
Determination of ion concentrations has been performed using NC to NC FRET through
analyte promoted NC aggregation398 The above NC sensing protocols can be very
accurate to low concentrations of analyte; however the probe is consumed during the
process making sensing irreversible. Coupling the NC directly to chromophores or
fluorophores with an absorption spectrum dependent on the concentration of an
analyte creates a reversible probe (Figure lI-5Errorl Reference source not found.b).
Conjugating a pH sensitive chromophore to an NC permitted reversible sensing of pH
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through the changes in NC emission due to modulation of the FRET efficiency. However,
calibration and in vivo sensing in this setting is difficult due to the single emission unless
fluorescence lifetime measurements are performed 403. A ratiometric pH probe based on
conjugation of an NC with a pH-sensitive fluorophore demonstrated internally
referenced pH sensing due to the presence of two detectable emissions and
maintenance of an isosbestic point4*4.
In summary, linking a NC to an environmentally sensitive fluorescent dye in which there
is a donor-acceptor FRET relationship allows for ratiometric spectral comparison (via
modulation of energy transfer or dye emission lifetime/intensity) dependent upon
analyte concentration. With judicious dye selection, so that there is limited direct
excitation, a reversible internally calibrated ratiometric biosensor is possible due to the
photostability and environmental insensitivity of the NC. The entire construct inherits
the broad excitation spectrum and large two-photon excitation cross-section of the NC -
highly desirable attributes for use in vivo with MPM. The pH sensor developed in this
Thesis (Figure 11-6) employs this design for a ratiometric pH probe for use with
multiphoton FRIM.
II.12 Optical Coherence Tomography
Image contrast in coherent microscopy like optical coherence tomography (OCT) is
derived from the dependence of optical scattering on endogenous tissue structure and
function rather than from fluorescent labels as in MPM. These differences in technique
allow OCT systems to circumvent some of the limitations of MPM. Because the beam
focus is not used to select specific depths, OCT alleviates the requirement for high
numerical aperture optics, thereby simplifying wide-field imaging. Furthermore, OCT can
image at longer wavelengths where penetration depth in tissue is improved to several
millimeters, and can image frequently over prolonged periods without concern for
accumulation of fluorescent tracer. However, methods for effectively characterizing
biological parameters of tumor microenvironment and structure through optical
scattering are lacking in OCT
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IL12a PRINCIPLES AND TECHNIQUES
Optical coherence tomography405 (OCT) is an alternative approach for in vivo
microscopy. OCT uses the delay of light reflected from tissue, i.e., the "time of flight", to
image across depth, analogous to ultrasonography. Classically, OCT is performed in the
time-domain using an interferometer which measures the cross-correlation of a sample
and reference beam from the same light source (Figure 11-7). The time delay of the light
along the reference path determines the imaging depth, while the amplitude of the
interference pattern represents the intensity of the reflected (backscattered) light not
randomly scattered in the sample. Low coherence light sources, which contain a number
of optical frequencies, are employed in OCT due to the small coherence length. The
coherence length, or distance over which interference can occur, defines the axial
(depth) resolution of the OCT system. Significant resolution down to 1pm is achievable
with ultrafast mode-locked laser sources due to the short coherence length, although
imaging depth is limited due to the NIR wavelengths (~800nm) of the sources*6 -4 8.
Most OCT systems use infrared light around 1300nm, which allow depth penetration up
to a few millimeters due to lower scattering in biological tissues0941. Radial resolution
is set by the beam focusing lens and spatial sampling density of beam scanning or
sample translation. Because OCT uses interferometric techniques to determine the
amplitude and time delays of the reflected signal very low light intensities can be
detected.
In time-domain OCT, depth scanning is performed through translation of the reference
arm to adjust the time delay of the system. This method limits the imaging speed of the
system due to mechanical translation for depth. An alternative approach is to perform
OCT in the frequency domain, whereby depth is encoded as a function of wavelength4 .
This approach eliminates the need to scan the reference beam, significantly speeding up
the imaging time. Frequency-domain OCT also improves the detection sensitivity by
several orders of magnitude because all depth information is obtain simultaneously
rather than only within the coherence length of the light source as in time-domain
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methods -4 1 . Frequency-domain can be performed by 1) using a spectrometer at the
detector to obtain the cross-correlation interference signal as a function of wavelength,
a technique known as "spectral radar" 4 5 and spectral-domain OCT; or 2) using a
wavelength-swept broadband laser source416 known as optical frequency domain
imaging (OFDI). In this Thesis, OFDI will be used for all coherent microscopy studies.
OCT instrumentation and methodology can be adapted to probe a number of
parameters in biological tissue. At a basic level, the image contrast in OCT is derived
from optical scattering in the tissue which is both a source of signal and noise - termed
speckle 417 . Tissue scattering in OCT allows differentiation of anatomical boundaries and
pathological features. Measurement of in vivo tissue birefringence using polarization
sensitive OCT has been shown to indentify collagen and other fibrillar proteins as well as
vascular smooth muscle418'419. Spectroscopic OCT, which measures the wavelength
dependence of the backscattered light, has demonstrated sensitivity to discriminate
scattering particles of various sizes420 ,421 . Finally, phase-resolved OCT or Doppler OCT
can be used to detect movement of scatters such as fluid flow in vessels422.
II.12b APPLICATION TO TUMOR BIOLOGY
OCT has been applied to cancer imaging mainly as a histological technique for assessing
tumor size and boundaries. A number of studies in animal models and clinically relevant
dermatological cancers have demonstrated tumors generally have a high scattering
signature in OCT relative to normal tissue42327. The scattering difference between
tumor and surrounding normal tissues is due to the increased nuclear to cytoplasm
ratio428. Given the increased reflectance observed between tissue boundaries, OCT has
also been used to study changes in the layers of the epithelium during tumorigenesis429.
Application of high-resolution OCT to ex vivo clinical samples has demonstrated good
correlation of microanatomical structures like calcifications, cysts, enlarged nuclei and
blood vessels with histology430 . Histological changes observed in tumor grading may also
be detectable with OCT431432. Heterogeneous scattering patterns have also been
observed in tumor tissue, although investigations into the underlying mechanisms are
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lacking424,432. In model tumor spheroids, high scattering regions in the core have been
attributed to necrotic tissue433 434 . It has additionally been suggested that OCT may be
qualitatively sensitive to edema as reflected in low scattering regions429.
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Figure 11-7 Basic principles of optical coherence tomography. Light from a coherent source is split into a
sample and reference arm. After interacting with the scattering sample, the sample and reference arms
are recombined on a detector forming an interference pattern (inset).
Doppler OCT techniques have also been applied in both animal and human tumors to
assess vascular function. Some investigators have provided quantitative measures of
flow, but in most cases changes in perfusion are monitored. The effects of both vascular
disrupting agents and photodynamic therapy on vascular perfusion have been studied in
animal models 435 ,436. To date, three-dimensional morphological parameters of tumor
Source
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vascular have not been presented in the literature, although simple reconstructions of
superficial large vessels have been demonstrated437 . However, Doppler OCT has been
used to measure cross-sectional areas and diameters of perfused vessels according to
the phase modulation signal438. In these studies, the measurements are limited to
vessels around 100pm and severely influenced by "shadowing" 437 due to increased
backscatter from the blood. Doppler OCT techniques have also been adapted to
endoscopic instrumentation for applications in the human gastrointestinal tract with
preliminary results suggesting in vivo perfusion studies may be possible439
H.13 Specific Aims
Understanding the role of the tumor microenvironment in the progression of disease
and response to therapy will lead to better therapeutic regimens and clinical outcome.
Particularly important in the microenvironment are the physiological parameters of
oxygen tension (p02) and pH. These variables have been shown to directly or indirectly
impact response to radiation therapy (p02) and chemotherapy (p02 and pH)7'8. By
modifying the technique of multiphoton microscopy 25,345 to perform phosphorescence
quenching microscopy440, I will develop a non-invasive method to quantify PO2 in living
tissue at high-resolution. I will adapt novel fluorescence resonance energy transfer-
based nanocrystal (NC) biosensors404 for use with MPM to quantify pH in living tissue at
high-resolution. I will measure PO2 and pH in vivo during tumor growth and
antiangiogenic treatment with the VEGFR-2 blocking antibody DC101 in orthotopic and
ectopic tumor models. While MPM demonstrates utility and adaptability in the study of
cancer and response to therapy, new techniques are needed to non-invasively study
pre-clinical tumor models and assess cell viability. To this end, I will apply Optical
Frequency Domain Imaging 416 to study solid tumors over wide fields with microscopic
resolution.
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II.13a HYPOTHESIS 1. PHOSPHORESCENCE QUENCHING MPM CAN PROVIDE
QUANTITATIVE P02 SENSING IN TUMORS.
Anti-angiogenic therapy has been shown to alter the tumor vasculature morphology and
function, paradoxically improving the efficacy of chemotherapy and radiation
treatment. Recently, trastuzumab was demonstrated to modify the tumor vasculature
in a manner analogous to many vascular targeted anti-angiogenic agents336. The
structural morphology and functional characteristics of vessels in tumors dictates
oxygen and nutrient delivery to the cells. This directly impacts efficacy of both
radiotherapy and chemotherapy. Therefore, I expect that an understanding of the
dynamic changes in P02 during therapy with trastuzumab or DC101 will help schedule
more efficacious combined therapeutic regimens for the treatment of solid tumors315.
Aim la. Adapt phosphorescence quenching microscopy to the technique of MPM and
measure P02 in vitro and in vivo.
By modifying the technique of MPM, I will adapt the principles of phosphorescence
quenching microscopy (PQM) to the nonlinear optical regime. I will select, characterize
and optimize porphyrin-based oxygen sensors for use in vivo with MPM. Calibration will
be obtained in vitro in a closed system for the range of physiologically relevant dissolved
PO2 using MPM. In vivo measurements of oxygen tension will be assessed using MPM in
transparent window mouse models. Proof of principle for the technique will be
demonstrated by confirming the Krogh tissue cylinder model 74 in skeletal muscle fibers
in mice.
Aim 1b. Measure changes in PO2 during tumor growth.
Using solid tumors grown in dorsal skin-fold chamber, mammary fat pad, and cranial
window mouse models, PO2 will be quantified during tumor progression.
Measurements will be made both in the interstitial and intravascular spaces of the
tumor microenvironment.
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Aim 1c. Measure changes in P02 during anti-angiogenic therapy with DC101 in solid
tumors.
I will perform high-resolution multiphoton phosphorescence quenching microscopy in
both a human colorectal adenocarcinoma model (LS174T) and murine mammary
carcinoma (MCalV) implanted ectopically in the DSC during administration of DC101.
Further, I will assess tumor microenvironmental P02 in orthotopic murine mammary
carcinoma (E0771) in response to anti-angiogenic therapy by DC101. Morphology of the
tumor vasculature will also be assessed by MPM angiography and correlated with P02
measurements.
Aim 1d. Measure changes in PO2 in breast cancer tumors during monotherapy with
trastuzumab.
Fluctuations in the intravascular and interstitial P0 2 due to trastuzumab will be
measured with PQM using MPM in HER2-positive mammary tumors in the MFP
transparent window chamber mouse model. Morphology of the tumor vasculature will
also be assessed by MPM angiography and correlated with PO2 measurements. These
results will help identify potential treatment windows during which vascular function
may be altered by trastuzumab.
II.13b HYPOTHESIS 2. NC-CONSTRUCTS CAN PROVIDE QUANTITATIVE FRET-BASED
PH SENSING IN TUMORS.
Aim 2a. Measure pH in vitro and in vivo using a NC-biosensor for pH and MPM.
I will optimize the in vivo use of FRET-based NC-biosensors with MPM by determining
construct stability, minimal particle size, biological pKa, and maximally detectable
fluorescence emission and sensitivity. Calibration will be conducted in vitro and in ex
vivo tumor tissue for the range of physiologically relevant pH. In vivo measurements of
pH will be assessed using MPM in transparent window mouse models.
Aim 2b. Measure changes in pH during hyperglycemia.
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Using transparent window mouse models, I will measure dynamic changes in pH during
experimentally induced hyperglycemia. The pH sensitive FRET signal from the NC-
biosensor will be monitored by MPM in the interstitium and correlated with the tumor
vasculature.
II.13c HYPOTHESIS 3. OPTICAL FREQUENCY DOMAIN IMAGING CAN NON-INVASIVELY
PERFORM THREE-DIMENSIONAL MICROSCOPY OF VASCULAR NETWORKS, LYMPHATICS,
TISSUE VIABILITY AND MICROANATOMY IN SOLID TUMORS.
High resolution, intravital multiphoton microscopy has provided powerful mechanistic
insights into tumor biology. However, the requisite high numerical aperture and
exogenous contrast agents result in a limited capacity to investigate substantial tissue
volumes or to probe dynamic changes repeatedly over prolonged periods. By using
coherent optical principles distinct from multiphoton microscopy, optical frequency
domain imaging circumvents these limitations and may provide an unprecedented
ability to probe critically important aspects of tumor biology.
Aim 3a. Perform non-invasive, high-resolution, wide-field angiography of tumor vascular
networks without the administration of exogenous contrast using OFDI.
By applying Doppler principles, OFDI can detect vasculature through contrast derived
from the intrinsic fluid motion within the vessels. I will demonstrate the ability of OFDI
to monitor vascular morphology and geometry frequently and over prolonged
timescales in solid tumors. Further, I will characterize the performance of OFDI
angiography through direct comparison with multiphoton microscopy.
Aim 3b. Perform contrast-free functional lymphangiography using OFDI.
By taking advantage of the optical scattering differences between functional lymphatic
vessels and the surrounding tissue, OFDI can map lymphatic networks without the use
of exogenous dyes. I will show that OFDI lymphangiography supersedes standard
methods by providing an ability to map lymphatic networks over larger regions and
more frequent timepoints.
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Aim 3c. Characterize in vivo tissue viability using OFDI.
Based on differences in tissue reflectance, OFDI can differentiate necrotic/apoptotic
regions from viable tissue. I will show that OFDI can monitor tissue viability during
tumor progression and demonstrate that the spatial distribution of viable tissue can be
correlated with the distance to the vascular network.
Aim 3d. Assess multiparametric responses of both vascular-targeted and cellular-
targeted therapies using OFDI.
To demonstrate the utility of OFDI as a tool to monitor anti-cancer therapy, I will
perform multiparametric imaging of tumors during either antiangiogenic therapy by
DC101 or direct targeting of tumor cells through the use of diphtheria toxin.
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III.1 Introduction and Motivation:
Non-invasive methods for quantitatively probing the tissue microenvironment in vivo
from normal to disease states, including cancer, are needed. Particularly important is
the metabolic microenvironment, which influences normal processes such as
embryogenesis, inflammation, and maintenance of bone marrow cell lineages'-4.
However, it is often perturbed in pathophysiological disorders ranging from
atherosclerosis5 to cancer 6' . Alterations in these metabolic parameters can serve both
as an early indicator of disease in Alzheimer's8 and response to anticancer therapy 5''' 9 .
Oxygen plays a key role in the metabolic microenvironment; promoting stem cell
development', modifying tumor progression, modulating metastasis10-12 and
moderating response to therapy13. Interestingly, the effects of oxygen depend on the
concentration, which varies greatly in both normal and disease processes. Further, the
oxygen gradient in the tissue microenvironment does not always necessarily correlate
with supply from the vasculature, particularly in disorders such as cancer where vascular
architecture is abnormal. Therefore, an ideal tool for quantifying oxygen concentration
would enable high-resolution three-dimensional measurements at significant depths in
the context of the surrounding tissue microenvironment.
The quenching of phosphorescence by molecular oxygen provides an optical method for
measuring oxygen tension (P02). Since the biological application of this technique was
first introduced by Vanderkooi and co-workers'4 , phosphorescence quenching
microscopy (PQM) has been utilized to measure both vascular and interstitial p02
gradients in vivois- 7. Unfortunately, these techniques offer decent lateral spatial
resolution, but limited tissue penetration (~50 tm) and no depth resolution. In the past
decade, a novel form of optical microscopy has been developed utilizing ultrafast lasers.
This technique, multiphoton microscopy (MPM), provides non-invasive optical imaging
with significant depth penetration at high three-dimensional resolution'1 9. The intrinsic
properties of multiphoton excitation allow MPM to image fluorescently labeled
structures in tissue with a three-dimensional resolution of ~1 pm up to depths of 450-
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600 tm, depending upon the tissue type. The simple theory behind multiphoton
microscopy allows for implementation in a variety of experimental designs. The
compounds that are used for imaging can be quite versatile, permitting the use of some
that respond to tissue physiology. This allows for simultaneous imaging and
physiological monitoring of tissue.
This Chapter introduces the technique of multiphoton phosphorescence quenching
microscopy (MP-PQM) developed for routine in vivo use in a variety of biological
models. The methods of phosphorescence quenching microscopy will be described in
context of luminescent lifetime measurements. The principles of multiphoton
microscopy will be briefly discussed; highlighting considerations in the use of
phosphorescent luminophores. The development, design, characterization and
implementation of MP-PQM will then be presented. Finally, some brief physiological
studies utilizing MP-PQM will be illustrated. Measurement of oxygen in the tumor
microenvironment is reserved for Chapter 4.
111.2 Experimental Design of MP-PQM
Multiphoton microscopy provides the capability of imaging deep in biological tissues
with an intrinsically defined three-dimensional excitation focus of femtoliter volume
limiting out of plane photobleaching 921. Further, the use of near-infrared excitation
(700-1000nm) which is within the "optical window" of biological tissue22 allows deep
tissue penetration (up to 1mm depending on tissue type)23 . Details of the relative merits
and photophysical processes underlining multiphoton excitation have been described in
the Introduction. This section describes the decisions and development of MP-PQM for
use with phosphorescent metalloporphyrins.
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Figure 1ll-1 Methods to measure luminescent lifetime. (a). In the time domain, lifetime is directly
measured from the exponential decay after an excitation pulse. (b). In the frequency domain, lifetime is
determined from both the phase delay, #, and modulation, m.
111.2a TIME DOMAIN VERSUS FREQUENCY DOMAIN
There are two techniques for measuring the luminescent lifetime of a molecule which
are related through the Fourier transform. The time domain, or impulse method, can be
technically difficult for short lifetimes or complex decays, but it directly outputs the
emission decay24. Simply, in the time-domain a pulse of excitation light much shorter
than the luminescence lifetime is used and the decay of emission is measured from the
end of the pulse. The decay is typically fit to a single or multiple exponential decay
depending if the sample is heterogeneous or not.
e(t) = Ic -% 1(t) = Ae-I/i 111.1
The second technique is the frequency domain or phase-modulation method whereby
luminescence is excited by intensity-modulated light 24. The excitation is modulated at a
frequency comparable to the inverse of the lifetime (to oc 2wr x r-1) with delayed
luminescence responding with the same frequency but phase-shifted (<p) and reduced in
modulation (m). The lifetime can then be determined from the following relationships.
................................................................
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tan <p = 11r M + 2 2 I .
There is debate over which method of lifetime measurement is better. What has been
demonstrated is that frequency-domain measurements are ideal in high signal
environments and posses a faster measurement duty cycle25. However, in low signal
environments, the time-domain methods, particularly single-photon counting, provide
much better signal to noise ratios (SNR) and have been shown to determine lifetimes
with greater accuracy 26 . The basic principles of the two measurement types are shown
in Figure 1ll-1.
The application of time-domain luminescence imaging has been performed in
multiphoton microscopy in a variety of ways. The three most common are: 1) pulse-
picking with time-gating" [Eq. 111.3], 2) time-correlated single photon-counting28
triggered by each selected pulse or 2) the streak-camera method which measures
spatial temporal intensities along a single line scan (x, t) and creates a lifetime image
(x, y, -) by fitting exponential decays [Eq. 111.1] to each temporal component 29.
AT
nl(IA/IB)
Here in Eq. 111.3, the calculation of lifetime is given for time-gating with two gates (A, B)
with an interval of AT separating them.
Frequency-domain lifetime measurements have been effectively performed to measure
luminescent lifetimes in vitro30, but to date no studies have been successfully
demonstrated in animals larger than C. elegans25. Further, in larger animal models, such
as mice, the amount of luminescent probe will likely be very low, except in the
vasculature, limiting SNR for frequency domain techniques. As will be shown, this is
particularly the case for Pd-porphyrins which have a low two-photon absorption cross-
31section . In addition, this limits the ability to provide appropriate modulation to the
excitation signal to excite the porphyrins probe at all times.
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III.2b EXPERIMENTAL SETUP
To perform MP-PQM, I chose to use the single photon counting technique triggered by
the selection of pulses from the excitation source. While the time to collect
measurements is increased in the time domain, it permits the integration of signal to
improve SNR, a critical factor for in vivo measurements. Additionally, the analysis of the
lifetime decay is straightforward and simple enough to include fitting to multiple
components. Additionally, online analysis of the lifetimes permitted real-time display of
the oxygen tension.
To adapt the technique of multiphoton microscopy to PQM, the rate of porphyrin sensor
excitation must be taken into account. The lifetime of the sensor, Ts, is much greater
than the ~100 femtosecond pulses from the excitation laser source, TL. However, the
repetition rate, f, of the laser is much faster than the decay of phosphorescence. For
multiphoton excitation, the commonly used Ti:Sapphire laser has a repetition rate of
~80Mhz. This limits the time between pulses to only 12.5ns, much shorter than the
lifetime of Pd-porphyrin in the presence of oxygen (10 - 700ps). To overcome this
obstacle and modulate the excitation of the porphyrin at a rate greater than its decay, I
chose to use an electo-optic modulator.
Electro-optic modulators (EOM) have been successfully applied to multiphoton
microscopy to perform fluorescence recovery after photobleaching (FRAP) 32. In the case
of lifetime measurements, no monitoring power is required, only a brief excitation pulse
is used. Another group has employed an acousto-optic modulator (AOM) for temporal
gating in lifetime measurements33. Acousto-optic modulators typically have better
extinction ratios than EOMs. However, because the emission is dependent on the
quadratic (or higher) excitation of light in multiphoton microscopy, the contribution of
extinction phase is minimal. Two characteristics of AOMs prompted my selection of an
EOM: 1) AOMs are slower at switching than electro-optic modulators; 2) group delay
dispersion (GDD) is also higher than EOMs, increasing the femtosecond pulse duration
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and reducing multiphoton excitation3. GDD can be corrected, but with additional often
complex optics3s
The MP-PQM system incorporates a KD*P Pockels cell (Model: 350-50; Conoptics, Inc.,
Danbury, CT) EOM and accompanying amplifier/driver as the temporal gate for pulse
selection. The duty cycle (excitation pulse width x repetition rate) of the Pockels Cell
was operated in the range of 0.1-0.6%. This equates to excitation pulse durations of
approximately 1.28 to 15.36ps for rates of ~680 to 360 Hz, respectively. These repetition
rates allowed even the longest decays to be recorded, while permitting biological
recovery of the sample between excitation pulses. Excitation pulses shorter than 1.28ps
in solution (1mg/ml) or ~5.12ts in vivo did not produce any observable
phosphorescence.
The voltage to the EOM was modulated by custom-built electronics; amplifying and
switching the triggering pulses from a digital delay generator (DG535, SRS, Sunnyvale,
CA). The experimental square wave trigger pulse originating from the DG535 defined
the repetition rate; while a second delayed square wave pulse defined the excitation
pulse. The voltage and hence laser power of the excitation pulse was adjusted by
custom pulse conditioning electronics. As mentioned, the excitation pulses ranged from
1.28 to 15.36 ps in duration indicating that sample excitation was performed by a train
of femtosecond Ti:Sapphire laser pulses ranging in number from ~100 to 1230. These
durations were still shorter than the experimental lifetimes of the phosphorescent
porphyrins oxygen sensor. Using an oscilloscope (Model: TDS-3052, Tektronix,
Beaverton, OR) and photodiode at the rejection site of the EOM, the applied voltage and
optical response were monitored.
To perform photon counting, I used a multichannel scaler (SR430, SRS, Sunnyvale, CA) to
histogram the counts with bin sizes ranging from 1.28 to 10.24ps depending on the
experimental protocol. Typically, the number of bins was maintained at 1K (1024).
However, for long decays the bin number was increased to 3K depending on the bin
size. The number of records accumulated by the multichannel scaler was adjusted for
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each bin size to keep the integration time equivalent across an experiment. The
integration time was usually maintained at 6.5s for in vivo and ~3s for in vitro
measurements.
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Figure 111-2 Mufliphoton Phosphorescence Quenching Microscopy Setup. Modification to the MPM
instrumentation permitted time-domain measurements of phosphorescent lifetime for real-time oxygen
quantification. Tp,, - temporal duration of the excitation pulse width. T., - duration of the experimental
triggering time, i.e. one single pulse and photon counting record. Arrows indicate direction of
communication. Dashed grey lines to the computer control were 2-way.
Phosphorescent emission (~690nm) of the Pd-porphyrin was detected by a GaAs
photomultiplier tube (PMT; H7421-50, Hamamatsu, Inc., Bridgewater, NJ) for the
majority of experiments. This detector has a quantum efficiency (QE) of ~10% around
700nm. To enhance detection, I employed a silicon avalanche photodiode detector
(APD; SPCM-AQR-12-FC, PerkinElmer, Fremont, CA) with a QE of 70% at 700nm. In non-
turbid media, the collection efficiency (CE) of the setup with the APD was ~8x better
than the GaAs PMT. However, in vivo measurements in highly scattering thick tissues
revealed a lower CE for the APD.
The components for MP-PQM were incorporated into a custom-modified multiphoton
microscope based on the Fluoview 300 laser scanner (Olympus FV300, Optical Analysis,
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Center Valley, PA). A broadband (710-1020nm) Ti:Sapphire femotosecond laser (MaiTai
HP, Spectraphysics, Mountain View, CA) was used as the excitation source. The output
of the laser was adjusted using a zero-order half-wave plate (10RP52-2, Newport Corp.,
Irvine, CA) and Glan-Laser polarizer (10GLO8AR.16, Newport Corp., Irvine, CA). During
phosphorescence quenching microscopy, the maximum laser power was permitted to
pass and intensity modulation was performed by the electro-optic modulator. Due to
magnification of the beam diameter in the EOM and the limited reflective area of the
galvanometer scan mirrors, no beam expansion was needed. I did determine that the
output of the EOM did not experience beam divergence over 5m. Silver coated mirrors
(PF10-03-PO1, Thorlabs, Newton, NJ) were used for all beam steering.
The scanned output of the galvanometers was collimated through a scan lens into the
back of a microscope (Olympus BX61WI Optical Analysis, Center Valley, PA). The near-
infrared excitation light and visible emission were separated using a short-pass dichroic
mirror (720DCXPR, Chroma Technology Corp., Rockingham, VT). Focusing and collection
of light was performed with a 20x, 0.95 NA water immersion objective lens (Olympus
XLUMPIanFI, Optical Analysis, Center Valley, PA). Given the short spectral separation
between the long emission of the phosphorescent sensors (~690nm) and the excitation
laser wavelengths, a short-pass (<750nm) AR-coated filter was used in the detector path
(750SP-2P, Chroma Technology Corp., Rockingham, VT) to limit background counts from
the laser. A 690/90 bandpass filter (690/90M, Chroma Technology Corp., Rockingham,
VT) and focusing lens were used in front of the GaAs PMT to collect phosphorescent
emission. The complete experimental setup is illustrated in Figure 111-2.
Lifetime measurements were performed by a stationary beam and not in scanning
mode. Typically, the excitation beam was parked in the center of the field of view (FOV)
and the intensity was modulated by the EOM. Different points in the sample were
measured by scanning the sample with an automated mechanical XY stage (H101; Prior
Scientific, Rockland, MA). Axial depth was adjusted using the automated focusing
apparatus built into the microscope and the accompanying Fluoview software (Olympus,
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Optical Analysis, Center Valley, PA). For point measurements in a single FOV
(intravascular), the stationary beam was manually positioned using the software.
Figure 111-3 Custom
environment.
III.2c MP-PQM
user interface for MP-PQM experiments. Programming performed in LabView
EXPERIMENT PROTOCOLS
The MP-PQM instrumentation was automated and controlled by a custom-built user
interface (Figure 111-3) created in the LabView programming language (National
Instruments, Austin, TX). This interface automated five different experiment protocols
for collecting oxygenation data.
1. Single Point Measurement - ideal for quantifying oxygen within the vasculature.
Allows the user to select points and collect data from each point. Beam
positioning is performed manually.
2. Vessel profiles - performs a series of linear measurements with spacing defined
by the user. Allows the user to measure oxygen profiles from single vessels by
defining the imaging angle in the focal plane that perpendicularly bisects the
vessel (Figure ll-4a). Beam positioning is automated.
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Figure 111-4 MP-PQM experimental protocols for in vivo measurements. (a). Vessel profile measurement
from a single tumor (HT1080) vessel. (b) Oxygen tension map of an entire tumor (Mu89) at a single depth.
Image is a depth projection. (c) Krogh cylinder measurements in the capillary network of skeletal muscle
tissue. Image is a depth projection.
3. Oxygen Tension Maps - performs measurements in a rectangular grid pattern in
a region of interest (ROI) and grid size defined by the user (Figure 1ll-4b). The
user manually selects an ROI in the sample using the motorized stage. To
automatically determine the measurement points within the grid, the user
specifies the number of grid points in the X and Y direction. For a 12 x 12 grid,
the measurement time is approximately 16 minutes (144 points). The oxygen
tension map is collected in a raster pattern. To measure at different depths, the
user manually focuses to the specified depth and inputs it into the interface.
Defining an ROI also permits the user to image the sample with the multiphoton
microscope in a raster pattern with mosaic tiling determined by the FOV size.
4. Muscle (Krogh Cylinder Measurements) - Quantifies oxygen in regularly spaced
capillary networks typically found in skeletal muscle. This mode is typically used
for performing three-dimensional measurements of the Krogh tissue cylinder.
Analogous to the vessel profile measurements, the user defines the imaging
angle in the focal plane that lies perpendicular to the capillary network with
respect to the vertical axis. A series of grid measurements at different depths are
performed with spacing defined by the user (Figure Ill-4c).
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5. FOV Oxygen Tension Map - Similar to the oxygen tension map, except a user-
defined ROI is not required. A raster grid pattern of measurements is made
within the confines of the objective field of view.
In all experimental protocols, the oxygen tension is calculated in real-time using Stern-
Volmer (see Chapter 1) calibration values for the sensor. Single and two-component
exponential fitting [Eq. 111.4] to the phosphorescent decay is performed within the
LabView environment by code written in MatLab (MathWorks, Natick, MA). Two
different fitting algorithms are utilized. One performs an unconstrained nonlinear
optimization to find the decay constants and amplitudes that minimize the residuals.
The second performs a constrained nonlinear least squares fit (Levenberg-Marquardt
algorithm) to the raw data to find the same parameters. The difference in fit values is
less than 5% between the two methods. However, the unconstrained minimization
procedure fits data with low SNR much better than the Levenberg-Marquardt algorithm.
The importance of the single and two-component fitting of the lifetime data will be
discussed in the Calibration section.
I=Ae-+C I =Ae/T +Be-t 2 +C II14
111.3 Multiphoton Excitation of Pd-Porphyrin p02 Sensor
The initial challenge in developing multiphoton phosphorescence quenching microscopy
was characterizing the multiphoton excitation properties of the oxygen sensor. The
porphyrin molecule used for all studies was a Pd-meso-tetra-(4-
carboxyphenyl)porphyrin dendrimer (OxyphorR2, Oxygen Enterprises, Ltd., Philadelphia,
PA). For experiments, both the ideal excitation wavelength and evidence of multiphoton
excitation (MPE), or two-photon excitation in this case, at that wavelength needed to be
determined. Further, the phosphorescence lifetime is always much greater than the
timing between femtosecond laser pulses, so the effects of excitation saturation needed
to be explored. Employing equations describing phosphorescence saturation under
pulsed illumination, I show that saturation was not obtained during typical experiments.
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Figure 111-5 Two-photon excitation of Pd-porphyrin phosphorescent oxygen sensor. The nonlinear
behavior of the phosphorescence with excitation power is observed for both 900 and 1020nm excitation
in these logarithmic plots.
III.3a Two-PHOTON ExcITATION OF PD-PORPHYRIN
It has been previously demonstrated that the two-photon absorption cross-section of
the tetraphenylporphyrin free base is very low compared to typical fluorophores31 .
Literature values of only 1-6 Goppart-Meyer (GM, 10~50 cm4 s~1 photons-' molecule')
were reported. For in vivo measurements, particularly in the interstitial space, low
concentration of sensor further diminishes the phosphorescent yield. The low yield
requires the accumulation of a series of pulses in the time-domain to improve SNR
(111.2).
In two-photon excitation of luminescence, the emitted intensity should be proportional
to the square of the excitation intensity: I, oc I, 19. To determine if the excitation of the
phosphorescent sensor occurred by a two-photon process, I measured the
phosphorescent emission with different excitation laser powers. Measurements were
performed in anoxic (0% p02) phosphate buffered solutions (PBS) at pH 7.4 and 37 *C.
The phosphorescent lifetime was fit from the point immediately after the excitation
pulse to determine the average background counts within each photon counting bin, C
in Eq. 111.4. The background count was then subtracted from the signal within each bin.
To obtain total emission counts, the signal was then summed from immediately after
the excitation pulse to the end of the measurement period. Alternatively, an estimate of
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total photon counts can be obtained by integrating the single exponential decay [Eq.
111.1] to infinity: IOr. The excitation of phosphorescence was found to be a two-photon
process for excitation at both 900 and 1020nm (Figure 111-5). In vivo two-photon
excitation (n ~ 1.84) was also confirmed for intravascular measurements at 900nm
(Figure 111-6). Further, the in vivo measurements were performed in the presence of the
MPM angiographic marker fluorescein isothiocyanate (FITC) - dextran 2M MW. Because
the photon counts were determined from lifetime measurements, this experiment
illustrated that FITC-Dextran2M does not affect MPE or lifetime of the P02 sensor.
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Figure 111-6 In vivo two-photon excitation of Pd-porphyrin oxygen sensor. Nonlinear excitation of
OxyphorR2 sensor in the vasculature of a tumor (left). A series of time-domain lifetime measurements
were performed in the center (*) of a perfused tumor vessel (right). Green - fluorescein isothiocyanate -
dextran 2M MW used for MPM angiography.
To determine the two-photon excitation spectrum (action cross-section) for the Pd-
porphyrin oxygen sensor, I measured the photon counts after time-domain pulsed
excitation analogous to the nonlinear power spectrum. The excitation spectrum for
MPM was obtained from 780-1020nm keeping the total power at the sample constant.
Slight fluctuations in the true action cross-section would occur due to differences in
photon energy, i.e. the number of photons incident on the sample, for the longer
wavelengths. However, this contribution should be minimal to the shape of the
spectrum. For comparison, the single-photon excitation spectrum was obtained using a
spectrophotometer (Beckman Instruments Inc., Fullerton, CA) with continuous
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illumination from the visible to near infrared (400-1000nm). The single- and two-photon
excitation spectrums both share similar shapes (Figure 111-7), although the two-photon
spectrum is slightly broader and blue-shifted due to different parity-selection rules
between the two excitation processes21. The quantum yield of phosphorescence is
~10%36,37 and should be the same for two-photon excitation since luminescence
emission does not change with nonlinear excitation processes38
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Figure 111-7 Single- and Two-photon action cross-sections for Pd-porphyrin soluble oxygen sensor. The
notable features of single-photon excitation spectrum are visible in the two-photon action cross-section.
The single photon excitation spectrum also shows no absorption/emission in the wavelength range used
for two-photon imaging (780-1000nm). The lone peak at 690nm is due to excitation light at the same
wavelength as the emission band-pass filter in the spectrophotometer.
As can be seen in Figure 111-7, there are two possible choices for excitation of the oxygen
sensor: ~800 or ~1020nm. I selected to use 1020nm for the following reasons:
1. Although absorption of water is around 5x less at 1020nm than 800nm 34, more
biological molecules, such as NADH, have much higher two-photon absorption at
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800 than 1000nm 39. Further, studies have shown increased cellular damage at
wavelengths ~800nm than those above 980nm 34.
2. The excitation light at 1020nm is less scattered than 800nm light due to the
inverse dependence of scattering on the fourth-power of the wavelength.
According to the principles of Rayleigh scattering, 800nm is 2.6x more scattering
than 1020nm. This should improve excitation deeper in tissue at powers lower
than would be needed for 800nm.
3. Excitation light at 800nm is very close to the phosphorescence emission, which
extends to 780nm. Therefore it is difficult to separate the laser light from the
emitted photons, particularly when using highly sensitive detectors to the near-
infrared light range.
III.3b PHOSPHORESCENCE SATURATION
The luminescence of a molecule is a function of its excitation intensity. However, this
relationship is not linear at all excitation intensities. As incident illumination is increased,
the ground state of the luminescent molecule is depleted and the excited state(s)
populated. The photophysical properties of a molecule, defined by its electronic excited
states (Figure 11-2) and their lifetimes (rate constants), and its initial concentration limit
the maximum emission intensity. This can be summarized in a simple equation:
N
oc kilex 111.5
NTO
where Ng is the number of molecules in the ground state, NTot is the total number of
molecules, kg represents all rate constants defining the molecular states, and I,x is the
excitation intensity. Precise equations of state for common fluorescent molecules like
fluorescein under continuous wave illumination have been worked out in detail by
others40 . These derivations take into account all possible pathways for excited molecules
including triplet states and photobleaching (irreversible loss of fluorescence). The
saturation of luminescence can be used to determine many photophysical constants
including the absorption cross-section, molecular state lifetimes, quantum yields and
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luminescent lifetimes. Interestingly, fluorescence saturation experiments have been
proposed as a possible use to characterize complex organic compounds"1 .
For fluorescent compounds, ignoring any triplet state contribution, the steady state
fluorescence emission under single photon illumination is (adapted from 34):
Qf kfN, = aQfkf 111.6Q~S1=a + kf I.
Here, Qf is the quantum efficiency of fluorescence, kf is the fluorescence decay rate, a
is the excitation rate (uI), and N1 is the number of molecules in the excited singlet state.
Eq 111.6 illustrates that after an initial linear increase in the fluorescence with excitation
intensity, the fluorescence emission slowly plateaus.
Phosphorescence saturation has been investigated since the 1940s, starting with G.N.
Lewis42 . The saturation properties of phosphorescence, due to its long-lived nature,
have allowed the investigation of many interesting photophysical properties such as
paramagnetism42. Under continuous illumination by a light source (laser), a
phosphorescent molecule would reach steady-state saturation in a time defined by:
(kzo + Qisc akl - 111.7
a + k1i
where k2o and kjo are the decay rates of the triplet and singlet states, respectively. The
quantum efficiency of intersystem crossing is given by Qisc.
I estimated kjo for the OxyphorR2 Pd-porphyrin used in this study to be 4.00 x 108 s1
based on literature values for other porphyrins43. The quantum efficiency of
phosphorescence for Oxyphor R2 is reported to be 10%36. To estimate the time constant
for continuous wave illumination at 1020nm, but with two-photon absorption, a is given
by a 2 2. The two-photon absorption cross-section for Pd-porphyrins has been reported
to be in the range of 1-2GM. Assuming a constant illumination of 1mW (5.1 x 1015
photons s') and a maximum phosphorescence lifetime (k2 j 1 ) of 650ps, a time
constant of 650ps is obtained. However, true MPE utilizes a pulsed laser source, which
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greatly enhances the excitation power by packing photons into small pulses. The
squared power dependence is actually given by the average squared intensity rather
than the squared average intensity of continuous wave excitation21 :
(I(t)2 ) gp(I(t)) 2  111.8fT-
where gp is a factor that describes the beam shape (0.66 for Gaussian beam), f is the
laser repetition rate (~80MHz), and T is the pulse width (~150fs). Employing Eq 111.8 to
determine a obtains a steady-state time constant of 25ns.
Three issues must be addressed here regarding saturation determined in this manner.
First, the phosphorescence saturation will be dependent on the concentration in the
sample. Second, for every one emitted photon, two were introduced for two-photon
excitation. Finally, Eq. 111.7 does not take into account the temporal characteristic of the
laser source during which excitation only occurs within the femtosecond pulse.
Applying the derivation of Xu and Webb 38, a rate equation for the population of the
ground state for each ensuing pulse can be written:
No (n + 1) = NTOT - [aQjscNo (n) + NTOT - No(n)]e /T2f 111.9
Here, n denotes the number of pulses, TC2 is the phosphorescence lifetime, a is
excitation probability per pulse and NTOT is the total population or No prior to any
pulses (n = 0). It is assumed that the intersystem crossing rate is much faster than the
repetition rate (Tsc « f ). Because the excited singlet to ground state transition rate,
kjo ~2.5ns, is less than the pulse separation (~12.5ns), the population of the singlet
state can be ignored (NTOT = NO(n) + N2 (n)). Therefore an equation for the triplet
state population can be obtained:
aQisc [1 - (1 - aQsc)ne '1T2f
e/T2f + aQisc - 1
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Assuming that there is a 1% probability (a = 0.01) that molecules in the focal volume
are excited by a single pulse, which is a generous assessment for the MPE of this
porphyrin given the small two-photon cross-section, and the number of laser pulses in
the range of excitation pulse durations for MP-PQM (205 - 1230), a triplet state fraction
N2(n)) from 0.2 to 0.7 is obtained for a phosphorescence lifetime of 650ps. These values
NTOT
are below saturation for nearly the longest detectable lifetime of the phosphor. In
section Ill.5a the experimental effect of excitation pulse duration will be fit to this model
to define the effect on phosphorescence saturation.
III.4 Calibration of MP-PQM p02 Measurements
To quantify oxygen tension using phosphorescence quenching microscopy, the
parameters of the Stern-Volmer relationship must be determined. Assuming a linear
Stern-Volmer relationship, a minimum of two measurements at known oxygen tension
is required. For some phosphorescent porphyrin sensors, it has been reported that the
dynamic quenching response was nonlinear44. In this case at least 3 calibration
measurements are needed and fit to a second order Taylor expansion of the Stern-
Volmer relationship.
1 1
- = - + kq [P 0 2]+ kg [p02] 2  111.11
T TO
III.4a CALIBRATION CONSIDERATIONS
Because the absolute concentration of oxygen in tissue depends on Henry's law 45 [Eq.
111.12], for which the coefficient is often unknown and variable in vivo, calibrations are
performed for the oxygen tension or partial pressure of oxygen (P02). Additionally,
temperature affects the solubility of oxygen and therefore Henry's constant (derived
from van't Hoff Equation, Eq. 111.13), so all calibrations should be performed at the
temperatures found in vivo (32-370C). Calibrations are performed in PBS, so if actual
oxygen concentrations are desired Eqs. 111.12 and 111.13 can be used.
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P 0 2 = kH [02] 111.12
AH' 1 11
kH,T = kH,298K exp R T T' III.13
Here, Henry's constant is kH, AH' is the enthalpy change of the solvent (PBS) at
standard temperature and pressure, R is the gas constant, and T is the temperature of
the sample.
The Pd-meso-tetra(4-carboxyphenyl) porphyrins dendrimer used for oxygen sensing
(Oxyphor R2) is susceptible to other parameters in its local environment that should be
addressed. Most importantly is the binding of the sensor to albumin or other binding
proteins in vivo. In general, the lifetime increases and quenching constant decreases
with increasing concentrations of albumin3637 46. Studies have suggested that the effects
on Stern-Volmer sensing parameters are saturated at physiological concentrations of
albumin 6,37,46 . However, as will be shown, MP-PQM discerns differences at even higher
concentrations of albumin. This prompted me to explore the development of a two-
phase or two-component calibration mechanism as presented in the next section.
Additional parameters that may affect kq and roare the temperature, pH, and tonicity
(ionic strength). The effect of temperature on Tois significant, however it is also follows
a linear relationship. As temperature increases, the lifetime of the phosphor decreases
due to increased molecular collisions and therefore increased quenching. For Oxyphor
R2, it has been shown that the quenching constant, kq, increased by 3% per *C and the
lifetime in the absence of oxygen, -ro, decreased by 0.7% per degree with increasing
temperature36. The pH has been shown to have minimal effect on the calibration
constants in the range of extracellular pH (pHe) found in vivo in both normal and tumor
tissues (6.4 - 7.4)36,37. Similarly, the tonicity showed no effect in the same study.
Therefore in considering calibration of the phosphor for in vivo measurements, I chose
to perform all calibration procedures at 32 or 37 0C and a pH of 7.4 in PBS. If the
temperature of the sample under investigation is kept constant within this range of
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temperatures, kq may change by up to 15% and To by 3.5%. The error in calculated P02
is determined by these two parameters can be estimated47:
AP02 = P02Akq 0 111.14kq kqro TO
For P02 values measured in tissue (0 to 60mmHg) this gives an error of around 0.15 to
9mmHg. In general, due to homeostasis and proper maintenance of the sample
temperature, the error in kq and To should be much smaller, typically around 1-2%.
Further, the measurement error will also depend on the sample P02 since the technique
is most sensitive to low P02.
Peristaltic
T nn
Tu git
Variable
Fiber Optic s-10mt/min
Oxygen Probe
Calibration
Solution Fiber
In Water Bath Oxygenator
Flow Cell
Heating Pad
Figure 111-8 Recirculating sealed calibration system employing a fiber oxygenator. Diagram of the
calibration setup indicating direction of fluid and gas flow and placement of flow cell for MP-PQM. An
independent PO2 measurement is made with an optical fiber ruthenium-based probe.
III.4b CALIBRATION PROCEDURES
The simplest procedure for calibrating the phosphor oxygen sensor is to bubble known
mixtures of oxygen and an inert (no dynamic quenching) gas like nitrogen into an
aqueous solution of phosphor. Typically, the solutions are allowed to mix for 20-30
minutes which allows the partial pressure of oxygen in the gas mixture to equilibrate
with the solution. The calibration samples are then placed in a sealed capillary tube or
other optically transparent material that is impermeable to oxygen. This procedure has
been successfully employed in a number of studies-' 17 '47'48, often coupled with an
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independent measure of P02. The solutions are either saline (PBS) or plasma from the
blood of the experimental animal.
Other methods for calibrating the oxygen sensor take advantage of enzymatic and
chemical reactions that consume oxygen. The two most common enzymes and
substrates used in the literature are: 1) ascorbate oxidase and ascorbate37 or 2) glucose
oxidase (with catalase) and glucose'6 . Chemical consumption with sodium dithionite has
been successfully used to titrate the amount of soluble oxygen for phosphorescence
measurements49. In the appropriate environment, all of these oxygen consuming
reactions are capable of producing anaerobic solutions.
To perform PO2 calibration measurements, I developed a sealed recirculating system
employing a fiber oxygenator to equilibrate the circulating fluid with gas mixtures of
known oxygen concentration balanced with nitrogen (Figure 111-8). The inclusion of a
fiber oxygenator reduced surfactant effects observed with solutions containing albumin.
The oxygen tension in the calibration solution was independently measured using a fiber
optic ruthenium-based sensor (FOXY, Ocean Optics, Inc., Dunedin, FL). All tubing in the
system was impermeable to oxygen (Tygon PVC, McMaster-Carr Supply Co.,
Robbinsville, NJ). Flow was maintained at 5-10ml min' by using a peristaltic pump
(Ismatec 7331-10, Cole-Parmer Instrument Co, Vernon Hills, Illinois). A solution of 1mg
ml' (3.6 x 10~4 M) OxyphorR2 in PBS at pH 7.4 was equilibrated with known nitrogen gas
mixtures of 0, 1, 2, 5, 10% oxygen (0-80mmHg) using a fiber oxygenator (Hemophan*
Membrane Fiber Oxygenator, Harvard Apparatus, Holliston, MA). The oxygenator had
an 18ml priming volume, so ~50 ml of OxyphorR2 solution was prepared for each
calibration. After equilibration with the applied gas mixture, the solution was passed
through an oxygen impermeable spectrophotometer flow cell with 500gm thick walls
(45-Q-2, Starna Cells, Inc., Atascadero, CA). MP-PQM calibration measurements were
performed within the flow cell. Both the calibration solution reservoir and flow cell were
maintained at 37'C.
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Figure 111-9 MP-PQM calibration of Oxyphor R2: in the absence (a) and presence (b) of varying BSA
concentrations. Solid lines are linear regression fits to the data to determine the Stern-Volmer constant.
The Stern-Volmer constants (kq) for Oxyphor R2 solutions containing 0, 1, 2, 3, and 4%
by weight bovine serum albumin (BSA, Sigma-Aldrich, Co., St. Louis, MO) were
determined using this system (Figure 111-9). All measurements were made at 370C and, if
necessary, the pH was adjusted to 7.4. The bin size on the multichannel scaler was set to
2.56 pts/bin and the pulse duration was 5.12 pts for all measurements. MP-PQM
calibration measurements commenced once the measured lifetimes stabilized. This
usually took 15-20 minutes after initiating the system. As can be seen from the linear
fits, the quenching constant decreases with increasing BSA concentration (Table ll-1).
At low BSA concentrations (1-2%), the data does not fit as well (increased standard
error). However, these concentrations are below physiological levels of albumin and
other binding proteins found in vivo.
Table Ill-1: Stern-Volmer Quenching Constants determined by linear regression for single exponential
decay.
BSA (% b/w) kg (mmHg' s-) SE -95% Cl +95% Cl
0% 3205 78 2957 3453
1% 480 46 332 627
2% 385 17 310 460
3% 357 8 333 382
4% 322 1 317 327
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Figure 111-10 Schlenk line freeze-pump-thaw method. Samples are shown during the pump process to
create deoxygenated solutions
The values of kq determined by MP-PQM and the recirculating calibration system fit
those in the literature very well. The Wilson group, who developed the Oxyphor R2
sensor, reports a quenching constant of 430±10 mmHg 1s 1 for 1.5% albumin at 380C and
a pH of 7.4.36 In a separate paper, they report a kq of 410 mmHg-'s 1 at 2% BSA46.
The fiber oxygenator calibration system served well for obtaining quenching constants,
but not the anoxic lifetime of the OxyphorR2. Pure deoxygenated solutions are very
difficult to obtain, even in closed systems. The method of freeze-pump-thawing yields
solutions that are almost entirely anoxic. This method employs flash-freezing of the
solution with liquid nitrogen followed by opening the sample to a high vacuum (Figure
111-10). Once the pressure reaches the baseline value of the vacuum, the sample is
closed and the gas is released as the solution is thawed with warm water. The process is
repeated until upon reopening of the sample to the vacuum, no change in pressure is
observed. Schlenk flasks modified with a quartz 10 mm pathlength cuvette (Starna Cells,
Inc., Atascadero, CA) created by James Glass, Inc (Hanover, MA) are used in the process.
Over repeated cycles the vapor pressure above the frozen solution is reduced to the
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order of 10-6 Torr. These low vapor pressures are obtained by an Edwards (West Sussex,
England) B34431976 diffusion pump.
Using the vacuum line freeze-pump-thaw method, solutions of Oxyphor R2 containing
different amounts of BSA at pH 7.4 were deoxygenated. The anoxic lifetimes were
determined using MP-PQM. Using a single exponential fit, it can be seen that to
continues to increase, even at 10% BSA (Table Ill-1). Unlike single-photon
measurements which excite a large volume of phosphor throughout the samples, MP-
PQM appears sensitive to unbound (free) phosphor.
Table 111-2: Oxyphor R2 calibrated lifetime in anoxic conditions (TO).
BSA % (b/w) To Se ro Bound* SE
0% 273.7 0.4
1% 407.8 1.5 746.2 13.1
3% 483.2 1.4 726.9 7.0
5% 524.7 0.6 723.0 3.7
7% 534.1 1.1 712.3 5.1
10% 584.6 1.5 722.3 7.0
+ - Standard error of at least 10 measurements
* - To of bound component determined by fitting to two-component decay with free o constrained
III.4c Two-PHASE CALIBRATION
When the calibration solutions were absent of any albumin, single exponential decays
[Eq. 111.4] fit the data extremely well with evenly distributed residuals. However, in the
presence of albumin, the single exponential fits were poor demonstrating residuals that
skew at the early timepoints (Figure Ill-11a). These effects for single-component fitting
were also seen in most in vivo measurements. This suggested that there may be two or
more species contributing to the phosphorescence decay. In the case of the calibration
solutions, there were assumed to be only two states for the phosphor molecules:
albumin bound and free.
[phosphor] + [BSA]++ [phosphor - BSA] 111.15
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Each of these states contributes to the phosphorescence decay proportional to their
concentration. It appears that the high-resolution of the MP-PQM is sensitive to the
contributions of the two components.
a.b. Two-Component
6o Single Exponential Decay Exponential Decay
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Figure Ill-11 MP-PQM disecerns two species of phosphor In the presence of albumin. At 10% BSA (b/w),
fitting to a single exponential (a) results in skewed residuals, particularly at early timepoints (*). By
constraining the known lifetime of the soluble free species in a two-component exponential decay, the
lifetime of the bound species can be determined. The fit demonstrates evenly distributed residuals (b).
Using the anoxic lifetime determined in the absence of albumin, I fit each of the
deoxygenated solutions to a two-component exponential decay model [Eq. 111.4] to
determine 1o of the albumin bound species (Table 111-2). The bound lifetime determined
for each solution was independent of albumin concentration above 1% (P-value: 0.21).
The mean anoxic lifetime was determined to be 726.1 ± 6.2ps. The constrained two-
component exponential decay fitting produced evenly distributed residuals at all
timepoints (Figure Ill-11b). Additionally, the fraction of bound and free species could be
calculated by determining the emission due to each species using the product of the
exponential amplitude and the lifetime for each species.
In order to properly measure PO2 in vivo, the effect of both species on phosphorescence
should be taken into account. Therefore, assuming both species follow a linear Stern-
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Volmer relationship, I derived an equation to relate the lifetimes of the two species at
any P02. At a given oxygen tension the following relation should hold:
- -l( - -- = - - - - -- 111.16k'q,1 0 ro,= kq,2 T2 7o,2)
where the numbered subscripts denote each of the two species. Solving for the lifetime
of the second species gives the same form as the original Stern-Volmer relationship.
1 1 1 1
k + -- 111.17
T2 kg, 1 (ri r1 ,2 T,
This relationship can now be replaced in Eq. 111.4 to fit for a single lifetime.
I = Ae t/T + Be-t(T(T) T2 +C 111.18
To apply this equation to phosphorescence decays obtained from samples with
unknown P02, the quenching constants and anoxic lifetimes of both species need to be
known. To obtain these values, calibration samples containing 0% or 5% BSA at pH 7.4
were prepared using the freeze-pump-thaw method. After obtaining an atmospheric
pressure of 2x10-6 mmHg within the modified Schlenk flasks, each sample was placed
under oxygen pressures ranging from 10-80 mmHg. Phosphorescence lifetimes for the
0% BSA samples were obtained using MP-PQM and fitting to a single exponential decay.
MP-PQM measurements were then performed on the 5% BSA samples. The raw data
was fit to both the single and two-component exponential decays, constraining one
component in the two-component model to the 0% BSA lifetime at that oxygen tension.
Linear Stern-Volmer relationships were fit to both the free and bound species to obtain
kq (Figure 111-12). The quenching constant obtained for the bound species (285 mmHg~
1s1) was lower than that of that obtained from samples containing any concentration of
BSA (Figure 111-9). Using the lifetimes and peak amplitudes to determine the total
photons attributed to each species, the bound fraction was determined to be 94.6 t
0.3% across all oxygen tensions.
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Figure 111-12 Calibration of the free (left) and albumin bound (right) phosphor species using MP-PQM.
The calibration curve of the single component fit to the 5% BSA solutions is also given for comparison. The
Stern-Volmer constant, kq, is give for each fit.
I1.5 Characterization of MP-PQM
The experimental parameters defining time-domain multiphoton phosphorescence
quenching microscopy may alter measured P02 or the apparent resolution of
multiphoton microscopy. The instrument response to parameters such as gating and
excitation pulse duration can directly affect the measured phosphorescence lifetime.
The excitation wavelength utilized to perform two-photon excitation of the phosphor
may also alter lifetime. Phosphorescence saturation or diffusion of phosphor during the
measurement may decrease the resolution of oxygen measurements. Further, the
repeatability of in vivo measurements should be measured to define measurement
error. To fully characterize the technique, I quantified the effects of these parameters in
vitro and in some cases in vivo under different oxygen tensions.
III.5a PHOTON COUNTING BIN SIZE
The multichannel scaler counted photons as a function of time by partitioning counts
into different histogram bins of a given duration and time from the trigger pulse. In a
typical MP-PQM experiment, the bin size should be less than the lifetime in order to
acquire an accurate decay. To determine if the size of the photon counting bins
correlated with the measured lifetime, I altered the bin size for phosphor solutions
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under oxygen tensions ranging from 0 to 75 mmHg and with either 0% or 5% bovine
serum albumin. The effect of photon counting statistics (Poisson statistics) was
controlled over the experiment by increasing the number of records collected with each
smaller bin size to keep total photon counts constant. At all oxygen tensions the
measured lifetime was found to be independent by a one-way ANOVA (P-value > 0.05)
of all bin sizes less than 50% of the phosphor lifetime for the free species ( Figure 111-13).
Further, no statistical difference was found between any pair-wise comparison of bin
size (N = 10). For the bound component, bin sizes of 0.64 lts at the longer and 10.24p s at
the shorter lifetimes were found to be statistically different from the rest of the group.
For all in vivo experiments, bin size was maintained at 2.56ps which showed no effect on
lifetime ( Figure ll-13b) and was always much less than the lifetime (bin size « ).
1000 a. 1000 b.
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Figure 111-13 Effectof photon counting bin size on measured lifetime. (a). At different oxygen tensions
and 0% BSA the lifetime of OxyphorR2 was found to be independent of bin size. (b) However, for the
bound component, bin sizes on the end of the range demonstrated significant differences from the rest. *
- P-value < 0.05
IIL.5b EXCITATION PULSE DURATION
The technique of multiphoton microscopy is ideally suited for fluorophores with short (<
4ns) lifetimes. The repetition rate of the pulsed femtosecond excitation source is
typically around 80Mhz. The period of the laser cycle (12ns) allows the decay of
fluorescence to occur between pulses without saturating the sample38 . However,
phosphorescent molecules have much longer lifetimes, so as discussed in the
development of the MP-PQM methodology, the duty cycle of the EOM needs to be 0.1-
0.6% select only a relatively small portion of pulses.
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Figure 111-14 Effect of excitation pulse duration on measured phosphorescence lifetime for both 0% (a)
and 5% (b) BSA. * indicates duration at which all later points are statistically different from the earlier
excitation pulse durations.
I determined the effect of the duty cycle by gradually increasing the excitation pulse
durations of the electro-optic modulator. The effect of pulse duration on the lifetime
was observed for 0% and 5% albumin solutions of Oxyphor R2 at all oxygenation levels
used in the calibration (Figure lil-12a). Interestingly, the measured lifetime tends to
increase with pulse durations that are typically longer than the lifetime of the phosphor
(Figure 111-14). With each increase of the excitation pulse duration, more laser pulses are
incident on the sample. For the 80MHz Ti:Sapphire laser source, the number of pulses
incident on the sample increased from ~410 to nearly 160,000. If heating of the sample
was occurring, the lifetime would decrease from increased collisional quenching due to
the higher average kinetic energy. Even taking into account the exponential decays of
numerous subpopulations excited at different times [Eq 111.10], the lifetime should still
be the same if the local environment is unchanged. However, for nearly every sample
studied, the lifetime increased, even at 0 mmHg. One possible explanation for increased
lifetime is secondary excitation of the triplet state of the porphyrin to even higher triplet
states, thus lengthening the lifetime. This effect has been observed in many luminescent
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molecules and particularly affects optical microscopies employing pulsed laser sources,
such as stimulated emission depletion microscopy (STED) 50.
The likely explanation for this finding is that the oxygen within the focal volume of the
multiphoton microscope is being consumed by extended periods of quenching with the
phosphor. The consumption of oxygen (and potential creation of free radicals) is well
known for porphyrins". In this case, it is likely that oxygen within the local environment
is decreasing due to consumption; therefore, the apparent phosphorescence lifetime is
increased. The effect of changing lifetime is also observed in the exponential decay fits
which appear to be multicomponent.
Due to the Stern-Volmer relationship, changes in lifetime have a larger magnitude at
higher oxygen tensions. However, the actual percentage change in measured oxygen is
less. For example in Figure lIl-14a, at 37mmHg and 18mmHg, the percentage changes
are ~27% versus 50% at the same excitation pulse duration. Any errors due to
consumption of oxygen would be increased in areas of lower oxygen tension. The effect
of oxygen consumption was less apparent in the more oxygenated samples (75mmHg).
Here, more extended pulse durations would be needed to consume enough oxygen to
significantly alter the phosphorescence lifetime. For these experiments, which were in a
sealed cuvette, measurements immediately following the longer excitation duration
measured the appropriate PO2. This suggests that the effect of oxygen consumption is
only transient, corrected by the diffusion of oxygen from outside the focal volume. In
vivo this effect may not be observed, especially in hypoxic tissue regions. For this
reason, all in vivo pulse durations were limited to ~15[ts or less, well below the region
where the lifetime was found to be statistically different.
III.5c PHOSPHORESCENCE SATURATION - PRACTICAL EFFECTS
As discussed in section 111.3b, the photophysical properties of the phosphor determine
the rates of single ground state depletion and triplet state population. Using a pulsed
laser source, such as in MP-PQM, the population fraction of the triplet state is
dependent on the number of excitation pulses incident on the sample (n), the fraction
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of molecules excited with each laser pulse (a), the repetition rate of the laser source (f)
and the lifetime of the triplet state (Ty). By fitting the phosphorescence emission during
excitation pulses of extended duration (Section 1ll.5b) to Eq 111.10 in aqueous solutions of
OxyphorR2 with known PO2 (oC -ry), the excitation fraction per laser pulse can be found.
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Figure Ill-15 Phosphorescence saturation during the excitation pulse of MP-PQM at different oxygen
tension. Dashed red lines indicate the fit [Eq. 111.10]. Dashed green lines indicate the number of incident
laser pulses where stead-state saturation is reached for the fits.
I measured phosphorescence saturation of OxyphorR2 under excitation pulses of
increased duration at 9,18, 37, and 75 mmHg. Fitting to the model, I found an excitation
fraction per laser pulse (a) of 0.001 - 0.006 depending on the oxygen tension. It is likely
that there are a lot of factors affecting a. In fitting Eq. 111.10 to real data, the true
excitation probability of the phosphor was not taken into account. In reality, a is a
combination of the system detection properties (<p), two-photon absorption cross-
section (a2), phosphor concentration (C), beam-shape or second order temporal
coherence of the excitation laser (g2) and excitation power (Io):
1
a oc 1pCo-2 g2(IO (t)) 2  1.19
Concentration and excitation power were controlled across samples, while the intrinsic
properties of the detection system and laser would not change. Therefore it is likely that
the range of a is due to changes in the lifetime or quantum yield of the phosphor.
At samples under 0, 37 and 75mmHg of oxygen, it can be seen that the
phosphorescence saturation relation does not fit as well at lower oxygen concentrations
(Figure il1-15). This is due to the consumption of oxygen changing the lifetime of the
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phosphor. No more is this apparent than in the tails of the raw data, which do not level
off indicating a steady-state, but continue to increase (37mmHg). Only at 75mmHg does
steady-state saturation appear to occur. This is likely due to the buffering of oxygen
consumption due to the higher concentration, faster rate to saturation because of the
shorter lifetime and smaller changes in lifetime due to oxygen consumption.
Interestingly, the range of a follows the oxygen tension, suggesting that at the higher
tensions, the value is more accurate (6.2 ± 3.5 x10_3 at 75 mmHg). Steady-state
saturation does appear to be reached at OmmHg, however, fits at shorter number of
pulses demonstrate oxygen consumption. This observation is likely due to the fact that
the solution is nearly devoid of molecular oxygen, thus the consumption of the small
amount remaining in the focal volume occurs relatively rapidly and stead-state is
reached.
Another property can be observed in the fits to the saturation data (Figure 111-15). The
number of pulses required to reach steady-state saturation decreases with increasing
oxygen tension due to the decreased quantum yield (dashed green line). For the
samples shown (0, 37, and 75 mmHg) the corresponding number of pulses to reach
saturation was 65000, 8000, and 1300. Given 12.5 nanoseconds between pulses, the
time to saturation (800, 100, and 16 ps) is about 3x the phosphorescent lifetimes for
each sample (273, 7.3 and 4.3 pLs). This is greater than that estimated by steady-state
continuous excitation [Eq. 111.7].
III.5d INSTRUMENT RESPONSE
A difficulty in many time-domain lifetime experiments is the shape of the excitation
pulse. Many optical excitation sources have characteristic decay times, often interfering
with the measured lifetime. This requires either deconvolution of the excitation pulse
from the decay24 or calculating lifetimes with much data removed to reduce the effect
of the excitation light33. The former is often technically difficult, while the latter may
give incorrect lifetimes due to the reduced counts and limited data.
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Figure 111-16 Excitation laser MP-PQM pulse incident on the sample. (a) Typical in vivo experimental pulse
at 2.56ps bin photon counting. (b) Same pulse as in a, except the collection bins are smaller allowing
assessment of the fall-time. (c) A shorter excitation pulse duration.
To characterize MP-PQM, I observed the excitation laser pulse at 15.36pts or 5.12ps in
duration with typical or high resolution photon counting bins (Figure 111-16). Ordinarily,
the 1020nm excitation laser pulse is not observed during the experiment due to the
placement of a shortpass filter (<750nm) in the emission path. On all excitation pulses, a
rise-time of 1ps is observed, which is within the parameters of the electro-optic
modulator. The fall-time after the applied voltage is dropped across the EOM is around
2[ts, much less than any experimentally measured decay time in vivo (bound species).
With shorter excitation pulses (5.12ps; Figure 111-16c), a slight decay is observed after
the excitation pulse height has dropped ~10% of the peak. The intensity of this decay is
much less than that required to excite the phosphor. Thus, there is likely little
interference of the excitation pulse in the measured lifetime.
III.5e Two-PHOTON EXCITATION WAVELENGTH
Previously, I determined that 1020nm would be the ideal wavelength for in vivo
excitation of the phosphor. However, no literature exists on the effect of excitation
wavelength for TPE on the lifetime of the phosphor. To determine if any change in
wavelength occurs, I measured the lifetime at wavelengths ranging from 800 to 1020nm
in an anoxic solution of OxyphorR2 (Figure 111-17). Average excitation power was kept
constant, although this means that there still would be more incident photons at
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1020nm than 800nm (- per mW or 1.275 in this case). Repeated measurements were
Al
collected at each wavelength (n = 5).
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Figure 111-17 Change in phosphorescence lifetime due to two-photon excitation wavelength. Errors are
given as standard deviation. (*) indicate wavelengths with lifetimes significantly different from 1020nm.
As the excitation wavelength decreases from 1020nm, the lifetime decreases by ~2[ts
every 10nm. This change with wavelength is significant over the tuning range of the
Ti:Sapphire laser. The variance in the measurement also increases with decreasing
wavelength. This could be due to increased detectable background from the laser,
temperature fluctuations, or alterations in the photophysics of the phosphor.
In photon counting, statistical noise typically follows a Poisson distribution34. This means
that 63% of the measurements will be between n ± hi. For the measurements here,
the statistical noise in the background level increases almost 10-fold from 1020 to
800nm. This is likely a large source of the variance in the exponential fits to the data.
Increased heat due to two-photon absorption of the chromophore has been shown to
be negligible for even the highest absorption cross-sections34. However, single photon
absorption of near-infrared laser light may increase heating. Of course, the absorption
of water is higher at 1020 than 800nm, suggesting that any temperature effects would
be reserved for the longer wavelengths. To approximate the temperature increase for a
Gaussian laser beam parked for a time t, the following relation can be used for single
photon absorption at the focal spot3 4:
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cXwTD / 2 Rq (t
T(t) = 2ag In +1 111.20
Pwc 7T(4 2 ) TD
Here, aw, pw, and cw describe the absorption coefficient (0.4 cm' at 1020nm), mass
density (1 g mi1) and specific heat (4.2 J g_'C') of water. Pav and w are the average
excitation power and width of the focal volume, respectively. The characteristic
diffusion time of water, 'r, is given by:
D = k 111.21
where kw is the thermal diffusivity of water (1.4 x 10-3 cm2s'). The beam waist for
1020nm light and a 0.95 NA objective lens was estimated to be 0.25pm. The pulse
duration for the experiment in Figure 111-17 was 5.12 pts. Substituting all factors into Eq.
111.20, a temperature rise of 0.6 0C is estimated for 1020 nm, while at 800nm it is around
0.02 C. These temperature changes would cause fluctuations of much less than 1% in
the lifetime 36 and does not explain why 800nm lifetimes are shorter than 1020.
A probable explanation may be stimulated emission of the phosphor from the triplet
state. Stimulated emission is a quantum mechanical process whereby a photon induces
an electron in an excited state to lose energy through emission of a photon. This
contrasts with phosphorescence (or fluorescence), which is a spontaneous, typically
thermally regulated, process. The emission from the Oxyphor R2 compound is very
broad: peaking around 700nm with a long tail up to 800nm. In theory, if population
inversion occurs and the triplet state contains a significant portion of the excited state
molecules, which is possible given the discussion in Section 111.3b, stimulated emission
may occur. Further, the two-photon absorption cross-section of OxyphorR2 is larger
around 800nm than at 1020nm suggesting an increased excitation rate populating the
triplet state. Stimulated emission of phosphorescence from organic molecules has been
demonstrated in the early 1960s51. Work since then has been in limiting the population
of the triplet state to enhance stimulated emission from the singlet state in optical
devices such as lasers52or in STED microscopy to limit photobleaching50.
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III.5f MEASUREMENT RESOLUTION - EFFECTS OF PHOSPHOR DIFFUSION AND FLOw
The oxygen sensor has a relatively long lifetime compared to other fluorophores
commonly used in MPM. During phosphorescence emission, the excited molecules can
diffuse into and out of the focal volume. An estimate of diffusion distance for a single
molecule can be made assuming a three-dimensional random walk.
(r 2 ) = 6Dt 111.22
Here the mean square displacement, (r 2 ), is related to the diffusion coefficient, D, and
time. Using this relation, the probability distribution for a particle starting at r = 0 can
be obtained for given lifetimes of the phosphor ().s3
p(r, T) = 1 3 e 4DT 111.23
8(rDT)/2
The diffusion coefficient for the solvated form of OxpyhorR2 was estimated from the
Stokes-Einstein relation:
Do = kBT 67r RH 111.24
where, Boltzmann's constant, kB, is 1.3807 x 10-23 J K1, T is the temperature (310K in
vivo), and r7 is the viscosity of water (6.92 x 10-4 kg m1 s-1 at 310K). The hydrodynamic
radius, RH, was estimated from the molecular structure (including dendrimers assuming
a solvation shell) to be 55 x 10-10m. This gives an estimated diffusion coefficient of 5.96
x 10-7 cm2 s-1, which is close to both albumin (~ 6.1 x 10-7) and hemoglobin (~6.9x 10-7)53.
Using the Stern-Volmer relation and the calibration constants determined for the bound
species, I calculated the probability distributions for a molecule at r = 0 for the
lifetimes at 0, 45 and 90 mmHg (Figure ll-18a). Only at very low oxygen tensions do the
phosphor molecules near the edge of the focal volume radii for the 0.95NA objective
lens used in MP-PQM. In practice, lifetime measurements are performed by collecting
the entire decay in the time-domain. This means that the signal will have decayed more
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than 1 or 36.7%. Typically, the signal decays below 1% of the peak intensity. Defining the
e
time constant [t, = -T ln(O.01)] for such a signal decay and replacing in Eq. 111.23 for T,
new probability distributions are obtained (Figure lil-18b). For measurements in anoxic
environments, around 2% of the molecules from the center of the focal volume are
outside the radial 1 distances at a time constant equivalent to the phosphor lifetime.
This value is even higher (28%) when considering decay to 1% of peak intensity.
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Figure ill-18 Diffusion of oxygen center from center of focal volume for different oxygen tensions. Radial
diffusion distances for the decay time (a.) and to 1% of peak intensity (b.) are given. The radial (xy) and
axial (z) 4 distances for the MPM focal volume are noted with dashed lines.
e2
To determine the three-dimensional resolution of the oxygen measurements, the three-
dimensional shape of the excited state focal volume and its change over time need to be
taken into account. Temporal changes in the focal volume are applied to measure
diffusion in multiphoton fluorescence recovery after photobleaching (MP-FRAP).
Following the derivation of Brown et a32, the relation for the fraction of emitting
phosphor molecules was obtained for two-photon excitation:
[ 4nz 2  1 4nr2  1
c(r, z; t) _ ~"e ~ COzz 1 + (16nDt/Wz 2 ) r 2 1 + (16nDt/Or2 )] 111.25
Co _ n! (1 + 16nDt/Oz2)'/2(1 + 16nDt/(or2 )
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The axial (oz) and radial (r) 1 widths for the three-dimensional focal spot are readily
apparent, as well as the diffusion coefficient (D). The parameter f# defines the initial
rate of excitation [Eq. 111.19] over the excitation pulse of the MP-PQM.
1
U2 g2(IO(OO))AT 111.262
Here the detection efficiency (<), two-photon absorption cross-section (U2) and second-
order temporal anisotropy (g2) are defined as in Equation 111.19. The squared intensity
of the stationary beam over the excitation pulse (Ar) determines the total amount of
photons incident on the sample.
Assuming an intensity of 50mW at the sample surface and a 15.36 pts excitation pulse
duration along with the other relevant constants for the phosphor (used previously) and
the focal volume dimensions of a 0.95NA objective, I determined the concentration
profiles of previously excited phosphor at 10% of peak phosphorescence (Figure 111-19).
As can be seen the shape of the concentration probability profile of excited molecules in
the three-dimensional excitation volume changes over time. The most dramatic effects
are the decrease of concentration in the center of the focal volume, C(r,z) = C(0,O),
as the phosphor diffuses out of the original excitation volume (Figure 111-19). The volume
resolution is higher the more oxygen that is present because quenching occurs over a
faster period (c is shorter). However, even at 100 mmHg the volume containing
phosphor at 10% of the decay is nearly two times the original volume (Figure 111-20a). In
anoxic conditions, the effect is even more dramatic, with the volume resolution being
nearly 15 times that of the original volume. The actual volumes are on the order of 0.3
to 3 femtoliters for 90 and OmmHg, respectively. The greatest change due to diffusion
occurs in the radial plane visible in the base of the concentration probability profile
(Figure ll-20b). Even at 0 mmHg, the full width half maximum (FWHM) of the
probability distributions along either axis (1.04pm radial and 1.53pm axial) are smaller
than those of other techniques54, especially in the z (axial)-direction.
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Figure 111-19 Three-dimensional concentration probability profiles determine the volume resolution of
MP-PQM. (a). The profile immediately after the excitation pulse. (b). At OmmHg the concentration
probability has spread out in all directions, enlarging the actual measurement volume. (c and d). At higher
oxygen tensions, the lifetime of the phosphor is shorter and less diffusion out of the focal volume occurs.
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The above probability distributions are useful for estimating the resolution of MP-PQM
for diffusion in water. Of course in vivo the diffusion constant would potentially be
lower than that in water. Further, much of the phosphor is bound to proteins, thus
increasing the hydrodynamic radius and slowing the diffusion rate. In the case of
intravascular measurements, the blood flow rate will decrease the resolution of the
measurement in the direction of flow. In addition to the changes in the volume
resolution caused by molecular diffusion during the lifetime of the phosphor (Figure
111-19), convection will further displace these volumes.
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Figure 111-20 Measurement volume for MP-PQM. (a). The actual volume of distribution for the phosphor
at 10% of the peak intensity immediately after the excitation pulse. (b). Contour plots of the base of the
three-dimensional concentration probability profiles illustrating the diffusive spreading for a range of
oxygen tensions.
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Figure 111-21 Volume resolution displacement during intravascular MP-PQM measurements in
unidirectional flows. Color gradients indicate increasing displacement with decreasing oxygen tension
and increasing blood flow rate.
In normal brain capillaries the blood flow ranges up 1mm/s 55, while in tumors it can be
non-existent, although an average of 100 -300 tm/s is often observed 56. Assuming
unidirectional flow, I determined the approximate displacement of the resolution
volumes in Figure 111-19 for flows ranging from 0.05 to 1500 mm/s (Figure 111-21). At high
flow rates, local environments with low oxygenation experience substantial
displacement, up to 7Rm. However, at rates found in tumors (~350Rm/s), the
displacement is only around 1pm.
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Figure 111-22 MP-PQM measurement error. (a). Series of repeated measurements in vitro demonstrating
no deviation over time. (b). In vivo measurements show increasing standard error with higher oxygen
tensions. Dashed line - Pearson's correlation of 0.41.
III. 5g MEASUREMENT REPEATABILITY IN VITRO AND IN VIVO
In addition to characteristic errors in excitation of the phosphor and effective resolution,
intrinsic P0 2 measurements all suffer from a measurement error. To assess the standard
error in quantified P02 obtained with MP-PQM, I performed either 100 repeated
measurements in vitro at different oxygen tensions or a series oxygen tension maps in
vivo taking three measurements at each location. At either high (77mmHg) or low
(100mmHg) oxygen tensions, the deviation in the measurement over time is negligible:
42.3 ± 1.0 and 257.3±3.7 mmHg, respectively (Figure III-22a). The standard error at the
lower oxygen tension is larger than at higher values; however the actual fluctuation in
measured P02 is small due to the Stern-Volmer relationship. This is apparent during
measurements in vivo where the standard error is positively correlated (Pearson's
Correlation Coefficient: 0.41) with quantified P02 (Figure Ill-22b). Interestingly, at
normoxic oxygen tension, the bound fraction is around 80-90% with little correlation
with P0 2 (0.18), while in hypoxic environments it ranges from 40-90% over a very short
range (2-10mmHg).
III.6 In vivo Demonstration and Application
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I further characterized MP-PQM by demonstrating both significant oxygen tension
alterations under hyperoxia in normal tissue and mapping oxygen profiles in skeletal
muscle of the mouse. Application of the phosphorescence quenching method using Pd-
porphyrin sensors in normal tissue has been previously demonstrated in lower
resolution epifluorescence microscopy 47' 57'58 or frequency domain measurements by a
number of investigators59. Many of these measurements have focused on the
intravascular space rather than interstitial.
III.6a PERTURBATION OF TISSUE OXYGENATION
Altering the amount of inspired oxygen increases the oxygen saturation of the blood in
healthy animals. Interestingly, hyperoxia has been studied as a means of improving the
interstitial oxygen tension in a tumor to improve the efficacy of radiotherapy with
limited effect60'61. In clinical applications, hyperoxia is usually performed under
hyperbaric conditions. In murine skin, increased vascular oxygen under normobaric
conditions should improve tissue oxygenation, which would be detectable by MP-PQM.
In male SCID mice bearing dorsal skinfold chambers (DSC) exposing the underlying
muscular layers of the dermis, I mapped the oxygen tension under both 21 and 100%
inspired oxygen (Figure 111-23). Measurements at altered fractions of inspired oxygen
(FiO 2) were performed over the same location at three different depths in the same
animals. The increase in tissue oxygenation was dramatic with tissue around the large
arteries and arterioles demonstrating the largest increase in p02 (Figure lI-23b,c). Some
regions in the capillary networks do not demonstrate increased oxygen tension in the
interstitial space.
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Figure 111-23 Hyperoxia in normal murine skin quantified by MP-PQM. (a). Colorized depth projection of
normal vasculature. (b). Oxygen tension map at 80pm deep and 21% inspired oxygen. (c). Oxygen tension
map at 80pm deep and 100% inspired oxygen. (d). Oxygen tension probability distributions for normal
and hyperoxic skin in b and c. Inset - mean tissue PO2 is statistically different between 21 and 100% FiO 2-
The oxygen tension probability distribution under normobaric hyperoxia reveals a
shifted mean peak (~32 versus ~52mmHg) and increased variance (Figure Ill-23d). Also
visible is a sharp peak at 122mmHg. This is the MP-PQM systems oxygen resolution limit
using 2.56 ts photon counting bins. Assuming a lifetime on the order of the bin size for
the free species, the calculated oxygen tension from the Stern-Volmer relationship and
calibration constants is ~122mmHg. Using a smaller counting bin size, maximal detected
P0 2 would extend to ~250mmHg for 1.28 ts bins. The actual increased oxygen tension in
the arteries is probably much higher than 122mmHg. Other investigators have
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measured P02 levels above 470mmHg under similar conditions in an analogous hamster
model62. The increased width of the probability distribution under hyperoxic conditions
is reflected in the heterogeneity of the oxygen tension map (Figure ll-23c). Still the
average tissue oxygen tension was significantly higher (P-value << 0.05) under hyperoxic
conditions (Figure 1ll-23d Inset).
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Figure 111-24 Murine skeletal muscle oxygenation. (a). Maximum intensity projection of the skin
musculature (blue) and associated capillaries (green). The series of planar measurements made at
different depths are shown (red). The profiles shown in c are taken from the middle series ( ). (b)
Each individual depth slice where the measurements depicted in a were taken. (c) Oxygen tension profiles
along the highlighted line in a ( ). (d) The profile with the lowest oxygen is outlined on the enface
slice showing measurements were taken within the muscle cells. Scale bar - 50pm.
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III.6b OXYGENATION OF SKELETAL MUSCLE - KROGH TISSUE CYLINDER MODEL
In 1919 physiologist August Krogh developed a cylindrical mathematical model for the
diffusion of oxygen from capillaries in muscle tissue based on observations of capillary
distribution in skeletal muscle6 3,6 4. To date, the Krogh tissue cylinder model for oxygen
diffusion in three-dimensions has not been experimentally demonstrated by measuring
P02. This is partially due to inherent complexities in the biological systems studied5,
but mostly to lack of an appropriate tool for quantifying oxygen tension at significant
depths with three-dimensional resolution. Using MP-PQM to measure P02 in living
tissue addresses these latter difficulties.
I made measurements in the skeletal muscle of the murine skin within the DSC of SCID
mice (Figure ll-24a). Measurements of P02 profiles (200pm) were made with 10pm
spacing. The skeletal muscle fibers are around 5-10pm, typically surround by capillaries
of 4-6pm in diameter, as seen in each depth slice (Figure 111-24b). Muscle fibers were
imaged by second harmonic generation of the myosin thick filaments70 in the
scaromeres using MPM. Oxygen tension profiles at each depth (Figure ll-24c) reveal
dramatic differences in oxygenation (4.0 ± 1.0 versus 28.9 ± 5.3mmHg) between
measurements within muscle fibers and those outside (Figure ll-24d). By applying semi-
automatic tracing to the MPM vascular images71,72, I was able to measure diameters and
distances to each capillary in three dimensions. Using this information with the oxygen
measurements, I estimated the values obtained by the Krogh tissue cylinder models 3:
Q02 R( 2 r2 - Ry2  r
P 0 2,tissue = p0 2,vessei + 4DS2 R - 21n 111.27
Point measurements of P02 were taken in each nearby capillary vessel to determine
source levels (P0 2, vessel). The average radial distance between capillaries (RO) within the
networks was determined to be ~50pm from the angiographic images. The capillary
diameters (2Rv) and radial distance to the vessels (r) from the tissue P02
measurements were determined from the vascular tracing. The diffusion rate (D02) and
solubility (S0 2 ) of oxygen in tissue was estimated from literature values to be 2.0 x 10-s
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cm2/s and 2.05 x 10-5 m10 2 cm- 3mmHg-1, respectively. The oxygen consumption
vertebrate skeletal muscle ranges from 8.0 x 10-5 to 2.5 x 10-3 mlO 2/cm3 s and depends
on the blood flow of the associated capillaries73. This is assuming a constant muscle
density of 1.06 g/m1 74. Distances beyond Ro for a given capillary and tissue measurement
pairing were ignored. This follows the assumption of the Krogh cylinder model that no flux
occurs beyond Ro.
Various values of oxygen consumption within the range for skeletal muscle were used to
fit to the Krogh Cylinder model. The sum of the calculated P02 values were compared to
the MP-PQM measured values at each point. By minimizing the sum of the calculated
P02 through adjustment of the tissue oxygen consumption (Q02), I found a value of 1.65
x 10-4 m10 2 cm 3mmHg ', well within the range of that reported in the literature7.
However, the standard deviation of the sum was very large due to measurements in
regions of different oxygen consumption (muscle fibers versus interstitial space).
Additionally, P02 measurements inside of the muscle fibers exhibited lower oxygen
tension. Interestingly, the measurements inside the muscle fibers also showed less
protein bound species than those outside (0.52 ± 0.09 versus 0.86 ± 0.04). This suggests
the muscle fibers must be more permeable to the free species. Further, the value of Ro
appears to be anisotropic in three dimensions. Along the XY plane, the separation is
around 50pm, while is much less in the axial dimension in many cases. This likely
invalidates the Krogh tissue cylinder model due to overlapping oxygen sources.
111.7 Further Considerations and Future Outlook for MP-PQM
The application of phosphorescence quenching for quantification of P02 to multiphoton
microscopy provides the ability to probe tissue oxygenation in three-dimensions with
high-resolution. I have defined the characteristics and methodology of MP-PQM
including techniques for measuring in vivo P0 2. With additional equipment and proper
software automation standard MPM in biological laboratories will be easily adaptable to
perform oxygen tension measurements using phosphorescent porphyrins.
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Through standard techniques, I demonstrated that common porphyrin-based oxygen
sensors can be used with nonlinear excitation. However, commercially available
porphyrins have small two-photon action cross-sections limiting their efficiency with
two-photon excitation. The potential for overcoming the low absorption cross-sections
of porphyrins have been recently investigated using F6rster resonance energy transfer
(FRET) 7 -77 . Through the use of a two-photon absorbing antennae, the phosphorescent
yield can be increased. However, none of these probes have been characterized in the
context of an in vivo environment Further work in this area should lead to more efficient
optical oxygen sensors for MP-PQM.
Given the reduced two-photon action cross-section, I attempted to improve the
sensitivity of MPM to porphyrin phosphorescence using detectors with higher quantum
efficiencies. Using an avalanche photodiode detector, improved sensitivity was observed
for solutions, but not turbid samples or in vivo tissue. This was likely due to the fact that
the active area of the APD was ~180ptm, while that of standard PMTs are 8mm. In
whole area detection (WAD) 34 of thick samples, the emitted photons are no longer
ballistic, but scattered in an array of angles collected by the objective lens. The ability to
focus these scattered photons onto the smaller active area of the APD was greatly
diminished in thick tissues. It is possible that descanned detection 34 with a pinhole
above the confocal limits would permit use of an APD. However, in highly scattering
tissues the lower collection efficiency observed with pinhole detection than WAD may
offset any possible gain.
A concern regarding luminescent probes with long lifetimes under pulsed excitation is
saturation of the excited state. In the case of a phosphorescent molecule, the triplet
state may be saturated. Using a commercially available porphyrin sensor, I showed that
using the MP-PQM techniques and time-domain methodology proposed in this work,
excitation saturation of the triplet state does not occur under standard settings. I did
demonstrate at longer impulses in the time-domain, however the time to saturation was
longer than theoretically predicted. The longer time to saturation is likely due to the low
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fraction of Pd-porphyrin molecules excited per laser pulse (0.006). Therefore, phosphors
with improved two-photon absorption cross-sections would reach saturation faster. Any
new phosphorescent molecules used with MP-PQM must be assessed for this property
to determine the appropriate excitation pulse widths to employ. It should be noted that
saturation does not abrogate MPE, but instead alters the shape of the focal volume38
decreasing the three-dimensional resolution of the system. In certain experiments, such
as multiphoton fluorescence correlation spectroscopy, the shape of the focal volume
can significantly alter the measurement outcome78 . In the case of MP-PQM, saturation
will only probe larger tissue volumes and potentially affect the issues of oxygen
measurement resolution reported here.
It was also important to determine the expected in vivo P02 measurement resolution
based on diffusion characteristics of both the sensor and oxygen as well any convective
forces that may be present. Generally, I found the resolution scaled nonlinearly with
oxygen tension increasing up to volumes of 3 femtoliters in anoxic environments for a
0.95 NA objective lens. At higher P02, the resolution is much higher due to the shorter
phosphorescent lifetimes limiting the diffusion time. In cases of convection, such as
measurements in a perfused and flowing blood vessel, the excited sensors to move with
the flow. The distance traveled is dependent on both the fluid velocity and P02, with the
largest error in measurement spatial resolution occurring in high flows (> 750 pm/s) and
low oxygen tensions. Most blood vessel velocities in both normal and neoplastic tissue
are below this range. Physiologically, low oxygen tensions will never be found in areas of
high flow in normal tissues, abrogating the dramatic effect of convection on the volume
resolution. Further, most vessels in tumors that have low flow are also less
oxygenated5 4 .
I demonstrated the feasibility of MP-PQM in measuring in vivo oxygenation of normal
tissue in mice including with perturbed FiO 2 and in the skeletal musculature of murine
skin. Under normobaric hyperoxia, the oxygen tension was found to increase as
expected. However, when correlated with vasculature in three-dimensions, the
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response appeared heterogeneous. Further, the probability distribution of oxygen
values was also found to have a larger variance than that of tissue under normoxia. It
has been previously shown in the skin muscle of mammals that hyperoxia induces
vasoconstriction in vessels on the order of capillaries79. Studies in the musculature of
anesthetized surgical patients have also revealed decreased vascular flow (presumably
due to vasoconstriction), although the effect was heterogeneous and led to lower
oxygen tensions over time o. Therefore, the heterogeneity in the oxygen distribution is
likely not due to changes in consumption, but instead a reduction in function capillary
density6 2.
In the second in vivo experiment, I attempted to apply the Krogh tissue cylinder model
to skeletal muscle in murine skin. Overall, I found that the model did not apply well or
predict the measured P02 values. The capillary networks of the skeletal muscle in the
skin possessed regular spacing in two-dimensions (XY plane), but not in three-
dimensions. This asymmetry negates a major assumption of the Krogh tissue cylinder
model. More interesting was that the oxygen consumption appeared to be
heterogeneous throughout the musculature. Even though musculature in the skin is
probably not as metabolically active as muscle elsewhere, low oxygen values were
measured in some muscle fibers. The low values of P02 measured within the muscle
fibers can be explained by increased contraction in those particular fiber groups. It has
been shown that the oxygen tension within muscle fibers depends on their level of
activity l. Such studies reported oxygen tension values ranging from 25 to 5mmHg in
lower metabolically active muscle, in agreement with my results. Other investigators
have shown higher values in muscle using other optical techniques8 2,83. However, these
single photon phosphorescence quenching measurements would only measure the
average p02 in a much larger volume at shallower depths (~ 25-50 pim). Therefore, they
may not be able to discern the effects of individual vessels and cells on the oxygen
diffusion profile unlike MP-PQM.
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111.8 Summary
In this Chapter I have demonstrated the development of quantitative oxygen tension
measurements by applying the principles of phosphorescence quenching to multiphoton
microscopy. To perform in vivo measurements, I created an automated software
interface that allows a user to apply different data collection algorithms with real-time
oxygen quantification. I developed multiple methods of calibration and showed for the
first time that both protein bound and free oxygen sensor species can be differentiated
using MP-PQM. This was previously believed to prevent the use of many porphyrin
oxygen sensors in the extravascular space8 3. I fully characterized the technique of MP-
PQM including the two-photon excitation of the Pd-porphyrin dendrimer oxygen sensor,
effects of phosphorescence saturation, practical application issues in time-domain
lifetime imaging, and resolution of the oxygen measurements. In vivo application of MP-
PQM was demonstrated during conditions of normobaric hyperoxia. Further, I applied
the Krogh tissue cylinder model to the capillary networks and muscle fibers in the
murine skin. I showed that in three-dimensions, this model may not be applicable for
capillary networks in the skin musculature due to the anisotropic arrangement of the
muscle fibers. In the next Chapter, I will apply MP-PQM to the study of solid tumor
oxygenation during tumor progression and response to targeted therapy.
111.9 Additional Materials and Methods
III.9a ANIMAL MODELS
For oxygen perturbation measurements, dorsal skinfold chambers (DSC) were prepared
on male SCID mice using previously described methodss6. Briefly, the back of the mouse
is shaved and depilated. One-half of a pair of symmetrical titanium frames (weight 3.2 g;
Workshop, Department of Radiation Oncology, MGH), is implanted on the backside of
the extended double layer of skin. The exposed layer of skin is removed in a circular area
approximately 15 mm in diameter matching the opening in the chamber faceplate. The
remaining skin layer, consisting of epidermis, subcutaneous tissue, and striated muscle,
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is covered with the second half of the titanium chamber which contains a glass coverslip
(Figure 111-25). Following implantation of the chamber, animals are allowed to recover
from microsurgery and anesthesia for 48 hours before in vivo microscopy studies.
Figure 111-25 Dorsal skinfold chamber implanted on a SCID mouse.
To explore the Krogh tissue cylinder model, I developed a transparent window mouse
model to non-invasively image skeletal muscle and quantify P0 2 using MP-PQM. A
dorsal skinfold chamber is prepared as described above, however, rather than removing
all of the skin, a layer of striated skeletal muscle is surgically exposed and cleaned
followed by placement of the transparent coverglass. The skeletal muscle fibers and
supporting vasculature are imaged by second harmonic generation 39,84 (SHG) and
multiphoton excitation of intravenously injected fluorescein isothiocyanate (FITC)
dextran 2M MW (Sigma-Aldrich Co., St. Louis, Mo.), respectively, using MPM. All animal
work was approved by the by the MGH Institutional Animal Care and Use Committee.
III.9b PREPARATION OF OXYGEN SENSOR
Palladium meso-tetra(4-carboxyphenyl) porphyrin dendrimer (Oxyphor R2) was
obtained from Oxygen Enterprises, Ltd., Philadelphia, PA. For in vitro studies Oxyphor R2
was prepared as 1mg/mI (0.36mM) solutions in phosphate buffered saline. Prior to any
measurement , the pH was adjusted to 7.4 using either 1M sodium hydroxide or 1M
potassium phosphate where appropriate. For in vivo measurements, 10mg/ml (3.6mM)
solutions of Oxyphor R2 were prepared with mixed 8mg/mi (4pM) FITC-Dextran 2M in
PBS. The pH was adjusted to 7.4 and the sample filtered (20pm) prior to administration.
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Samples were administered intravenously (200pl) either by tail vein or retro-orbital
injection. The dosage of Oxyphor R2 was 100mg/kg.
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IV.1 Introduction and Motivation
In solid tumors, the amount of oxygen in the microenvironment plays an important role
in progression and response to therapy. Tumors are typically characterized by low
oxygen tension, i.e. hypoxia1,2: P02 values less than 10-15mmHg in tissue. In the clinic,
increased hypoxic fraction has been linked to poor prognosis3-6. Additional studies have
shown a high degree of correlation with hypoxia and metastatic potential7 10 . In fact, it
has been demonstrated that hypoxia promotes the selection of tumor cells with
reduced apoptotic potential". Hypoxia has been shown to independently regulate gene
expression including the hypoxia inducible factor (HIF-1 and -2) pathways12 j 4 and the
family of angiogenic promoters, vascular endothelial growth factors (VEGF)s,16. Even
microscopic tumors once considered too small to be hypoxic, have been shown to have
significant hypoxia in some disease states17'1 . The degree of hypoxia also directly
impacts the formation of the abnormal and irregular tumor vascular networks 9. Recent
work indentifying tumor stem cells has also suggested hypoxia may play an important
20
role in maintenance of these cell populations and their gene expression
While levels of oxygen in tumors may impact many aspects of tumor progression, one of
the most clinically important is response to therapy. It is well known that oxygen
sensitizes a tissue to radiation21 . Therefore, hypoxia in tumors is protective against
radiotherapy, particularly if cancer stem cells are immune to such treatments19.
Furthermore, many chemotherapeutics demonstrate reduced cytotoxicity in low oxygen
environments . Initially, it was believed that targeting the tumor vasculature through
antiangiogenic therapy would starve the tumor of its blood supply. However, in the last
decade, antiangiogenic therapy as a single agent has produced limited success in both
animal models and patients ,24. Since oxygen sensitizes a tissue to radiation, one would
expect antiangiogenic agents and radiotherapy to be antagonistic. Interestingly, it has
been demonstrated that certain antiangiogenic therapies coupled with radiation
treatment can produce synergistic results25-28. Additionally, antiangiogenic therapy
coupled with certain chemotherapeutics has demonstrated increased efficacy in
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colorectal and lung cancer patients over either individual treatment29,30. Antiangiogenic
therapy may prune the immature and inefficient tumor blood vessels improving
perfusion and potentially "normalizing" the metabolic microenvironment including
p0231 34 . A "normalized" tumor microenvironment with increased P02 may sensitize the
tumor to radiation and maximize cytotoxicity of certain chemotherapeutics.
To realize the full potential of this concept, it is important to gain a deeper
understanding of the spatial and temporal changes in tumor P0 2 during disease
progression and treatment. Previous techniques for measuring PO2 in vivo were
constrained by the significant spatio-temporal heterogeneities found in tumors35 ,36.
These techniques also demonstrated limitations in their tissue penetration, depth
resolution, spatial resolution and all lacked true three-dimensional resolution3- In
addition, some methods are invasive and lack the ability to perform measurements in
real-time40. Multiphoton phosphorescence quenching microscopy (Chapter 3) eliminates
many of these constraints, providing a new opportunity to probe the P0 2 of the tumor
microenvironment. Therefore, in this Chapter, I will demonstrate the application of MP-
PQM to multiple tumor models during progression and treatment.
IV.2 Oxygen Profiles in Solid Tumors
The application of MP-PQM to the measurement of P02 in the microenvironment of
tumors implanted in window chamber models allows characterization of three-
dimensional interstitial oxygen profiles. Up to 400pm deep, P02 profiles from single
vessels in a human melanoma (MU89) xenotransplant in SCID mice were obtained.
These were compared to similarly sized vessels (10-20gm in diameter) in the skin of
mock-transplanted chamber mice (Figure IV-1). A distinct separation between the p02
level in normal tissue vascular oxygen profiles and those in tumors was readily apparent.
The mean intravascular P02 (distance = Ogm) between normal (49.1 ± 5.5mmHg) and
tumor (19.2 ± 3.4mmHg) vessels was statistically different (P-value << 0.05). However,
the mean oxygen gradients over the lengths of the profiles were not found to be
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different. This suggests that in vivo oxygen consumption of the melanoma tumor cells
was very similar to that found in normal tissue.
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Figure IV-1 Vascular oxygen profiles from similarly sized vessels in tumors and normal tissue. P0 2
profiles from normal murine skin are depicted in blue. Profiles from single vessels in a human melanoma
xenograft (MU89) are shown in red. The dashed grey line indicates the separation in oxygen level
between normal and neoplastic tissue. The dashed blue profiles in normal tissue were carried out beyond
~80pm through the use of nanovascular surgery to cauterize nearby vessels.
In melanomas, oxygen profiles longer than 70tm were readily measureable due to
increased intervascular spacing. However, in normal tissues, vessels are spaced
relatively close together, often negating any gradient due to oxygen consumption. To
obtain such profiles, I performed nanovascular surgery41 43 using the multiphoton
excitation laser on vessels nearby the target vessel. Exposure to 1 or 2 high average
power (80-100mW) line scans across the diameter of the vessel induced clotting and
ceased perfusion beyond the point of claudication (Figure IV-2). Using this technique,
P0 2 profiles out to ~200 tm were measurable (Figure IV-1 - dashed blue). Nonetheless,
oxygen diffusion from vessels located nearby in three-dimensional space still
contributed to a higher oxygen tension than that found in the tumor vascular profiles.
This suggests that the vascular architecture in such normal tissues provides better
metabolic (p02) support for the tissue.
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Figure IV-2 Nanovascular surgery using multiphoton microscopy. (a). In order to obtain extended
interstitial oxygen profiles in normal murine skin, nearby perfused vessels were cauterized using the
multiphoton excitation laser (red). The principles of multiphoton excitation limited the tissue damage to
only a small three-dimensional space around the blood vessels. (b) After nanosurgery was performed
some extravasated angiographic marker was visible. However, beyond this point perfusion and therefore
oxygen delivery was limited permitting longer oxygen profiles to be measured (
While the measurement of oxygen profiles from single vessels is possible in three-
dimensions using MP-PQM, in tumors heterogenous temporal variations in flow limit
repeatable measurements. Often times during the collection of a single vascular oxygen
profile (5-10minutes), the vessel would undergo transient blockage due to changes in
red blood cell flux. This temporarily lowered measured P0 2 in the interstitial space due
to cellular consumption and reduced supply of oxygen. Once the blockage was freed,
the interstitial space was reoxygenated and P02 levels increased. Many other
investigators have observed this effect in tumors on both a single vessel and
44-46macroscopic scale -*. Vascular supply fluctuations precluded the use of local vascular
oxygen profiles to assess the dynamics of P02 in the microenvironment during tumor
progression and treatment.
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Figure IV-3 Three-dimensional mapping of tumor oxygenation using MP-PQM. (a). Axial cross-sections
through the tumor are shown along vertical and horizontal planes. A depth projection of multiphoton
angiography of the tumor vascular network is illustrated relative to the cross-section. Color denotes depth
(green-red-white). (b). Oxygen tension maps at four different depths within the tumor. The angiographic
depth slice at 50pm is shown for comparison with the oxygen map. Black outlines on the maps indicate
the morphometry of the tumor vessels. Scale Bar - 500tm.
IV.3 Three-dimensional Mapping of Tumor Oxygenation
The technique of MP-PQM allows measurement of P0 2 at single points confined to the
three-dimensional excitation volume of the multiphoton microscope. To quantify the
oxygenation in the tumor microenvironment in preclinical models and assess the spatial
heterogeneity in PO2, I chose to collect in vivo measurements along a grid at multiple
depths (Figure IV-3). This process reduced the effects of temporal fluctuations in P02
observed with single vessel oxygen profiles. Further, it allowed oxygen measurements to
be performed with multiphoton angiography. Correlation of the tumor vasculature and
P02 in three-dimensions throughout the tumor were then possible.
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Table IV-1: Correlation of PO with vessel diameter (d) or interstitial distance (r) across multiple tumors.
Bold Pearson's correlation coefficients denote significant difference (P-value < 0.05) from no correlation
(0). N - Number of animals in each group.
E0771 MDA-MB-361HK LS174T MCaIV-DSC MCaIV-MFP
Day d r d d r d r d r
0 -0.003 -0.27 0.069 -0.33 0.014 -0.25 0.18 -0.47 0.066 -0.39
3 -0.046 -0.29 0.029 -0.47 -0.034 -0.42 0.31 -0.39 0.014 -0.34
6 0.045 -0.26 0.047 -0.37 0.022 -0.39 0.22 -0.41 0.036 -0.39
9 -0.14 -0.33- -0.023 -0.31 0.048 -0.61 0.074 -0.39
N=4 N =8-10 N=6-10 N= 5-6 N=2
IV.3a CORRELATION OF P02 AND VASCULAR METRICS
Tumor oxygenation has been shown to depend on the vascular network parameters
including geometry and function'. In vivo interstitial measurements have
demonstrated that pO2 generally decreases with increasing distance from the vessel
wallas4 _ One of these studies also showed that there is no correlation between tumor
vessel diameter and intravascular pO2. However, all of these measurements have been
based on single vascular profiles or limited to intravascular measurements. Any studies
that have assessed the global oxygenation of a solid tumor have either relied on
mathematical modeling or state that their measurements are intravascular36. No study
to date has compared real-time microscopic measurements of P02 directly with the
tumor vascular network over macroscopic regions.
Using MP-PQM, I was able to obtain oxygen tension maps and high-resolution
angiography during the same measurement period. Data was collected over large
regions (~16mm 2) and up to 350pm in depth across multiple tumor types. pO2
measurements were collected at single points over a grid spaced at 100-200pm.
Vascular metrics, including diameter and length, from the three-dimensional
multiphoton angiography were determined using a semi-automatic tracing algorithm 0 .
The Euclidean three-dimensional distance (r2 = AX2 + Ay2 + Az2) from each
measurement point to the closest vessel was determined over the entire oxygen map.
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Table IV-2 Correlation of p02 with vessel diameter (d) and interstitial distance (r) in normal tissues.
Bold Pearson's correlation coefficients denote significant difference (P-value < 0.05) from no correlation
(0). N - Number of animals in each group.
d r N
Skin 0.37 -0.096 4
MFP 0.13 0.067 2
Brain Cortex 0.15 0.014 3
Across all tumor types, a significant negative correlation was found between distance to
closest vessel and P02 (Table IV-1). The Pearson's correlation coefficients remained
relatively constant over 9 days of tumor growth for all tumor types except LS174T. The
human colorectal adenocarcinoma (LS174T) implanted in the DSC increased to a
maximum correlation of 0.61 by day 9. These correlation were much higher than those
found in normal skin, mammary fat pad (MFP) and cortical brain, where the P02 was less
correlated with distance from nearest vessel (Table IV-2). As will be seen, in normal skin,
cortex and mammary fat pad an oxygen gradient from the vessel wall is nearly non-
existent in three-dimensions. The difference in vascular network structure is notable
between normal MFP tissue and an orthotopic murine mammary carcinoma (E0771;
Figure IV-1a and b). Oxygen tension measured at random locations in the E0771 tumor
demonstrated a decrease with distance to nearest vessel, while in normal MFP it
remained constant (Figure IV-4c).
At first glance, these results may seem counter to previous interstitial in vivo P0 2
studies. However, many of those were performed in the stretched rodent abdominal
mesenterys1 ,52, which is essentially a two-dimensional tissue. Interstitial oxygen
gradients and correlation between oxygen tension and distance have been reported in
skeletal muscle53 and cortical brain54, which are representative of three-dimensional
vascular networks (> 200 ptm thick tissues). In muscle, oxygen gradients and therefore a
correlation with distance from blood vessel exist due to consumption by the muscle
fibers55. I demonstrated that such gradients can exist in murine skin skeletal muscle due
to increased oxygen consumption in Section 1116b. In cortical brain, the authors of the
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previous study note that it was very difficult to find locations where gradients existed,
suggesting they are limited under normal conditions.
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Figure IV-4 Correlation of P02 with vascular metrics. (a) Angiographic depth projection of the vasculature
in the normal mammary fat pad of a female SCID mouse. (b) Vascular network of an orthotopic murine
mammary carcinoma (E0771). (c) Spatial correlation of tumor PO2. Normal tissue in the MFP shows no
correlation with distance to the closest vessel (dashed line). Tumor vascular networks demonstrate a
negative correlation with P0 2 and distance to nearest vessel (solid line). (d) Conversely, in normal tissues
P0 2 demonstrates a positive correlation with vessel diameter, while measurements in tumors do not
display any correlation. c and d: e - normal * - tumor. Scale Bars - 500pm.
It is well known that vascular oxygen tension is highly correlated with vessel diameter in
both the arterial and venular branches56. Phosphorescence quenching microscopy
experiments in rodent skin have demonstrated longitudinal P02 gradients following the
branches of the arterial network - the smaller the vessel diameter, the lower the
oxygen5 7. The proposed source of the longitudinal gradients is two-fold. First is that the
vascular wall endothelial cells consume oxygen and larger vessels with thicker walls
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52,53
consume more oxygen . Second, the capillaries are not the sole source of oxygen
diffusion to tissue. Instead larger arterioles also supply oxygen to the tissue which have
also been shown to play a significant role in the modulation of blood transport to
56tissue
Three-dimensional measurements in both the intravascular and interstitial space in
murine skin, mammary fat pad and cortex revealed significant correlation of P02 with
vascular diameter (Table IV-2). All normal tissue demonstrated Pearson's coefficients
greater than 0.1, however murine skin displayed the largest correlation (0.37). In the
neoplastic tissues studied in Table IV-1, only MCaIV, a murine mammary carcinoma,
demonstrated significant correlation of oxygen tension with vessel diameter. All other
murine tumor models had non-significant Pearson's correlation coefficients: typically
less than 0.05. Supporting these results, previous studies performed in a human
colorectal adenocarcinoma xenograft (LS174T) demonstrated no correlation with tumor
vessel diameter3 ' 49 . In most cases, the heterogeneous structure and morphometry of
tumor vascular networks abrogate the normal transport of oxygen to the tissue58-60. The
irregular geometry and heterogeneous flow patterns in tumor vasculature uncouple the
normal dependence of tissue P02 on vascular diameter. The murine mammary
carcinoma E0771 demonstrates these effects quite well in comparison to normal
murine MFP (Figure IV-4d).
The unusual result from the MCaIV mammary carcinoma may be explained by the
ectopic microenvironment (dorsal skin) providing better oxygen supply or inducing the
formation of a more efficient network. Fractal analysis of the tumor vascular network of
MCaIV in the DSC demonstrated a significant difference from normal skin and increased
tortuousity (decreased transport efficiency)61. This suggests that increased efficiency is
not likely the reason for increased correlation. Interestingly, the same tumor type
implanted in the mammary fat pad exhibited no correlation with tumor vessel diameter
throughout tumor growth (Table IV-2: MCaIV-MFP). This is further confounded by the
fact that both locations exhibit tumors with similar mean diameter vessels (~54ptm for
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DSC and ~68ptm for MFP) for tumors of equal volume. Therefore differences in the
tissue microenvironment and vascular supply must account for the increased correlation
in the DSC.
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Figure IV-5 Tumor oxygen profiles and consumption. (a). Histogram of the number of measurements for
a given oxygen tension at a given distance to the nearest vessel. The mean P0 2 profile is overlaid (white)
illustrating the gradient in oxygen with distance. The effect of oxygen diffusion from vessels outside the
mosaic image volume (~4x4xO.3mm) is noticeable at farther distances (*). (b). Zero-order diffusion-
reaction fit (green) to the PO2 data in a to determine the oxygen consumption.
IV.3b TUMOR OXYGEN CONSUMPTION
The increased correlation in solid tumors between P02 and distance to nearest vessel is
due both to vascular architecture and increased tissue oxygen consumption. The large
avascular spaces found in most tumors coupled with the high metabolic activity of the
tumors cells reduce the oxygen concentration. In reality, energy metabolism in tumors is
a complex process dependent on the metabolites (oxygen and glucose) available' 62 ,63
However, to a first approximation the decreasing level of oxygen in tumor tissue with
increasing distance from the vasculature (Figure IV-5a) can be assumed to result from
oxidative respiration.
Oxygen metabolism follows Michaelis-Menten kinetics in biological tissues. However,
above very low oxygen concentrations, the reaction can be approximated as zero-order
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kinetics"4. In this situation, the oxygen consumption was assumed to be constant at all
points from the blood vessels. While the actual measurements are three-dimensional in
nature, I estimated average tissue oxygen consumption for the entire tumor volume
measured using a one-dimensional first-order diffusion-reaction model.
d2p0 2
D02S dr 2  2 = (lV.1)
Here D02 is the diffusion of oxygen (2 x 10-5 cm2s-1)6", S is the solubility of oxygen in tumor
tissue (2.05 x 10~5 m102 cm-3)", r is the three-dimensional Euclidean distance to the closest
tumor vessel and Q02 is the oxygen consumption rate in m102 cm-3s~1. The following boundary
conditions were used to solve Equation (IV.1): PO2 at r = 0 is equal to the oxygen tension within
the vessel (P0 2,esset) and the solution reaches a minimum (402 = 0 PO2 at some
critical distance (p02min) from the blood vessel. The solution is of the form of a second order
polynomial.
Q02 _Q 2 (P:C2vesse1 - P02min)P02(r) = r2 _ 2s r + P 0 2vesseL (IV.2)
The values of P0 2,essel and P0 2mm were independently determined for each tumor and
timepoint from the scatter plot of oxygen tension versus distance from nearest vessel (Figure
IV-5b).
Table IV-3: Mean oxygen consumption across turnor types. Bold values indicate a significant difference
from all other tumors for a given tumor at a specific timepoint.
E0771 MDA-MB-361HK LS174T MCalV-DSC MCaIV-MFP
Day Qm (M 2 cm3s-a x 10~s)
0 6.55± 2.04 1.25±0.22 2.94±0.68 7.03±1.99 1.15±0.98
3 4.85±4.32 2.15±0.03 2.05±0.54 8.19±2.81 3.82±0.38
6 2.71±1.27 2.20±0.62 4.37±1.10 5.53±1.91 5.89±4.21
9 1.21±0A7 0.96±0.49 3.80±0.66 5.86±1.74
ANOVA 0.251 0.44 0.049 0.526
N=4 N = 8-10 N = 6-10 N = 5-6 N=2
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I determined the mean tumor oxygen consumption during progression across multiple tumor
types and sites (Table IV-3). Previous in vivo measurements have all reported local oxygen
consumption rates determined from radial vessel profiles24,67. To the best of my knowledge, this
is the first time that oxygen consumption has been calculated from P0 2 measurements
throughout large regions of the tumor. At day 0 all tumors were approximately 4mm in diameter
by enface measurement. Only the oxygen consumption of the MDA-MB-361HK tumor was
significantly lower than all the other tumor types. The two murine mammary carcinomas (E0771
and MCaIV) were more metabolically (aerobically) active than the other tumor types, although
the difference was not significant. During tumor growth, the orthotopic E0771 murine
mammary carcinoma trended toward lower oxygen consumption. The Q0 2 for the LS174T
tumors significantly increased over time. The oxygen consumption of the other tumor types
remained relatively constant during tumor progression with MCaIV in the dorsal skinfold
chamber demonstrating consistently higher 002. The range of values determined in this study
were similar to those found previously for a different tumor type using profiles from single
vessels 24.
Assessment of tumor oxygen consumption using this method is an approximation. At
low, very hypoxic levels (P0 2 < 5mmHg), the reaction rate is first order, thus dependent
on the concentration of oxygen available48' 64. Hypoxic regions are often found in the
microenvironment of tumors including adjacent to vessels (typically with low
intravascular p02). Additionally, the diffusion-reaction model is semi one-dimensional.
Using a two-dimensional model (x and z), Dewhirst et ai calculated oxygen consumption
rates about 50% smaller than with the one-dimensional model67 . Since the radial
distance from the nearest blood vessel was used in this experiment a cylindrical model
could be applied47' 68. However, this would not be ideal in the irregular and
heterogeneous vascular network found in tumors. Secondly, endothelial cells in normal
vessels have been shown to consume oxygen across the vessel wall leading to sharp
transverse gradients69 . Given the abnormal structure of tumor vessels on the cellular
level70' 71, it is unclear if such gradients exist which would lead to loss of oxygen
longitudinally. Finally, although MP-PQM is a three-dimensional imaging technique it is
constrained by collection time from larger wide-field imaging. Further, due to signal to
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noise, measurements are typically performed no deeper than 400pm. Therefore, vessels
outside the imaging volume can contribute to the oxygen level (Figure IV-5a). The fitting
procedure attempts to ignore these few outliers when fitting the diffusion-reaction
model.
IV.4 Tumor Oxygenation during Growth and Across Models
Oxygen tension in the tumor microenvironment changes in response to numerous
factors during disease progression. Typically, as tumor volume and cellular burden
increase, the mean P02 decreases72'73. In clinical patients, most tumors have large
regions of hypoxic and necrotic tissue that are heterogeneously distributed74 . During
tumor growth, the formation of new blood vessels, or angiogenesis, is promoted by the
oxygen concentration usually through the VEGF pathway15' 75' 76 . Finally, in preclinical
models, I have shown in the previous section that different tumor types display different
rates of oxygen consumption. Therefore, the mean oxygen tension in the tumor
microenvironment is likely different across tumor types.
Table IV-4: Comparison of mean tumor oxygenation (mmHg). Statistical comparisons across time and
tumor types were determined using a single-factor ANOVA. Errors are given as standard error of the
mean. Bold measurements are statistically different (P-value < 0.05) than all others on that day.
Day E0771 MDA-MB-361HK LS174T MCaIV MCaIV-MFP ANOVA
0 32.7 ±4.8 23.7 ± 1.4 30.2 ± 2.7 33.4 ± 2.1 41.1 ± 2.8 4.2E-02
3 26.7 ±3.3 24.3± 2.9 25.4± 2.5 29.6 ± 2.0 28.4± 7.5 0.61
6 17.5 t 2.3 24.5 ±3.7 16.6 ±5.7 30.8 t 3.5
9 13.4 ± 3.0 18.1± 3.0 32.1 ±4.2 21.9±3.6
ANOVA 6.8E-03 0.49 0.38 7.7E-02
27.6 ± 5.5 5.4E-02
1.8E-02
N = 5 { N =5-10 N = 4-10 N =5-6 N=2
IV.4a TUMOR GROWTH: ANGIOGENESIS AND OXYGEN
As a solid tumor grows, it must trigger the formation of new blood vessels to support
continued growth. This process, termed the angiogenic switch, occurs in most tumors
after they reach a size (~400pm in diameter) limited by the diffusion of oxygen .
Angiogenesis has proved a predictive indicator of disease progression and response to
therapy in many tumor types79-81. Further, metastatic disease and angiogenesis of the
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primary tumor have been shown to be linked82. The level of oxygen has been shown to
be an important regulator of tumor angiogenesis1 ,83. It has even been suggested that
microvessel density (MVD) and molecular markers of angiogenesis (VEGF, etc.) are
84measures of tumor oxygenation
Figure IV-6 Angiogenesis during tumor growth. The vasculature of an LS174T colorectal adenocarcinoma
xenograft is shown over 9 days. Increased angiogenesis is notable throughout tumor growth. Tumor
vasculature is presented as a colorized depth projection (superficial to deep: green-red-white). Scale Bars
- 500pm.
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Table IV-5: Comparison of mean vascular radius (pm). Statistical comparisons across tumor types were
determined using a single-factor ANOVA. Errors are given as standard error of the mean. Bold
measurements are statistically different (P-value < 0.05) than all other measurements on that day.
Day E0771 MDA-MB-361HK LS174T MCalV MCaIV-MFP ANOVA
0 11.7 ± 0.3 12.1 ± 0.7 13.3 ± 0.5 18.9 ± 1.1 18.5 ± 2.0 1.7E-06
3 12.9 ± 0.7 11.6 ± 0.5 15.3 ± 0.7 27.8 ± 3.9 22.6 ± 4.5 1.1E-06
6 15.5 ±1.4 12.9 ±1.0 27.5 ±2.2 22.7 ±1.8
9 17.9± 2.9 12.7± 1.8 33.2± 3.2 27.6 ±2.0
ANOVA 4.4E-02 0.7 5.2E-04 5.2E-02
25.9 ±8.4 31E-07
1.3E-04
J N=5 N =5-10 1_N = 4-10__ N =5-6 N=2
Utilizing the window chamber models in mice allows tumor vascularization to be
followed over time providing critical insights into pathophysiology (Figure IV-6). Using
multiphoton microscopy to perform high-resolution angiography and automated
vascular tracing algorithms 50' 85, vascular metrics such as vessel diameter and vascular
volume fraction can be obtained. Correlating these morphological parameters with
tumor oxygenation provided by MP-PQM provides unique access to study the tumor
microenvironment during progression and across models.
Table IV-6: Comparison of vascular volume fraction. Statistical comparisons across time and tumor
types were determined using a single-factor ANOVA. Errors are given as standard error of the mean.
Bold measurements are statistically different (P-value < 0.05) than all other measurements on that day.
Day E0771 MDA-MB-361HK LS174T MCalV MCaIV-MFP ANOVA
0 5.5 ± 0.7% 3.7 ± 0.9% 5.1± 0.4% 6.2 ± 0.5% 9.3 ±1.7% 1.1E-01
3 5.6 ± 0.8% 2.9 ± 0.4% 6.0 ± 0.4% 11.6 ± 1.4% 5.6 ± 0.6% 5.9E-08
6 5.6 ± 0.4% 4.1 ±0.9% 5.9 ±0.7% 7.2 ± 1.1%
9 4.1 ±0.5% 3.8 ±1.1% 9.4 ± 2.0% 7.6 ± 1.1%
ANOVA 3.8E-01 0.76 1.2E-02 1.OE-02
3.2 ± 0.9% 7.2E-02
- 2.2E-02
N=5 N =5-10 N = 4-10 N =5-6 N=2
I measured the mean tumor oxygenation for multiple tumor types over 9 days using MP-
PQM (Table IV-4). The trend across tumors was decreasing P0 2 with tumor growth.
However, only orthotopic E0771, a murine mammary carcinoma, displayed a significant
change in mean P02 over time (P-value: 0.007). For the first week, the human and
murine mammary carcinoma tumors MDA-MB-361HK and MCalV, respectively,
demonstrated little change in tumor microenvironment P02 over time. Across tumors,
only at Day 0, when all tumors were ~4mm in diameter by enface measurement, and
169
CHAPTER 4
Day 9 was there a statistical difference in tumor P02. During the course of the
experiment all tumors increased in enface diameter and potentially depth, although
axial measurements are difficult in the chamber models. MDA-MB-361HK,
xenotransplanted in the MFP chamber of female SCID mice, had a significantly lower
P02 than all other tumors at Day 0. E0771, which demonstrated a significant decrease in
tumor oxygenation during growth, exhibited a significantly lower mean P0 2 than all
other tumors at Day 9.
E71DA MR M1HKL
Figure IV-7 Comparison of tumor vascular networks at Day 0 (top) and 9 (bottom). The higher degree of
angiogenesis is evident in LS174T and MCaiV tumors. Avascular regions (*) are apparent in both E0771
and MDA-MB-361HK tumors. Images are presented as a colorized depth projections (superficial to deep:
green-red-white). Scale Bars - 500pm.
Vascular parameters consisting of vascular radius, length and volume fraction were
determined from multiphoton angiography for all tumors. For all tumor types except
MDA-MB-361HK, the vascular radius significantly increased during tumor growth (Table
IV-5). In general, the tumors grown in the dorsal skinfold chamber (LS174T and MCalV)
exhibited significantly larger vascular diameters than those growing in the mammary fat
pad (E0771 and MDA-MB-361HK). The trends in vascular radius nearly matched those
found with vascular volume fraction (VVf, Table IV-6). However, even though vascular
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radius significantly increased in E0771, the volume fraction of the vascular network did
not. The human mammary adenocarcinoma, MDA-MB-361HK, also did not display any
increase in Wf. This suggests that although the E0771 and MDA-MB-361HK tumors
increase in size, their vascular networks maintain more avascular regions and are less
angiogenic than the other tumors (Figure IV-7).
Table IV-7: Hypoxic fraction during tumor growth. Statistical comparisons across time and tumor types
were determined using a single-factor ANOVA. Errors are given as standard error of the mean. Bold
measurements are statistically different (P-value < 0.05) than all other measurements on that day.
Day E0771 MDA-MB-361HK LS174T MCalV MCaIV-MFP ANOVA
0 13.5±6.9% 18.9±4.6% 9.3±3.3% 8.7±3.7% 2.8±0.5% 0.27
3 18.5±7.1% 21.9±6.8% 16.0±6.9% 13.6±5.0% 21.3±16.9% 0.18
6 37.1±10.8% 24.2±6.1% 12.2±4.3% 13.0±5.1%
9 59.8±10.1% 31.4±11.0% 9.7±3.8% 38.3±8.7%
ANOVA 1.1E-02 0.76 0.19 9.2E-03
36.8±10.1% 2.7E-03
N=5 I N =5-10 N =4-10 N =5-6 | N=2
The presence of avascular spaces in some of the tumors coupled with decrease tumor
oxygenation over time could lead to regions of hypoxia. I determined the hypoxic
fraction within each tumor and timepoint by calculating the number of measurements
less than 10mmHg (Table IV-7). At Day 0 both E0771 and MDA-MB-361HK had higher
hypoxic fractions than the tumors with higher VVf. The type of tumor does have a
statistically significant impact on the level of hypoxia over time. The hypoxic fraction
remained relatively high in MDA-MB-361HK tumors (~23%) and low in LS174T tumors
(~12%) without significantly changing. Both murine mammary carcinomas (E0771 and
MCalV) exhibited significantly increasing hypoxic fractions over time. However, MCaIV
also displayed increasing VVf, suggesting the spatial heterogeneity in relation to the
vasculature of hypoxic regions may be different between tumors.
To assess spatial heterogeneity in hypoxic regions, I spatially correlated each individual
MP-PQM oxygen measurement with distance to the closest vessel. The mean distance
from a hypoxic measurement was then determined from the correlated oxygen and
angiography measurement (Table IV-8). Overall, both MDA-MB-361HK and MCaIV
tumors displayed longer distances from hypoxic regions to the nearest vessel, while
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both E0771 and LS174T had hypoxic regions closer. Only in LS174T did the distance
show a significant change with tumor growth. At Day 9, the mean distance to nearest
vessel was farther.
Table IV-8: Distance (pm) from hypoxic regions to closest vessel. Statistical comparisons across time and
tumor types were determined using a single-factor ANOVA. Errors are given as standard error of the
mean. Bold measurements are statistically different (P-value < 0.05) than all others on that day.
Day E0771 MDA-MB-361HK LS174T MCaIV MCaIV-MFP ANOVA
0 73.1±24.7 173.5±40.1 76.6±14.3 149.9±43.3 162.1±100.1 0.27
3 53.3±14.8 175.3±31.8 85.3±5.6 87.9±16.6 87.9±23.1 2.8E-03
6 52.7±6.2 147.8±25.4 81.6±15.0 116.4±33.3
9 94.3±25.0 90.3±26.2 117.7±6.6 77.3±7.5
ANOVA 0.83 0.41 9.6E-03 0.39
134.6±9.5 9.0E-02
N=5 N =5-10 1_N=4-10_1 N =5-6 N=2
To gain a clearer understanding of the relationships between tumor angiogenesis and
vasculature, I correlated the vascular metrics with oxygen throughout tumor
growth(Table IV-9). Unsurprisingly, the vascular radius demonstrated no dependence on
mean tumor P02. This is in agreement with the results from individual tumors (Figure
IV-4) and previous studies35 49. However, in both MDA-MB-361HK and MCaIV, mean
vascular radius was significantly correlated with the hypoxic fraction of the tumor.
Specifically, over tumor progression as the mean vascular diameter increased, the
hypoxic fraction also increased. Interestingly, vascular volume fraction was uncorrelated
with hypoxic fraction and mean P02 in these tumors. Only the E0771 murine mammary
carcinoma exhibited a significant correlation of VVf with both PO2 and hypoxic fraction.
In this specific tumor, these relationships indicated that increased VVf is associated with
increased P02 and lower hypoxic fraction. For all tumors, a significant negative
correlation of hypoxic fraction with mean tumor P02 was observed. These correlations
served as a control since the hypoxic fraction was derived directly from the PO2
measurements. Finally, most tumors demonstrated no significant correlation for the
distance to nearest vessel from hypoxic regions with either the mean PO2 or hypoxic
fraction. Only LS174T exhibited a significant positive and negative correlation with p02
and hypoxic fraction, respectively. Therefore, in this tumor type higher tumor
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oxygenation and lower hypoxic fraction is found when hypoxic regions are far away
from the vessels. This makes intuitive sense when the diffusion and consumption of
oxygen is taken into account.
Table IV-9: Correlation of vascular metrics with tumor oxygenation and hypoxic fraction over time. All
correlation coefficients are Pearson product-moment correlations to determine if there is a linear
dependence between two factors. All significant correlations (P-value < 0.05) are given in bold.
Vascular E0771 MDA-MB-361H LS174T MCalV
Metric P02 P02 P02 P02
Radu -0.416 .0315 -. 041 -. 38
VVf '0.626 00.050 0.207 0.262
HypoxicF' -0.913 -0.765 -0.845 -0.875
HypoxicD) -0.3570.7073-.15
VVf -Vascular Volume Fraction; HypoxicF - Hypoxic Fraction; HypoxicD - Distance to nearest vessel from hypoxic region
Correlating measurements of tumor oxygenation and hypoxia with vascular metrics
provides unique insight into the tumor microenvironment during tumor growth. It is
readily apparent that different tumor types have different vascular phenotypes and
even different rates of angiogenesis. Further during tumor growth, the differential
between tumor oxygenation between tumor types becomes more apparent.
Unsurprisingly given the differences in tumor oxygenation during growth, the hypoxic
fraction also varies amongst tumor types. Hypoxia regions either remain constant over
time or increase with tumor size. Additionally, the location of these hypoxic regions with
respect to the vasculature is heterogeneous between tumor types. The lack of
correlation over time between the vascular volume and hypoxic fractions are not
unsurprising. Clinical studies using both histological and imaging modalities have shown
limited correlation between such metrics and hypoxia 4'86. However, previous studies
have demonstrated that tumor oxygenation (specifically hypoxia) can upregulate VEGF
expression, a potent angiogenic molecules'8 3 87. It is possible that other angiogenic
pathways independent of the HIF-1/VEGF axis are responsible for vascularization during
tumor progression in some of the tumor lines88.
The findings for E0771 that show a significant correlation between VVf and P02 or
hypoxic fraction indicate that with tumor growth as hypoxic fraction increases both
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tumor P0 2 and VVf decrease. A similar strong correlation using MVD as the metric of
tumor vascularization has been observed for certain endocrine tumors in patients89.
With disease progression, poor prognosis was associated with hypoxic tumors with low
MVD. Conversely, the human breast adenocarcinoma, MDA-MB-361HK, which over-
expresses the epithelial growth factor receptor Her2/neu, demonstrates no correlation
between VVf and P0 2 or hypoxic fraction. Histological studies of primary human breast
tumors expressing Her2/neu in patients showed a high degree of angiogenesis and low
levels of hypoxia90. Two explanations may account for this discrepancy. First, the
measures of angiogenesis and hypoxia were the histological markers of MVD and CA IX,
respectively. MVD provides only a snapshot of the tumor vasculature and may in some
cases serve as a poor marker of angiogenesis91. Endogenous markers of hypoxia have
92proved inconsistent at best and unreliable when only one molecular marker is utilized92
Second, the MDA-MB-361HK cell line originates from a metastatic breast tumor in the
brain, so while it is implanted in the orthotopic environment of the primary tumor
differences in cancer cell Pathophysiology may exist.
Finally, in most tumors, the mean distance from hypoxic regions to the nearest blood
vessel was found to be uncorrelated with either PO2 or hypoxic fraction. Across all
models, the tumor vascular network is both tortuous and heterogeneous interspersed
with random avascular regions (Figure IV-7). Non-invasive imaging studies in animal
models have shown no spatial correlation between hypoxic regions and vascular labels
(RGD peptides)93 . Further, vascular flow and delivery of oxygen is irregular and
heterogeneous in tumors. In vivo perfused vessels have demonstrated low oxygen
tensions suggesting regions of hypoxia may remain close to some detectable vessels 35.
Hypoxic regions in most tumors are likely heterogeneously distributed with little
correlation with the vasculature. This was observed with all tumors except the human
colorectal adenocarcinoma xenotransplant, LS174T. For this tumor, hypoxic regions are
located on average about 85pm from the closest vessel. On average, during tumor
growth, regions of hypoxia move closer to the vessels. Instead of decreased spatial
heterogeneity in hypoxic regions, this effect is possibly due to the significantly
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increasing in vivo oxygen consumption rate demonstrated by the L5174T tumor (Table
IV-3).
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Figure IV-8 Depth gradients in pO2 during tumor growth. (a). Median oxygen tension of an LS174T tumor
in the DSC at day 0 (blue) and 9 (black) at different depths in the tumor. The edges of the boxes indicate
the upper and lower quartiles with the median pO2 value represented in the center. Whiskers extend to
1.5 times the interquartile range. Asterisks indicate outliers. (b) Mean tumor P0 2 during tumor growth
remained steady. Errors are standard deviations. (c) Oxygen tension maps at 60 and 240ptm in the tumor
for days 0 and 9. Vascular casts overlay the maps from the angiographic imaging. At Day 0, most deep MP-
PQM measurements exhibited small signal to noise ratios and were not included (dark blue).
IV.4b TUMOR GROWTH: DEPTH GRADIENTS IN OXYGENATION
The application of MP-PQM to studying tumors allows non-invasive assessment of
spatial changes in tumor oxygenation up to 400tm deep in the tumor. Differences
between the superficial and deep portions of the tumor were determined during tumor
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growth. The effect of increased tumor volume and angiogenesis were observed in an
LS174T tumor in the DSC (Figure IV-8). In earlier stages of tumor growth, the deep
portions of the tumor were still supplied by oxygen diffusion from the supporting host
vasculature. In this tumor model, as the tumor grew in size, the mean oxygen tension
deeper in the tumor dropped (Figure IV-8a), while the overall average tumor P0 2
remained relatively constant (Figure IV-8b). In this case, the steady overall P0 2 is due to
increased vascularization near the tumor surface (~ 60pm). Further the heterogeneity in
tumor oxygenation at near the tumor surface decreased, while it increased deeper (120-
180p.m).
Longitudinal gradients in tumor P0 2 appear to increase from the fascial to tumor surface
in this model. This contradicts with previous studies in chamber models demonstrating
decreasing longitudinal gradients from the fascial to tumor surface94-96. The existence of
these gradients was proposed to occur from similar gradients in other metabolites
assuming that all vascular supply results from the underlying fascial vessels. In some
models this may be the case, however, in my experience, as a tumor grows in the
chamber models angiogenesis typically occurs across nearly the entire tumor surface by
2-3 weeks. Wide-field angiographic imaging from growing tumors in the chamber
models reveals vascular branches from vessels both underneath and around the
tumor . For all measurements presented in this chapter, I initiated studies only on
tumors with surface vascularization to eliminate any artifacts in P02 from transient
longitudinal gradients.
IV.5 Spatial Distribution of Tumor Vascular Networks Influence
Tissue Oxygenation
The combination of three-dimensional oxygen measurements with MP-PQM and high-
resolution angiography by MPM present unique opportunities to study the relation of
the tumor vasculature to the metabolic microenvironment. Previously in this Chapter, I
determined oxygen consumption using a semi-one dimensional diffusion-reaction
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equation that relied on distance to the nearest vessel. Here, I will show that the tissue
volume probability distribution with respect to the vasculature qualitatively predicts the
tissue oxygen profile (Figure IV-5) and oxygen tension probability histogram.
IV.5a CYLINDRICAL MODELS OF OXYGEN DIFFUSION IN TUMORS
Many theoretical approaches have been demonstrated for determining metabolite
concentrations, particularly oxygen, outside of the vasculature in a variety of tissues. In
regularly spaced capillary networks found in many normal tissues, a cylindrically
symmetric model was developed by Krogh97. Based on observations of the regular
spaced packing of capillaries and muscle fibers in skeletal muscle, an analytical solution
for steady state concentration was obtained. This model is now well known as the Krogh
tissue cylinder model. Analytical solutions for the diffusion of oxygen in other regularly
spaced planar and cylindrical geometries have been readily demonstrated".
O
r r+dr
Figure IV-9 Cylindrical geometry for describing diffusive processes. Diffusion of oxygen from a vessel
(red) to a cylindrical surface volume of tissue (brown) of width dr at a given radius, r.
The mass balance equation for the gradient of a diffusing species in a cylindrical
coordinate system (Figure IV-9) across a differential element of tissue with a
sink/reaction term, Mo, is given by Eq. (IV.3).
-D-l 2wrL+D- 2(r + dr)L - Mo dV = 0 (lV.3
r ,T r+dr
Here the area and differential volume are given by 27rrL and 2wrL dr, respectively. By
Taylor expanding the differential change in concentration over radius [Eq. (IV.4)] and
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eliminating second order terms [Eq. (IV.5)] the final cylindrical solution can be found
[Eq. (IV.6)].
aCi ac I 2CI
COcl 82C c
Or r+dr -- r + r- + (IVA4)
-D (2wrL) + D +drrz r] (2(r +dr)L) -M 0 21rL dr = {|V.5)
82C D aC
D +-- - Mo = 0 (IV.6)
Adaptations of cylindrical geometries have been applied to theoretically model the
diffusion of oxygen in tumors and prepare theoretical maps of oxygen tension8 '65'68.
Others have utilized more complex descriptions of the tumor vasculature adapted to the
cylindrical model including vascular spacing in the networks and with distance
weighting99 or an inherent heterogeneity in the spacing100.
IV.5b IN VIVO OXYGEN DIFFUSION FROM NORMAL AND TUMOR VASCULAR GEOMETRIES
While cylindrical models adequately portray vascular networks with relatively
homogenous descriptive parameters; they fail to account for higher-order branching
hierarchies found in many tissues and the truly abnormal vascular geometries in tumors.
Fractal geometries' 0' have been used to characterize vascular architecture in both
normal and neoplastic tissuesio2,103. The scale invariant behavior of fractal vascular
networks can be applied to models of metabolite and drug delivery to tumors64.
However, it appears that fractal characterization may be a less than ideal choice for
describing tumor vasculature given the heterogeneous networks found across tumors".
Distributions in the vascular spacing within tumors from two-dimensional histological
tissue cross-sections have been used to simulate tumor oxygenation10 4. However, this
theoretical work is limited to two-dimensional geometries and is subject to the limits of
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using microvessel density to describe tumor vasculature91 . It has been recently
demonstrated that a simple metric describing vascular network geometry in three-
dimensions provides powerful insight into diffusive processes in tumors. This metric, the
number of tissue voxels at a given distance from the closest vessel, n(S), can be used to
model the transport of drugs and metabolites in tissue, including tumors105. In fact,
theoretical simulations demonstrate that the need for scale-invariant geometry is not a
constraint with n(S) as it is with fractal descriptors.
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Figure IV-10 Normal and tumor tissue vascular networks described by number of tissue voxels at a given
distance from a vessel. (a) Cumulative distribution frequency of tissue voxels at a given distance for each
tissue type studied. (b) Probability distributions of n(8) for normal tissues. (c) Probability distributions of
n(8) various tumors at a size of 4mm in diameter. Normal skin: N = 4; Normal MFP: N = 5; Normal Brain:
N = 3; E0771: N = 9; LS174T: N = 13; MCalV: N = 9; MDA-MB-361HK: N = 20.
By spatially correlating the distance of each oxygen measurement to the nearest tumor
vessel, I determined n(S) across tumor types (Figure IV-10). The cumulative frequency
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distributions (CFD) were determined from all tumors of a given type at the same size
(4mm). A rightward shift in the CFD from normal to tumor vascular networks was readily
apparent (Figure IV-10a). The difference between normal and tumor vascular networks
was reflected in the broadening of n(8) and decrease in a peak maximum probability
distance for tumor vasculature in comparison to normal tissue (Figure IV-10a and b).
The E0771 tumor appeared to have most similarity with the distribution found in
normal MFP vasculature. An additional difference between tumors and normal tissues
was found in the maximum distance (6 max) of tissue volumes from vessels, which
increased in tumors. Normal skin, mammary fat pad and murine cortex displayed a 5max
of ~75, 140 and 90pm, respectively. In tumors the distance was notably longer, ranging
from 245 to 365pm for E0771 and MDA-MB-361HK tumors, respectively.
Differential
Volume of
Vessel Tissue
Wall
6 6+d8
Figure IV-11 Modeling the diffusion of a small molecule in an arbitrarily defined geometry using n(8).
Each probability distribution for the distance of tissue voxels in a vascular network
reflects the tissue oxygenation or diffusion of other metabolites or drugs105. If we
assume that diffusion near the vessels can be approximated one-dimensionally and
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scales with distance, the concentration profile of a diffusing species in an arbitrary
heterogeneous vascular geometry can be determined. Given the generalized
arrangement in Figure IV-11 we can describe the mass balance relationship at steady
state as in Eq. (IV.7).
aci acl
-D n(') + D n(8 + dS) - Mon(d)do = 0 (IV.7)
Similar to the derivation for the cylindrical model, we expand the loss out of the right
side of the differential volume tissue element in a Taylor series.
aC aC a2C
~6 =+& T1+d6 +--- (IV.8)
an
n(6 + dS) = n(6) + -- (IV.9)
Substituting the second-order expansions into the mass balance relationship [Eq. (IV.7)],
the final generalized form can be obtained.
aC1 6  aC1  azCI r n 1
-D n() + D - + da 2  n + d5 - Mn(S)dS = 0 (IV.10)
acl aC a C an a2C
a-D as6  D' S' Dd-DTnSn(S) +D n(S) +D I dsI + aDd8s (
+ Ddz 2- 88 a -Mon()dS = 0 (IV.11)
a2C D anaC
D + - Mo= 0 (IV.12)
The generalized form demonstrates an inverse dependence on the fraction of voxels
(area) at incremental distances from the vessel walls and directly proportional to the
growth/change in the number of voxels.
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Figure IV-12 Finite volume method to numerically calculate concentration profiles for the generalized
soultion to the diffusion from an arbitrary vascular network. A8 is the differential tissue element
separating two tissue surface areas defined by n. The differential volume is the product of the two.
The finite volume method10 6 can be used to numerically solve for the generalized
diffusion equation [Eq. (IV.12)] to find the concentration at given distances from the
vessel wall. Fluxes through a finite volume element are depicted in Figure IV-12, where
fluxes into the volume are defined as positive.
DA~ t_ D__+1,
' (ci_ - CO) + (ci+1 - ci) - MOA iAS = 0 (IV.13)
The tissue surface area is directly proportional to the number of tissue voxels.
(n_1 + ni
= ( ni+ + n i )
A =ni
(IV.14)
(IV.15)
(IV.16)
Substituting the tissue areas across which the conductance occurs into Eq. (IV.13) the
final finite volume formulation can be obtained.
D ni-_+ nh (Ci1 - Ci) + D nj+1 2+ ni (c1~ - cL) - Mn 1A6 = 0
AS 2 A(8_-c)+ 2 )c+-i-ogS 0 (IV.17)
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The diffusive conductance across either side of the differential tissue volume element
can now be found using the previously defined areas for the two tissue surfaces.
G _ D ( 2 + ) (IV.18)
D (f1+ngflGi+1,i = n 2 (IV.19)
Using the definition of the differential tissue volume element across which consumption
occurs (V = njAS), the final finite volume formulation can be described.
Gj_1,i(cij - ct) + Gi+1,i(ci+1,i - ci) - M0 Vg = 0 (IV.20)
Using Matlab, the finite volume formula was numerically integrated over time to find a
steady state solution for the concentration of oxygen in tissue given n(S). The
concentration at the vessel wall (CO) was defined in terms of oxygen saturation (0 - 1).
The diffusion coefficient of oxygen in tissue was assumed to be constant at 1.5 x 10-9
m2/s107. The consumption of oxygen in tissue was assumed to follow Michaelis-Menten
kinetics68.
M(Coz) = MO- C02M (IV-6)C02 + MI1  (
In Michaelis-Menten kinetics, the consumption of oxygen is dependent on the
concentration present. Typically, oxygen consumption follows zero-order kinetics at most
oxygen tensions. Only for low oxygen concentrations, defined as M1, does the consumption
deviate from M0 and follow first order kinetics. I assumed that in hypoxic environments, the
oxygen consumption would become dependent on oxygen, so a saturation value of 0.05 was
selected for M1 .
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Figure IV-13 Numerical simulations using the finite volume method to determine steady state oxygen
concentration profiles for generalized functions of n(6). (a) Volume fraction probability distributions for
given distances from the vasculature. (b) Oxygen concentration profiles in the tissue based on the
diffusion-reaction model for arbitrary three-dimensional geometries. (c) Oxygen probability distributions
determined from a and b. Normal - blue; Tumor - red.
To assess if the finite volume method was successful in determining oxygen profiles
from n(6), I tested some functions that gave representative distributions similar to
those found in normal and tumor tissue. The functions f(x) = xex and f(x) = -mx +
C adequately describe n(6) for normal and tumor tissue (Figure IV-10), respectively.
The steady-state oxygen concentration profiles were found for each of these functions
(Figure IV-13). The zero-order oxygen consumption (MO) was assumed to be twice as
high in tumors as normal tissue (0.1 versus 0.05). Given that many tumors exhibited
average tissue oxygenation values that were close to that of normal tissue (~30mmHg), I
applied the same source term (Co = 0.45) to both representative n(6) functions. In the
true tissue metabolic micronenvironment there would be a distribution of source
concentrations supplying the tissue.
184
CHAPTER 4
0' 50 100 150 200 250 300 350 400 0 20 40 60 80 100 120 140 160 180 200
Distance from Vessel (pm) Distance from Vessel (pm)
-Normal Skin -Normal MFP -Murine Brain -E0771 -L5174T -MCaV -MDA-MB-361HK
Figure IV-14 In vivo PO2 profiles for normal and neoplastic tissue determined from MP-PQM
measurements. (a) The normal tissues remain relatively flat up to Smax. Everything after this point is
artifact due to single measurement points potentially outside of the tissue. The tumors uniformly display
decreasing P0 2 profiles out to significant distances. Due to a limited number of points, this region is
noisier. (b) A truncated view of a.
The qualitative oxygen profiles and probability distributions shown in Figure IV-13
demonstrate many of the distinguishing features of those found in normal and
neoplastic tissue. The test function for normal tissue matches remarkably well to that
found in normal skin (Figure IV-10b). Similarly, the general linear function for the tumor
matches quite while to that found in MCaIV and MDA-MB-361HK (Figure IV-10c). It also
exhibits similar parabolically decreasing P02 profiles to those found in vivo (Figure
IV-14). Given greater probability of tissue voxels closer to the vessels in normal tissue,
the P02 profile is fairly flat as the tissue is well oxygenated matching the in vivo results.
For the simulation, oxygen probability distributions were determined from the functions
for n(S) and the p02 profile (Figure IV-13c). The oxygen probability distribution found
for normal tissue is too narrow in comparison to in vivo measurements (Figure IV-15b).
This is due to the fact that intravascular longitudinal P0 2 gradients are found in the
normal tissue vascular networks broadening the oxygen distribution38. For the
representative tumor, the oxygen probability distributions reveal a similar broadness,
but lack the normoxic and hypoxic peaks found with in vivo measurements (Figure
IV-15c). This is reflective of the fact that a distribution, possibly heterogeneous, of
source terms due to convective dispersion was not taken into account'05.
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Figure IV-15 In vivo oxygen tension probability distributions. (a) Cumulative frequency distributions
demonstrate a rightward shift to higher P0 2 in normal tissues. Multiple inflection points (normoxic and
hypoxic regions) in the tumor distributions are observable. (b) P0 2 probability distributions in normal
tissues. (c) PO2 probability distributions in tumors reveal a bimodal nature.
I applied the numerical method to find steady-state oxygen profiles for the tissue
volume fraction spatial distributions determined from in vivo MP-PQM. The zero-order
oxygen consumption (MO) for the tumors was assumed to be twice that of murine skin.
Given the measurements of oxygen consumption (Table IV-3) and gradients in the single
vessel profiles (Figure IV-1), this appears to be a good approximation. The source
oxygen saturation value was selected for each tissue type from the peak of the oxygen
probability distributions measured by MP-PQM. Given the in vivo n(S), the simulated
spatial oxygen profiles and probability distributions for LS174T, MCalV and skin
demonstrate striking similarities with the measured profiles and distributions (Figure
111-16). The results using LS174T illustrate a transition between normal vascular
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networks and the grossly abnormal vasculature found in MCalV. This is reflected also in
the shape of n(S), which has features found in the distributions for both normal and
MCalV vascular networks. Since a distribution of source terms was not applied to the
numerical procedure, the oxygen distributions lack the broadness found in the MP-PQM
measurements. This is particularly the case for the normal tissue, which is nearly a Dirac
delta function.
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Figure IV-16 Numerical calculation of oxygen profiles and associated oxygen probability distributions
from in vivo measurements of n(8). (a) MCalV and LS174T tumor tissue voxel distribution predict
decreasing p0 2 profiles and broadened oxygen distributions. (b) Conversely, tissue voxel distributions for
normal murine skin predict a very flat truncated oxygen profile and narrow oxygen distribution.
The oxygen probability distributions for the tumors obtained from the steady-state
solutions found using Eq. (IV.20) lack the bimodal distributions observed in vivo (Figure
IV-15). The limitations due to not accounting for a distribution in oxygen concentrations
from the vessels are likely not the only factors affecting these bimodal features. Large
heterogeneously distributed hypoxic regions have been demonstrated in tumors by
both imaging and histological methods84'108-11. Additionally, the vascular architecture of
many of the tumors studied in this chapter display random avascular regions that are
hypoxic as measured by MP-PQM (Figure IV-7). This coupled with the findings by myself
and others that highly-vascularized regions of the tumor microenvironment are well
oxygenated suggests two tissue populations exist*9.
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Figure IV-17 Invasion percolation networks reveal large avascular regions and define n(6). (a) Regularly
spaced capillary network. (b) Normal tissue vascular network with some heterogeneity due to the
hierchical vascular structure. (c) Representative tumor vascular network at the percolation threshold.
Large avascular regions outside the diffusion range of oxygen exist. (d) 2D vascular network below the
percolation threshold. e. Distance to nearest vessel histograms for a - d.
As mentioned, fractal analysis has been used to describe tumor vasculature. However,
large avascular regions found in tumors promote deviation of the vascular network from
the self-similarity required of fractal analysis. This has been well described using
invasion percolation networks to model the growth and transport of vascular
networks64. This previous study also modeled the transport and diffusion of oxygen in
two-dimensions from these networks revealing the presence of significant hypoxic
regions. With the invasion percolation model, the introduction of large avascular regions
amongst highly vascular regions is observed as the occupancy of the network is reduced
(Figure IV-17a-d). These large avascular regions are chronically hypoxic and diffusion of
oxygen into them does not occur. However, the highly vascularized regions are likely
well oxygenated as observed in vivo. This model helps explain the existence of the
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bimodal peaks in the oxygen distributions. In fact, even in two-dimensions, defining the
structure of the vascular network at various occupancies using invasion percolation
demonstrates tissue volume fraction probability distributions, n(6), with similar
features to those found in vivo (Figure IV-17e).
IV.6 Tumor Oxygenation during Targeted Therapy
As previously discussed, fluctuations in the tumor metabolic microenvironment during
therapy can have profound implications for optimizing combined treatment regimens. In
particular, the application of agents that either directly or indirectly target the tumor
vasculature can alter tumor oxygenation. Antiangiogenic therapy, which directly affects
endothelial cells, has been shown to promote morphological, architectural, cellular and
functional changes in the tumor vasculature7 28 3 . In 2001, my thesis advisor, Dr. Jain
proposed that judicious application of antiangiogenic therapy can improve vascular
function and thereby drug delivery by "normalizing" the vasculature of the
tumorn1 3234 m. What remains unanswered is how these changes affect the metabolic
microenvironment of the tumor, i.e. does the metabolic microenvironment undergo
"normalization". The application of MP-PQM to multiple tumor models to assess
response to targeted therapy reveals insight into alterations in the tumor
microenvironment and the potential impact on combined therapies.
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Figure IV-18 Breast tumor response to Herceptin. (a) The CFD of the tissue voxel fraction within a given
distance from the nearest vessel during treatment with either trastuzumab or rat IgG. Inset - Colorized
depth projection of the tumor vasculature in control and treated MDA-MB-361HK tumors. (b) Probability
histograms of PO2 for day -1, 5 and 8 with respect to treatment initiation. (c) Changes in metrics of both
the tumor vasculature and oxygenation during treatment. N = 6-10, both groups. Scale Bars - 500ptm.
Errors are standard error.
IV.6a MEASUREMENT OF P02 IN A BREAST TUMOR MODEL DURING THERAPY WITH
TRASTUZUMA B
Trastuzumab (Herceptin) inihibits the HER2/neu cell surface receptor, which is over-
expressed in a particularly aggressive form of breast cancer'13. Recently, trastuzumab
was shown to down-regulate a spectrum of vascular growth factors and in a xenograft
metastatic breast cancer model modify the tumor vasculature in a manner analogous to
many vascular targeted antiangiogenic agents" 4. Similar to other single-agent cancer
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therapies with antiangiogenic or cytotoxic agents, trastuzumab is likely to modify the
tumor metabolic microenvironment.
Using MP-PQM, I monitored the tumor vasculature and PO2 in mice bearing mammary
fat pad window chambers implanted with MDA-MB-361HK treated with either
trastuzumab or non-specific rat-IgG. Mice were treated every third day for 3 treatments
with MP-PQM occurring a day prior to each treatment timepoint. The overall response
to therapy by either angiographic or oxygen measurements was inconclusive (Figure
IV-18). The vascular structure appeared to exhibit increased avascular regions at the
conclusion of the treatment as indicated by the rightward shift in the CFD of the tissue
volume fraction at a given distance from the vessels (Figure IV-18a). Review of MP
angiography revealed no distinct vascular anatomical features between the two
treatment groups (Figure IV-18c). No statistical difference in mean tumor oxygenation,
hypoxic fraction or PO2 probability distributions was found with therapy (Figure IV-18b
and c). In both groups, the hypoxic fraction increased over time as exemplified in the
redistribution of oxygenation to lower values. No trend over time was found to be
significant within or between groups.
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Figure IV-19 In vitro Her2 assay of MDA-MB-361HK in comparison to other cell lines. (a) Western blot of
Her2 expression. (b) WST-1 assay of cell proliferation at different media concentrations of trastuzumab.
Fold growth is with respect to the cells growing in the absence of antibody. (c) Cell viability of the 100pg
dosage from b. 361HK: MDA-MB-361HK; 474: BT474; 361: MDA-MB-361.
The lack of response to trastuzumab was surprising given the same cell line was used by
Izumi and co-workers 14. Further, another group has recently demonstrated transient
increases in P02 with trastuzumab treatment in a human cancer cell line induced to
over-express HER2/neurls. Either the antibody used was defective and not delivered to
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the tumor cells, or the cells are no longer responsive. To differentiate between the two
possibilities, MDA-MB-361HK cells were subjected to in vitro growth assays in the
presence or absence of trastuzumab. The results of these experiments indicate that the
growth of the cell line, which still maintains very high levels of HER2 expression, is
uncoupled from the HER2 pathway (Figure IV-19). Others have shown in vitro inhibition
of the MDA-MB-361HK cell line with trastzumab at doses as low as 100pg/ml'1 6,
suggesting that the current cell line must have been altered during passaging.
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Figure IV-20 Murine mammary carcinoma (MCalV) response to VEGF-R2 blockade. (a). The CFD of the
tissue voxel fraction within a given distance from the nearest vessel during treatment with either DC101
or rat IgG. Inset - Colorized depth projection of the tumor vasculature in control and treated tumors at
Day 5. (b). Probability histograms of PO2 for day -1, 2 and 5 with respect to treatment initiation. (c)
Changes in metrics of both the tumor vasculature and oxygenation during treatment. N = 6 Control N = 4
treated. Scale Bars - 500 im. * - P-value < 0.05. Errors are standard error.
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IV.6b MEASUREMENT OF P02 DURING VEGF-R2 BLOCKADE
Angiogenesis is a fundamental process in the progression of solid tumors. A central
regulatory pathway in the process of angiogenesis is that of the vascular endothelial
growth factors (VEGF) 17'118. Many antiangiogenic therapies have been designed to
target either the soluble ligands (bevacizumab)1"9 or receptors in the VEGF pathway.
Blockade of this pathway in animal models has demonstrated decreases in angiogenesis
120-122and tumor growth- . In preclinical tumor models, an antibody against VEGF-
Receptor 2 (VEGF-R2) known as DC101123 has proved successful in combination
therapies25,2,23,u4 and potentially "normalizing" the tumor vasculature27. However, little
is known about the spatio-temporal effects of VEGF-R2 blockade on the metabolic
microenvironment.
The study of Tong et al demonstrated vascular "normalization" in both MCaIV and
LS174T tumors in SCID mice. "Normalization" in this case was defined by a reduction in
vascular diameter, vessel length density, permeability and interstitial fluid pressure, all
of which are typically increased in tumors. I performed survey studies on the effect of
treatment by DC101 in these two tumor types. In a treatment schedule analogous to the
trastuzumab study, I administered DC101 every three days for 3 timepoints. Similarly,
imaging with MP-PQM was performed a day prior to each treatment.
In the case of the murine mammary carcinoma (MCaIV) implanted in the DSC, the
vascular architecture appeared to change by visual inspection for most tumors.
However this was not reflected in the quantitative parameters (Figure IV-20a and b). By
Day 5, the mean tumor oxygenation decreased in the treated tumors. A shift to lower
P02 is reflected in the redistribution of the oxygen probabilities to more hypoxic values
(Figure IV-20b). Further, a statistical difference is observed in hypoxic fraction between
the two groups.
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Figure IV-21 Human colorectal adenocarcinoma xenograft (LS174T) response to VEGF-R2 blockade. (a)
The CFD of the tissue voxel fraction within a given distance from the nearest vessel during treatment with
either DC101 or rat IgG. Inset - Colorized depth projection of the tumor vasculature in control and treated
tumors at Day 8. (b) Probability histograms of p0 2 for day -1, 5 and 8 with respect to treatment initiation.
(c) Changes in metrics of both the tumor vasculature and oxygenation during treatment. N = 4-10 Control
N = 3 treated. Scale Bars - 500pm. * - P-value < 0.05. Errors are standard error.
The response of the human colorectal adenocarcinoma xenograft, LS174T, followed the
same trends as MCaIV with decreasing oxygenation and increasing hypoxic fraction
(Figure V-21). Visually, the vasculature was strikingly different at day 8 between the
DC101 treated and control tumors. This was reflected in analysis of the vascular
morphology which revealed a significant difference in diameter by Day 8 and a trend
toward separation in the vascular volume fractions (Figure IV-21c). In the control group,
the growth in both vascular diameter and volume fraction were significant over time (P-
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value < 0.05). Again MP-PQM revealed an increasing hypoxic fraction and redistribution
of the overall tumor oxygenation to lower values in the DC101 treated group. However,
these trends were not significant over the course of the experiment.
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Figure IV-22 Orthotopic murine mammary adenocarcinoma (E0771) response to VEGF-R2 blockade. (a)
The CFD of the tissue voxel fraction within a given distance from the nearest vessel during treatment with
either DC101 or rat IgG. Inset - Colorized depth projection of the tumor vasculature in control and treated
tumors at Day 8. (b) Probability histograms of p02 for day -1, 5 and 8 with respect to treatment initiation.
(c) Changes in metrics of both the tumor vasculature and oxygenation during treatment. N = 4-5 Control N
= 4-5 treated. Scale Bars - 500Lm. * - P-value < 0.05. Errors are standard error.
The previous tumor models treated with DC101 were implanted in an ectopic location
(skin) and in the case of LS174T a human tumor xenograft. The effect of the host tissue
microenvironment has been shown to play a role in angiogenesis and the progression of
disease for many tumor types, including breast cancer1 12 s,126. The metabolic
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microenvironment is different depending upon the surrounding stromal cells and tissue
structure. Therefore, the response to therapy likely depends upon the tissue in which
the tumor is growing.
To eliminate the issues associated with the potential effects of the host tissue
microenvironment, I repeated the DC101 experiment with a syngeneic murine
mammary adenocarcinoma (E0771) implanted in the mammary fat pad of female SCID
mice. The experimental course was identical to that previously applied to the other
tumors treated with DC101. In this tumor model, the response of the vasculature to
DC101 was dramatic. The vascular network was almost entirely pruned in most tumors
treated with DC101 (Figure IV-22a). This effect is readily apparent in the rightward shift
in the CFD of the tissue volume fraction at a given distance from the vessels across the
treatment duration. This indicates increasing avascular regions as seen in MPM
angiography. While vascular volume fraction is significantly different by Day 8, the mean
vessel diameters between groups did not changed (Figure IV-22c). In fact the average
vessel diameter in E0771 tumors was only slightly larger than those found in the normal
mammary fat pad (~10tm). Because a significant portion of vessels are pruned away,
the tumor oxygenation drops over time. However, the two treatment groups did not
show a significant difference at any time point or over the entire course of the
experiment. There was a significant difference in the hypoxic fraction at Day 8, which
again can be seen in a redistribution of the P02 to lower levels (Figure IV-22b).
Interestingly the tumors continued to grow in the DC101 treated group although at a
slower rate than the controls based on observations of the enface tumor diameter.
Overall, the administration of DC101 to each tumor type at the dose used in previous
studies decreased tumor oxygenation. However, it is apparent, particularly in the E0771
experiment, that DC101 significantly inhibited angiogenesis and promoted regression of
the vascular network (Figure IV-23). This effect is not observed in human patients
treated with antiangiogenic agents like bevacizumab (Avastin) due to toxicity levels at
the doses required29 30 ,127. These results suggest that for "normalization" of the tumor
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microenvironment to occur, the antiangiogenic agent needs to be titrated to prevent
complete abolition of the tumor vasculature. At lower doses it is possible that the tumor
oxygenation may increase if the vascular supply is made more efficient.
Day -1
Figure IV-23 Pruning of the vascular network in an E0771 tumor by VEGF-R2 blockade with DC101.
Multiphoton angiography images are presented as colorized depth projections (green-red-white). Scale
Bars - 500pm.
IV.7 Summary
In this Chapter, I have applied the technique of multiphoton phosphorescence
quenching microscopy developed in Chapter III to study the metabolic
microenvironment during tumor progression and response to targeted therapy. Oxygen
tension profiles from single vessels in normal and neoplastic tissue were acquired. The
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profiles in a melanoma tumor uniformly demonstrated lower P0 2 values from the vessel
wall into the interstitial space than those found in normal tissue. In fact, PO2 gradients in
normal tissue were difficult to obtain unless adjacent vessels were occluded using
nanovascular surgery techniques with the multiphoton microscope.
Because tumors display spatially heterogeneous fluctuations in blood flow over
relatively short time periods, relying on a limited number of P0 2 gradients from single
vessels reveals only a small part of the tumor metabolic microenvironment. The high
three-dimensional resolution and deep penetration (~400pm) of MP-PQM permitted
oxygen tension mapping in three-dimensional space over large regions (4 x 4mm) of the
tumor. Coupling the PO2 maps with angiography performed by MPM allowed
correlation of the P0 2 measurements with morphometric analysis of the tumor
vasculature. Correlation of P0 2 with vascular metrics demonstrated a lack of correlation
with vascular diameter and a strong negative correlation with distance from the blood
vessel. Fitting a one-dimensional diffusion-reaction model for oxygen to the spatial
distribution of P02 from the blood vessels allowed quantification of average tumor
oxygen consumption. A range of oxygen consumption rates was observed for different
tumor types that in many cases increased with tumor progression.
The vascular networks and oxygen tension mapping was compared across tumors. In
almost all cases, angiogenesis occurred as defined by an increase in both vascular
diameter and volume fraction during tumor growth. However, different tumor types
displayed various degrees of correlation with the tumor vasculature during the process
of angiogenesis. In some tumors, the vascular diameter correlated significantly with
hypoxic fraction, while in others the VVf displayed a negative correlation. Interestingly,
the human colorectal adenocarcinoma displayed a significant correlation of P02 with the
mean distance from hypoxic regions to the nearest vessel. Applying the depth sectioning
ability of MPM to the oxygen measurements allowed changes in mean P02 at given
depths in the tumor to be observed during growth. This revealed that often the tumor
surface remained well-oxygenated, while the deep core decreased in oxygen content.
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Quantitative assessment of the vascular architecture through the use of a simple metric
describing the tissue volume fraction at a given distance from the closest blood vessel
was shown to predict the tumor oxygenation measured by MP-PQM. Using a
generalized formula for oxygen diffusion based on the spatial probability distribution of
tissue volume with respect to the vessels simulations of both the tumor oxygen gradient
and probability distribution were performed. The results exhibited good agreement with
in vivo measurements in most cases except for an increasing redistribution to hypoxic
oxygenation in the tumor oxygen probability distributions. The bimodal nature of these
oxygen distributions is most probably due to the existence of two tissue populations
(normixic and hypoxic) in the tumor microenvironment. Describing tumor vascular
networks using an invasion percolation model reveals large avascular regions exist in
tumors that have spatial probability distributions of tissue volume with features
identical to those found in living tumors.
Finally, the metabolic microenvironment was probed with MP-PQM during targeted
therapy. Treating a human breast cancer xenograft model with trastuzumab revealed
minimal changes in both vascular metrics and tumor oxygenation. Further experiments
demonstrated that the cell line previously used in other studies no longer responded to
trastuzumab even though the drug target (HER2) was still over-expressed.
Antiangiogenic therapy in the form of VEGF-R2 blockade (DC101) was then administered
to 3 other tumor models including an orthotopic murine mammary adenocarcinoma.
The results of these studies demonstrated that antiangiogenic therapy with DC101
reduced both vascular volume fraction and tumor oxygenation. These outcomes suggest
that antiangiogenic therapies should be titrated for a limited dose response for
potential "normalization" of the tumor metabolic microenvironment.
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IV.8 Materials and Methods
IV.8a ANIMAL MODELS
Dorsal skinfold chambers (DSC) were prepared on male SCID mice using previously
described methods128. Mammary fat pad windows were prepared in SCID mice as
previously described129 . Briefly, prior to chamber implantation, the entire lateral flank of
the animal is shaved and depilated and the third nipple from the top is identified. A fold
is formed which contains the skin and nipple, mammary gland, adipose tissue and
cutaneous muscle layers on one side and the dorsal skin, adipose tissue and cutaneous
muscle layers on the other side. Two symmetrical titanium frames (weight 2.5 g;
Workshop, Department of Radiation Oncology, MGH), which are mirror images of each
other, are implanted centered over the third nipple so as to sandwich the extended
double layer of skin. A layer of skin on the dorsal surface is dissected in a circular area
approximately 15 mm in diameter to the reveal the fascial plane of the internal
mammary vein. The remaining layer of tissue, consisting of epidermis with nipple,
subcutaneous tissue, and mammary fat pad is covered with a glass coverslip
incorporated into one of the frames. Following implantation of the transparent access
chamber, animals are allowed to recover from microsurgery and anesthesia for 48 hours
before tumor implantation or intravital microscopy.
For both models, the appropriate tumor type was then implanted in the center of the
chamber 2-3 days after the initial surgery. The murine mammary adenocarcinomas
(MCaIV and E0771), and human colorectal adenocarcinoma (LS174T) were transplanted
from subcutaneous tumors grown in isogenic mice. The human mammary
adenocarcinoma (MDA-MB-361HK) was implanted as a single cell suspension of ~3x106
cells in 30 pil of Hank's Buffered Salt Solution (HBSS).
Cranial windows were prepared in nude mice as previously described3 0. In SCID mice,
the surface of the skin atop the skull is dilapidated and sanitized with antimicrobial
solution. After stereotaxically fixing the mouse skull, a longitudinal incision of the skin is
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made between the occiput and forehead. Then the skin is cut in a circular manner on
top of the skull, and the periosteum underneath is scraped off to the temporal crests. A
6-mm circle of the skull over the frontal and parietal lobes is removed using a high
speed air-turbine drill (CH4201S; Champion Dental Products, Placentia, CA) with a burr-
tip 0.5 mm in diameter. After careful removal of the bone flap from the dura mater, the
dura and arachnoid membranes are cut completely from the surface of both
hemispheres, avoiding any damage to the sagittal sinus. The window is sealed with a 6-
mm cover glass which is glued to the bone with histocompatible cyanoacrylate glue.
Animals were anesthetized with Ketamine/Xylene(10/1 mg/ml) for surgeries and
Isoflurane (1% in medical grade air) for all experiments. All animal work was approved
by the MGH institutional review board on animal care.
IV.8b MP-PQM
The principles and application of multiphoton phosphorescence quenching microscopy
was described in detail in the previous Chapter. MP-PQM was performed with a custom-
modified confocal laser scanning microscope (Olympus 300; Optical Analysis Corp.,
Center Valley, PA) using a broadband femtosecond source (High Performance MaiTai,
SpectraPhysics, Mountain View, CA) using a 25x, 0.95 NA water emersion lens (Olympus
XLUMPlanFI, Optical Analysis, Center Valley, PA) for imaging. Excitation pulses for time-
domain measurement of phosphorescence lifetime were selected using a Pockel's Cell
(ConOptics, Model: 350-50; Conoptics, Inc., Danbury, CT) driven by custom electronics
and a digital pulse delay generator (DG535, SRS, Sunnyvale, CA). Phosphorescence
emission was detected through a 690/90 emission filter (690/90M, Chroma Technology
Corp., Rockingham, VT) using a GaAs photon counting PMT (H7421P-50, Hamamatsu,
Inc., Bridgewater, NJ). Counts were binned and accumulated for 2500 repetitions using a
multichannel scaler (SR430, SRS, Sunnyvale, CA). All experimental protocols were
automated using custom instrumentation control created in LabView (National
Instruments, Austin, TX). Lifetimes were fit in real-time using built-in MatLab
(MathWorks, Natick, MA) code in order to display the tissue oxygenation.
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To prepare animals for MP-PQM measurements, a mixture (200pl) of 10mg/ml Oxyphor
R2 (Oxygen Enterprises Ltd, Philadelphia, PA) was injected retro-orbitally using a 28.5G
needle. This allows the sensor to diffuse into the tumor, where it binds to proteins in the
interstitium. Fifteen minutes prior to MP-PQM measurements, the animal was
anesthetized by Isoflurane (3% for 4 minutes) administered as an inhalant, Immediately
following a mixture (200jI) of 10mg/ml Oxyphor R2 with 8mg/ml 2M MW FITC-dextran
was injected retro-orbitally. This allows both highlighting the vasculature and real-time
measurements of PO2.
For oxygen profiles from single vessels, the laser beam was parked at given distances (5-
10pm steps) from the vascular wall. Five to ten repeated measurements were then
collected at each point. For oxygen tension maps, a rectangular region of interest was
manually selected using a motorized stage and input into the control software. An
automated series of mosaic multiphoton microscopy images was then collected
covering the ROI. Each image contained an axial series up to 400pm deep in the tissue at
a 5pm step size. Following collection of the angiography, phosphorescence lifetime
measurements were performed in a series of 144 points based on a 12x12 covering the
ROI at four equally spaced depth planes. Total data collection time ranged from two to
three hours depending upon the size of the ROL.
IV.8c OXYGEN TENSION MAPPING DATA ANALYSIS
Prior to processing the oxygen measurements, the angiography images were prepared
and analyzed. A depth projection was created of each individual mosaic MPM image and
semi-manually assembled in ImageJ (NIH, Bethesda, MD) using the MosaicJ plugin.
Custom code written in Matlab employs the log file from the MosaicJ output to
assemble the entire three-dimensional mosaic image stack. Overlap between adjacent
images was blended using an intensity weighting procedure based from the center of
the panel outward. Often times, angiographic contrast agent extravasates from the
permeable tumor vessels obscuring vessels below. To eliminate this artifact in
preparation of vascular tracing, a binary mask of the mosaic image was semi-manually
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created in ImageJ. A final mosaic image was created from the original MPM image
mosaic stack and the binary mask. Colorized depth projections were created from this
processed image using custom code in Matlab. Each depth layer was assigned to a
colormap level, opacity factor (for superficial depths) and corrected for optical
scattering loss by an exponential factor. Semi-automated vascular tracing was
performed on the mosaic image stack using an algorithm that models vascular segments
as superellipsoids to obtain three-dimensional trajectories and morphologyso,85
The output of the tracing algorithm was then correlated with each individual oxygen
measurement to quantify distance to nearest vessel and diameter of that vessel.
Phosphorescence lifetimes were determined by fitting to a two-component exponential
decay model to find the fraction of free and bound Oxyphor R2. Oxygen tension values
were then calculated using the Stern-Volmer relationship and the quenching constant
and anoxic lifetime determined from in vitro calibrations (Chapter 111). Oxygen tension
maps were then created in Matlab using custom code to overlay the mesh grid of P02
values with the outlines of the vascular tracing. Mean oxygen tension was determined
over all the measurements and at each depth plane at which they were acquired.
Oxygen consumption was calculated by fitting the one-dimensional diffusion-reaction
equation [Eq. (IV.2)] to the scatter plot of all p02 measurements versus distance to
closest vessel. A nonlinear Levenburg-Marquedt algorithm was employed in Matlab to
determine Q02. The probability distribution of the number of tissue voxels at a given
distance from the closest vessel was calculated from distance maps obtained from the
traced vasculature. The tumor oxygen profile was determined using a sliding averaging
procedure with a 10mmHg window and 2.5mmHg stepsize in Matlab. For each tumor
type, the distributions are a collection of all tumors imaged at that time-point or within
a specific treatment group.
203
CHAPTER 4
IV.8d NUMERICAL SIMULATIONS OF OXYGEN PROFILES AND DISTRIBUTIONS FROM IN
VIvo MEASUREMENTS
Using Matlab, the finite volume method was employed to numerically solve for the
generalized oxygen diffusion equation based on the tissue volume fraction spatial
distribution. The derivations of the appropriate formulas were described in detail in
Section IV.5b. For test functions, the integration time step could be selected at fairly
long times. The time-integration procedure was allowed to iterate until steady state was
reached. This was defined as no change in the oxygen concentration profile if the
maximum integration time was increased. For in vivo data, the time-step needed to be
reduced due to irregular features requiring more precise integration steps. The
minimum time-step was determined by comparing steady-state results at the same time
for multiple time steps. Once the steady-state oxygen concentration profile was reached
with no change between time steps, the minimum step was selected. Oxygen
probability distributions were determined using the numerically determined oxygen
gradient and the spatial probability distribution of tissue volume.
IV.8e INVASION PERCOLATION MODEL
The invasion percolation model accounts for the connectivity of a vascular network
according to occupied points on a two- or three-dimensional lattice64 . Essentially, the
invasion percolation network grows along paths of least resistance according to
randomly assigned "strength" values to each lattice point. The process is repeated until
a given fraction of lattice points are occupied. A vascular network is then described by
connecting each adjacent lattice point by a vessel segment. Flow through the network is
then simulated through one arbitrarily designated point on the lattice and segments
with zero flow are pruned. All simulations were performed using MatLab.
IV.8f TARGETED THERAPIES
Trastuzumab (Herceptin) was obtained by patient donations through the MGH oncology
pharmacy. Female SCID mice bearing MFP chambers implanted with MDA-MB-361HK
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tumors were treated with trastuzumab or nonspecific rat IgG administered
intraperitoneally at 30mg/kg as previously prescribed in this tumor type" 4 . In the other
tumor models, antiangiogenic VEGF-R2 blockade treatments with DC101 (ImClone
Systems Inc., New York, NY) or nonspecific rat IgG were administered intraperitoneally
at 40mg/kg as prescribed in previous studies27. Mice were imaged the day immediately
prior to each treatment. Therapeutic initiation was determined through monitoring of
tumor growth by visual inspection of the enface tumor diameter and angiogenesis of
the tumor. Animals were selected based on the criteria that 1) the tumor diameter was
approximately 4mm in diameter 2) the entire core of the tumor was functionally
vascularized and 3) the animal was in good health. Three treatments at three-day
intervals were given (defined as day 0, 3, 6), and imaging was performed through day 8.
IV.8g IN VITRO TRASTUZUMAB INHIBITION ASSAY
MDA-MB-361HK cells were seeded in a 96-well plate (10,000 cells/well) in 10%
Dulbecco's modified eagle medium (DMEM). The following day, the cells were treated
with trastuzumab (0-800 ig/ml) in 5% DMEM. After six days, the number of viable cells
was determined by a WST-1 proliferation assay (Cat. No 11 644 807 001), Roche
Diagnostics Corp., Indianapolis, IN). The concentration of the free formazan dye cleaved
by viable cells from WST-1 was quantified at 480/600nm in a (Benchmark plus, Bio-Rad
Life Science Research, Hercules, CA) plate reader.
IV.8h STATISTICAL ANALYSIS
Data are presented as mean ± standard error of the mean (SEM). Significant differences
between groups were assessed by a multivariate repeated measures ANOVA accounting
for response to treatment over time (Systat, Systat Software, Inc., Chicago, IL).
Individual timepoints were compared using a two sample Student's t-Test. P < 0.05 was
considered statistically significant for all comparisons. All correlations were determined
using the Pearson product-moment correlation.
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V.1 Introduction and Motivation:
This Chapter describes the development and application of an in vivo pH biosensor
based on resonance energy transfer between a fluorescent semiconductor nanocrystal
(NC) 1,2 and pH sensitive dye. The work shown here is the result of an active
collaboration between the Bawendi and Nocera labs at MIT and the Steele Lab for
Tumor Biology at MGH. The motivation for this work was the development of a
reversible internally ratiometric pH sensor capable for use with multiphoton microscopy
to quantify pH in the tumor microenvironment. The ideal pH sensor design for this
application should be characterized by the following parameters:
Physiologically relevant pKa (~7.0-7.4)
Biocompatibility (minimal charge and size)
Biostability and Photostability (robust construct and no
photobleaching)
Appreciable two-photon excitation (-2,NC a2,dye)
Broad two-photon excitation cross-section
* 810nm y=2.03x+0.86
R2 =0.99
U 940nm y-1.95x+0.78
R2=0.99
1.2 1.4 1.6 1.8
Log Power (mW)
X10
2 2.2 2.4 700
e 0.2 M NaOH
* pH7.0
*
*
* *
** **~* ~
*
750 sw a 0 h
wavelength (nm) 900 950 
1000
Figure V-1 Two-photon excitation of BCECF. (a). The fluorescent emission of BCECF at pH 7.0 obeys
quadratic dependence on the excitation power for both 810 and 940nm incident laser wavelength. (b).
The two different acid an base forms of BCECF are visible in both a solution of 0.2M NaOH and PBS at pH 7
in the normalized action cross-section. It is readily apparent that the two species have different two-
photon absorption cross-sections.
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While methods for measuring in vivo pH exist, none is characterized by both high three-
dimensional spatial resolution and significant depth penetration in tissue (Chapter II).
Further, most are unable to probe the tumor metabolic microenvironment in the
context of the vascular network. Multiphoton microscopy permits simultaneous
fluorescence ratiometric imaging and non-invasive angiography. The common pH
sensitive dyes cannot be applied individually to FRIM in the two-photon regime due to
different two-photon cross-sections of the acid and base forms3 (Figure V-1). The pH-
sensitive lifetime of BCECF has been used to quantify pH in murine skin using MPM, but
depth penetration in two-photon fluorescence lifetime imaging was limited to only
20p m4. Another study has demonstrated in vitro an emission ratiometric pH-sensitive
fluorescent dye (dicyanohydroquinone) that is not subject to differences in two-photon
absorption of the acid and base forms5 . However, the dye is potentially toxic in vivo as a
byproduct is hydrogen cyanide. Therefore, the need for an in vivo pH sensor compatible
with multiphoton microscopy still exists.
Numerous obstacles needed to be surmounted for the development of a ratiometric pH-
sensitive NC-construct. Foremost among these were biocompatibility, stability and in
vivo delivery of the construct. The steps from the synthetic chemistry of these
constructs to application in living tumors was constantly evolving to design and
implement the ideal in vivo pH probe. This Chapter will focus on the development and
application components of the design. Synthetic methods of all constructs discussed in
this chapter are described in detail elsewhere 8.
V.2 Multiphoton Multispectral and FRIM System
To study the NC pH biosensors under multiphoton excitation, a system that combined
both ratiometric imaging and multispectral fluorescence emission detection were
required (Figure V-2). Ratiometric imaging with multiphoton microscopy requires only
the selection of appropriate dichroic and bandpass filters to split and select the emission
signals of interest. Two-photon ratiometric imaging has been used to successfully detect
both zinc9 and calcium10 levels in cells using fluorescent emission ratiometric constructs.
215
CHAPTER 5
Scanner
__Beam I
Expander - -
Imaging PMTs &Scan Emission Filters
Lens Switchable
50/SO BS
Excitation
DichroicGaAsPT
PowerEmission Filter
Control Lens Filter
Fluorescence Spectrophotometer
c<-z-- Collection
Ti:Sapphire Laser 20X O.95NA
720 - 020nmObjective Lens
XY Automated Stage Computer
Control
Figure V-2 Setup for ratlometric pH measurements using multiphoton microscopy. The addition of a
fiber coupled spectrometer to the emission path of the system permits spectral characterization of the
two-photon excited emission.
Multiphoton spectroscopy requires modification to the emission path of a typical MPM
for multispectral detection. Multicolor multiphoton imaging has been performed using
an optical grating and multichannel PMVT with good signal to nos" However, with
typically only 16 channels, the spectral resolution is lower than needed for
photophysical studies. To achieve a high degree of spectral analysis, emission light from
multiphoton excitation can be coupled into a spectro photometer 1-1 . In proper
configurations both high-resolution spectral analysis and ratiometric imaging can be
performed nearly simultaneously. An additional design employs the use of a liquid
crystal tunable filter (LCTF) to reject all light outside a narrow bandwidth ("20-3Onm)
with sequential imaging to obtain a multispectral imaging'5. Preliminary work with a
LCTF in the setting of in vivo multiphoton microscopy demonstrated very low collection
efficiency. It should be noted that anytime fluorescence emission is split, the signal
intensity incident upon each detector decreases requiring increased integration time.
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Figure V-3 Ratiometric imaging of NC-biosensor constructs with multiphoton microscopy. (a).
Nanocrystal channel (540/40 filter). (b) Coupled dye channel (635/40 filter). (c) Image ratio map obtained
from dividing b by a. A colormap indicates the ratio values obtained from the 12-bit images (0-4095).
Scale bars - 100ptm.
All ratiometric imaging and spectral measurements in this Thesis were taken on custom-
built multiphoton laser scanning microscopes with selection of an emission output fiber-
coupled to a spectrometer. Multiphoton excitation was performed by a diode pumped
Ti:Sapphire laser (MaiTai; Spectra-Physics, Mountain View, California) using 800 - 1020
nm light at sample powers ranging from 10-60mW. The output of the laser was adjusted
using a zero-order half-wave plate (10RP52-2, Newport Corp., Irvine, CA) and Glan-Laser
polarizer (10GL08AR.16, Newport Corp., Irvine, CA). The multiphoton microscope
system contained a scan-head (MRC600, Bio-Rad, Hemel Hempstead, England or
Fluoview 300, Olympus America Inc., Center Valley, PA) coupled to an upright
microscope (Axioskop20, Zeiss, Jena, Germany or BX50W, Olympus America Inc., Center
Valley, PA). All measurements were collect using either a 20x/0.5NA (Zeiss Achroplan,
Jena, Germany) or 20x/0.95 (Olympus XLUMPIanFL, Olympus America Inc., Center
Valley, PA) water immersion objective. Fluorescence emission was split by a 50/50
beamsplitter (HQSP720M Chroma Technology, Rockingham, Vermont) directed to both
an imaging and spectral analysis path.
For ratiometric imaging, non-descanned fluorescence emission was detected by
different photomultiplier tubes depending if the emission was less than 620nm (HC125-
02, Hamamatsu Photonics, Bridgewater, New Jersey) or longer, requiring a GaAs PMT
(H7421-50, Hamamatsu, Inc., Bridgewater, NJ). Nanocrystal and dye fluorescence was
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directed to separate PMTs using either a 565nm or 585nm shortpass dichroic
(564DCXPR or 585DCXPR Chroma Technology Corp., Rockingham, VT) depending on the
construct design. The nanocrystal and dye channels were further selected according to
appropriate antireflective-coated broadband emission filters (Chroma Technology Corp.,
Rockingham, VT). For three-dimensional ratiometric imaging, image stacks (512x512
pixels and 5-micron z-step) were collected simultaneously for both the NC and dye
channels. The two detection channels (nanocrystal and dye) were corrected for non-
uniform illumination and ratiometric images (Figure V-3) were created using Matlab
(Mathworks, Natick, MA). To assess for any potential artifacts due to the detectors, the
ratiometric response of the PMTs was determined. The fluorescence emission of a
sample of free NCs was split using a 50/50 beamsplitter (21000, Chroma Technology
Corp., Rockingham, VT) and directed at both detectors used for all experiments. Image
stacks were collected with the MPM every 5min for 90 total minutes. The average ratio
was calculated for each image stack and timepoint. No drift was observed in the
response of either PMT (Figure V-4).
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Figure V-4 PMT response over time for ratiometric imaging with NCs. (a). The mean channel intensities
over time for both PMTs. (b) The mean ratio of the two channels over time. Errors are given as standard
deviations of all image pixels (512x512x100).
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For spectral analysis, the excitation laser was parked in the field of view and emission
light was coupled into a 100 m core fiber bundle after passing through a 720 nm short-
pass filter (HQSP720m Chroma Technology, Rockingham, Vermont). Spectra of the fiber-
coupled emission were collected on a spectrograph (Shamrock 303, Andor Technology,
Belfast, Northern Ireland) with CCD detector system (Newton DU-420, Andor
Technology, Belfast, Northern Ireland) using a 1004m slit opening and 20ms to is
detector integration depending on the signal. All post-processing of the spectra was
performed using custom code in the Matlab programming environment.
V.3 Multiphoton excitation of NC-constructs
Fluorescent semiconductor nanocrystals possess broad two-photon excitation spectra
(700-1000nm) and significant cross-sections up to nearly 50k GM16'17. They have been
successfully applied to MPM in both cellular and in vivo environments18-21. Initial design
considerations in the development of a NC-biosensor for use with MPM are the
photophysical properties of FRET-based NC constructs under two-photon excitation.
Recently, much emphasis has focused on the application of semiconductor nanocrystals
as two-photon antennas for other fluorescent dyes with minimal nonlinear excitation
cross-sections22
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Figure V-5 Two photon excitation of NC-CXR construct: demonstration of a two-photon antenna. (a).
Nonlinear excitation of each component (NC and CXR dye) and the construct at 800nm. (b) Two-photon
action cross-sections for each component and the construct.
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V.3a SEMICONDUCTOR NANOCRYSTALS AS TWO-PHOTON ANTENNAS
We chose to perform such an experiment with a dye molecule (carboxy-X-rhodamine,
CXR) that exhibits a significant two-photon absorption cross-section in its own right. We
hypothesized that the larger two-photon absorption cross-section of the NC would
determine the photophysical characteristics of a bound construct incorporating CXR.
Both components and the construct demonstrated nonlinear responses to excitation by
the femtosecond laser source (Figure V-5a). The nanocrystal exhibited near quadratic
dependence on the excitation power (1.74), which has been observed by others16. NCs
can easily reach excitation saturation under normal two-photon protocols, which
decreases the quadratic dependence and increases the focal volume. The rhodamine
dye, CXR, demonstrated no excitation saturation and excellent quadratic dependence of
fluorescence (2.01) at the same powers as the NC. The NC-CXR construct displayed the
same near quadratic dependence as the free NC (1.82).
Two-photon absorption cross-sections (u2) were determined at wavelengths ranging
from 730-990nm for the NC, CXR and construct (Figure V-5b). The absorption cross-
section was calculated from the fluorescence emission spectra of each molecule during
two-photon excitation using the fiber-coupled spectrometer. If both the time averaged
fluorescence (F(t)) and incident laser power (P(t)) on the sample are known, then U2
can be calculated.
7TA(F(t))
4<p7C 9 (P(t))2  (V.1)
Here, A is the excitation wavelength, < is the emission collection efficiency, and r7 is the
fluorescence quantum efficiency. The characteristics of the excitation laser are defined
by the second order temporal coherence (g(2)) and the laser repetition rate (f,). In this
study the laser source was 80MHz and assumed to consist of Gaussian shaped pulses
giving a value of 73500 for 92. Free acid fluorescein was used as a reference sample to
determine the collection efficiency of the multiphoton microscope detection path. The
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collection efficiency was found to be 0.40 ± 0.04% based on measured values of the
two-photon action cross-section at multiple wavelengths and those reported in the
literature . Excitation power was measured directly at the focal point of the objective
for each wavelength.
The two-photon absorption cross-section (q2) for the NC was found to be much higher
(1400-100GM) than that of CXR (350-50GM) at all wavelengths from 730 - 990nm. The
NC-CXR construct exhibited similar values (1600-160GM) across its excitation spectrum
to that of the free NC. By comparison, the sum of the two-photon absorption cross-
sections for the two independent species is slightly higher than the free NC or construct
at most wavelengths (1700-150). Only at longer excitation wavelengths (>950nm) does
the construct excitation spectrum begin to mirror the sum of the two components. It is
likely that at longer wavelengths, when -2 for the NC nears a minimum, there is direct
excitation of CXR. It is also possible that there is an exchange between the construct and
solution whereby CXR is separating from the construct at a given rate. In this case, low
concentrations of free CXR could be interfering with the measurement.
V.3b MULTIPHOTON EXCiTATION OF NC PH BIOSENSOR
Initial construct designs for a pH biosensor were based on coupling a squaraine dye25
26
with the NC. The squaraine dye itself does undergo significant two-photon excitation26
but as shown above the NC antenna defines the photophysics at most excitation
wavelengths. The problem with this construct was a basic pKa, which precluded its use
in biological environments. Instead a new construct was designed incorporating the red-
shifted pH-sensitive dye, SNARF-5F . The pKa of this dye is around 7.2 making it ideal
for in vivo applications27. The other common pH dye, BCECF 28, could not be used
because the absorption was too high in energy for efficient resonance energy transfer
from a luminescent NC. We determined the normalized two-photon excitation cross-
sections for free SNARF, free NC and the NC-SNARF construct at a pH of 7.0 (Figure V-6).
The concentrations of the unbound species were equal to those in the construct from
the total emission spectra. The NC-SNARF construct exhibits similar features to that of
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the free NC from 760-990nm. In particular, the construct does not demonstrate the
significant SNARF action cross-section maximum at 860nm. Therefore at wavelengths
900nm and below, two-photon excitation the NC-SNARF construct should occur through
the NC and all fluorescence from the bound SNARF dye should result from resonance
energy transfer processes.
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Figure V-6 Normalized two-photon action cross-sections for an NC-SNARF pH biosensor compared to Its
free components. NC - nanocrystal.
VA Biocompatibiity of NC-Biosensors
The greatest challenge in developing the NC-biosensor for pH is creating a stable
construct that does not interact with in vivo biomolecules. In their native state,
fluorescent nanocrystals are hydrophobic inorganic compounds2. The surface of the
nanocrystal must be passivated to be made soluble in an aqueous environment.
Typically NCs are capped with thiols through disulfide linkages onto the inorganic
surface of the NC. These thiols are typically attached to polymers with hydrophilic
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endgroups, such as carboxyl (-COOH) or hydroxyl (-OH) groups, or polyethylene glycol
(PEG) 29,30.
Complicating the design of an NC-biosensor is coupling the analyte sensitive dye to the
nanocrystal coating. Initial designs consisted of ester linkages6, due to the ease of
coupling the dye molecules onto a carboxylated PEG backbone31. However, such
coupling would be susceptible to esterases in the in vivo environment, particularly if the
construct was delivered intravenously. Amide linkages provide robust stability to
enzymatic degradation in biological tissues and were selected for second generation NC-
biosensor designs. Using amine surface functionalized nanocystals allowed amide bond
formation between dyes modified with N-hydroxysulfosuccinimide (NHS) 7.
A B
Figure V-7 NC-construct in vivo biocompatibility after intravenous injection. (a) The construct based on
a dendrimer coating around the nanocrystal exhibited significant non-specific binding and aggregation
within normal vasculature upon imaging by MPLSM. Second harmonic generation from adipocytes is
notable around the vasculature. (b) Amine (NH2) - capped DHLA-PEG constructs demonstrated good
distribution within tumor vasculature. Here cascade-blue dextran-500k was also injected intravenously as
a vascular tracer. Scale bars - 100 pm.
Once the stable linker was determined different surface capping strategies were
explored for their in vivo biocompatibility. Dendrimer-capped NCs using poly(amido
amine) dendrimer ligands provided ample amines for conjugation with the dye
molecules32. The dendrimer ligands were able to couple numerous dyes to a single NC,
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thereby increasing the FRET efficiency. However, upon intravenous introduction into a
mouse bearing a dorsal skinfold chamber (DSC) without a tumor, non-specific binding
was observed intravascularly for dendrimer constructs (Figure V-7a). The dendrimer
ligands possess a high positive charge, while both albumin33 and the angiogenic
vasculature in tumors and sites of inflammation possess significant anionic charges34.
Therefore, non-specific aggregation and binding with dendrimer-NCs preclude their use
as sensing moieties in the tumor microenvironment. Similar aggregation results were
also found with quantomer (octylamine-modified poly(acrylic acid)) functionalized NCs.
Using cysteine as a zwitterionic organic coating for NC construct enables small
hydrodynamic diameters (~5.5nm) and renal clearance upon intravenous injection3s
However, the stability of dye conjugates to the cysteine moieties was found to be
questionable.
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Figure V-8 In vivo extravasation of DHLA-PEG nanocrystal constructs from the tumor vasculature. (a)
Multiphoton spectral emission measurements were collected on and between two tumor vessels in a DSC.
(b) Emission spectra collected at the different points shown in a. When a tumor vessel is imaged, emission
spectra show both cascade blue - 500k MW dextran (~450nm) and NCs (~555nm). Only the NC emission is
present in the interstitial space of the tumor (black, blue and green). Measurements were collected
150gm below the tumor surface.
Recently, nanocrystals solubilized with dihydrolipoic acid conjugated to PEG (DHLA-PEG)
were shown to extravasate from blood vessels in an inflammatory model36 . Utilizing this
design, our collaborators in the Bawendi and Nocera groups developed new biosensor
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constructs employing DHLA-PEG functionalized with amine groups for coupling.
Intravenous injection of this construct exhibited no aggregation or binding
intravascularly within the tumor microvasculature of a mouse model(Figure V-7b).
Further investigation demonstrated that intravenously injected amino-DHLA-PEG NC-
constructs extravasate from the tumor vasculature less than 30 minutes post-injection.
When a tumor vessel is imaged, emission spectra showed both the fluorescence of the
vascular tracer (cascade blue - 500k MW dextran) and NCs. However, within the
interstitium, only the NC emission is detectable while the larger cascade blue molecule
remains in the vascular space (Figure V-8).
*, |-i~~ioN 0~' -20o -OH
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Figure V-9 In vivo distribution of NC-CXR constructs functionalized with various blocompatible ligands.
(a) DHLA-PEG400-OH (b) DHLA-PEG1000-OH (c) DHLA-PEG550-OCH 3.The ligand structure is given for each
construct above the representative in vivo image. All constructs were microinjected into the same tumor
type. The green color is the colocalization of both the NC and CXR emissions. Scale bars - 100pm.
Once the amino-DHLA-PEG nanocrystal construct was settled upon, the charge and size
needed to be adjusted for in vivo application. It is well known that size and charge play a
significant role in the delivery and transport of nanoparticles to and through the tumor
microenvironment37. While maintaining a concentration of 20% amino-DHLA-PEGs on
the NC surface for coupling to NHS prepared dye molecules, the remaining DHLA-PEGs
were adjusted for size and charge by modifying the PEG length and terminal
functionality. Three characteristic DHLA-PEG scaffolds (Figure V-9) were prepared and
incorporated into NC-constructs utilizing a dye molecule (CXR) insensitive to the in vivo
microenvironment. This construct design (a two-photon antenna) underwent FRET as
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shown in Section V.3. Therefore, the ratio of this dye should be equivalent at all
locations when imaged by multiphoton microscopy. The different NC-CXR constructs
were directly microinjected into a colorectal adenocarcinoma xenograft (LS174T)
implanted in the DSC of male SCID mice. Over a period of 90 minutes, the injection site
and nearby interstitium were monitored with MPM at 800nm. Each construct displayed
different interactions with the tumor microenvironment characterized by the diffusion
distance from the injection site (Figure V-9). The methoxy-terminated DHLA-PEG ligand
was found to distribute to the greatest extent in the tumor interstitial space (Figure
V-9c). The shorter hydroxy-terminated DHLA-PEG exhibited the greatest non-specific
binding, barely diffusing from the injection site (Figure V-9a).
Table V-1: Summary of NC construct results in vitro and in vivo. Constructs are identified by the type of
nanocrystal biocompatible coating utilized. DHLA - dihydrolipoic acid. PEG - polyethelyne glycol (chain
length). NH2 - amine caps on PEGs (cationic with degree depending on %). OH - hydroxyl caps on pegs
(neutral charge). OCH3 - methoxy caps on PEGs (neutral).
Nanocrystal Construct In vitro and in vivo results
Dendrimer Sticks to endothelial, stromal cells and tumor cells. Self-
aggregation and quenching.
Cysteine Permeable to tumor vessels, but questionable stability
Quantomer Non-specific binding and reduced FRET efficiency. Larger size.
Good intravascular stability.
DHLA-PEG, 0% NH2  Non-specific binding. Poor tissue penetration. Significantly
reduced FRET efficiency. Good intravascular stability.
DHLA-PEG, 10% NH2  Non-specific binding. Poor tissue penetration. Significantly
reduced FRET efficiency. Good intravascular stability.
DHLA-PEG, 20% NH2  Non-specific binding. Poor tissue penetration. pH biosensor ratio
similar to tumor slurry calibration, but significantly different from
PBS calibration. Good intravascular stability.
DHLA-PEG, 25% NH2  Non-specific binding. Poor tissue penetration. Good intravascular
stability.
DHLA-PEG(400)-OH + Non-specific binding. Poor tissue penetration. pH biosensor ratio
DHLA-PEG, 20% NH2  different from PBS calibration. Good intravascular stability.
DHLA-PEG(1000)-OH + Non-specific binding significant. Sensor ratio different from PBS
DHLA-PEG, 20% NH2  calibration. Good intravascular stability.
DHLA-PEG(550)-OCH 3 + Improved tissue penetration. Reduced non-specific interaction.
DHLA-PEG, 20% NH2  pH biosensor ratio different from PBS calibration. Good
intravascular stability.
The modulation of functionalized ligands on the NC-biosensor constructs does not alter
the ratiometric behavior in aqueous buffers containing no biomolecules. However, it
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does affect the ratio in ex vivo calibrations as the next section will demonstrate. All in
vitro and in vivo biocompatibility results with different NC-constructs are summarized in
Table V-1.
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Figure V-10 Multiphoton ratiometric spectral calibration of an NC-SNARF pH biosensor in PBS. (a)
Emission spectra at different pH buffers. (b) Calibration ratio of integrated emission areas for SNARF to
NC. (c) NC emission area at different pH. (d) SNARF emission area at different pH.
V.5 pH Calibration
Each new NC pH biosensor must be calibrated for response to solutions of known pH.
During synthesis of the NC-biosensor a variable number of SNARF molecules are
conjugated to the construct (typically between 1 and 6). This alters the FRET efficiency
and therefore the ratio. Additionally, the measured ratio values will depend on the
quantum efficiencies of the detectors and optical filters employed in the emission path.
Therefore, an appropriate calibration has to be performed with the same instrument on
which in vivo measurements are collected. We performed different calibration protocols
on each NC pH biosensor to determine any potential effects on the calibration ratio.
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Figure V-11 Calibration of NC-SNARF pH biosensor in phosphate buffered saline with 4% bovine serum
albumin. (a) and (b) Single photon excitation - normalized emission spectra and ratio of emission areas at
given pH. (c) and (d) Two photon excitation - normalized emission spectra and ratio of emission areas at
given pH. (e) and (f) Calibration example of a probe with bound SNARF:NC ratio ~6-7. Arrows indicate shift
in peak height with increasing pH (NC - green; SNARF - red). * - isosbestic point.
The simplest calibration we performed involved determining the spectral ratios for the
SNARF to NC emissions in solutions of different pH phosphate buffered saline. The
emission areas for both components are easily obtained from the collected emission
spectra under two-photon excitation allowing calculation of a calibration curve (Figure
V-10). A slightly modified calibration of the NC pH biosensor was also performed in
phosphate buffers containing 4% bovine serum albumin (BSA) from pH 6 to 8 at 370C
(Figure V-11). The introduction of BSA explores the effect of scattering media and
potential binding on the ratiometric emission of the pH biosensor. Data collected by a
spectrometer revealed both emission peaks of the NC and SNARF. Additionally, the
isosbestic point exhibited by SNARF was still observable in the NC-biosensor (Figure
V-11a, c, e). The calibration ratios were defined by the ratio of the spectral areas of
SNARF to the NC. Excitation either by single or two-photon processes exhibit different
ratio values. However, this is due to completely different detection schemes and not
different photophysical processes. Energy transfer processes and fluorescent emission
are independent of the excitation for one- and two-photon processes38,39. Constructs
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with different molecular ratios of dye to dot exhibit different FRET efficiencies;
highlighting the requirement of calibrating each new NC-biosensor (Figure V-11Errorl
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Figure V-12 Calibration using multiphoton FRIM. (a) Examples of emission channels for both SNARF (red)
and NC (green) at different pH in PBS. Colormaps on the ratiometric images reveal the different ratios for
each environmental pH. (b) Effect of multiphoton excitation wavelength on calibration for the samples in
a. (c) Effect of multiphoton excitation power on calibration.
Calibration for MP-FRIM was obtained using a dichroic filter at the isosbestic point (~585
- 600nm) of the NC-biosensor and imaging with two PMTs employing appropriate
bandpass filters to separately integrate the emission from the NC and dye molecules.
Mean depth projections for each emission channel obtained from axial image stacks
with the MPM were divided to determine the average ratio at each pH (Figure V-12).
The calibration values for PBS solutions are different using this method from those
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obtained by the spectrometer due to the altered detection mechanism and emission
path. We also investigated the effect of both two-photon excitation wavelength and
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Figure V-13 Ex vivo MP-FRIM calibration of NC-biosensor. (a) LS174T tumor slices in different PBS pH
buffers. Each image is a maximum intensity projection of 400pm of tissue. The emisison color changes
(green to red) as pH increases. Binding and resonance energy stabilization of the NCs are notable on the
damaged (due to removal of tumor) edge of the tumor slices by the increased green fluorescence. These
areas were ignored for calibration. (b) The ratiometric image calibrations for all image slices in a.
Calculated ratio values are the mean of 512x512x41 pixels. The standard deviations are large due to the
heterogeneous nature of the tumor tissue. (c) MP-FRIM calibration in PBS. Scale bar - 100m.
power on the calibration using MP-FRIM. Excitation between 800 and 900nm
demonstrated no significant difference in calibration values (Figure V-12b). However,
the signal to noise ratio was too low at 1000nm excitation to accurately calibrate the
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NC-biosensor. Further, as was demonstrated in Section V.3, at longer excitation
wavelengths, the SNARF dye may undergo direct excitation rather than resonance
energy transfer. Altering the excitation power had no effect on the calibration at 800nm
(Figure V-12c). This is expected as the NC-biosensor is internally referenced and should
not exhibit a change in either emission peak due to different excitation powers since
only the NC is excited in principle.
0.7
0.65
0.6
S0.55.
0
0.5
* PBS
0.45 a Tumor Slice
A Tumor cell
Suspension
0.4
5.5 6 6.5 7 7.5 8 8.5
pH
Figure V-14 Comparison of pH calibrations with the NC pH biosensor using MP-FRIM In both solution
and ex vivo tumor tissue. Black line indicates a linear fit to the PBS calibration data.
With many of our early constructs, we found that the solution calibrations did not
reliably match the in vivo ratiometric values measured in tumor models. Previous work
has suggested that calibration of fluorescent pH sensors like BCECF is best served in an
environment that mimics that encountered in vivo40. Interactions with biological
molecules in the local tissue environment may alter the FRET efficiency of the NC-
biosensor. To examine the effects of tumor tissue on pH calibrations with the NC-
biosensor, I developed two ex vivo systems. The first method involved performing
calibrations in ex vivo tumor slices obtained from subcutaneously grown tumors (Figure
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V-13). Preferably, the tumor type should be identical to those planned for in vivo
measurements to account for differences in interstitial components and cell types. MP-
FRIM of NC pH biosensors allowed to passively diffuse into tumor slices equilibrated in
phosphate buffers of known pH demonstrated a distinct change in fluorescent emission
(Figure V-13a). The pH calibrations from ex vivo tumor slices were slightly different from
those obtained in phosphate buffers (Figure V-13b and c).
An alternate method for calibrating the NC-biosensor employed single cell suspensions
obtained from the tumor type to be investigated. Similar to the ex vivo tumor slice
methods, the cell suspension, which contains both cancer and stromal cells, were
equilibrated in phosphate buffers prior to addition of the NC-biosensor. To compare
between calibration methods, the fractional SNARF emission ratio was used. The
fractional ratio was calculated from the individual PMT intensity ratios measured by MP-
FRIM:
Fractional Ratio = ISNARF
ISNARF + INC (V.2)
The fractional ratio constrains the values to between 0 and 1 making comparisons
between calibrations and with in vivo data easier. Calibrating an NC pH biosensor with
both ex vivo methods and phosphate buffer solutions showed that the tumor tissue may
have a buffering capacity at low and high pH (Figure V-14). It appears that the ex vivo
tissue samples do not fully equilibrate with the phosphate buffers, thereby altering the
expected pH. From these results, it seems that solution calibrations with the NC-
biosensor may be all that is required for in vivo measurements.
V.6 In Vivo Demonstration of NC-Biosensor
The ultimate goal in the development of ratiometric NC-biosensors for MP-FRIM is
studying the tumor metabolic microenvironment during progression and response to
therapy. However, prior to characterizing pH changes with targeted cancer therapies
such as antiangiogenic agents, we chose to confirm the ability of the NC pH biosensor to
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monitor experimentally imposed dynamic changes of in vivo pH in the tumor
microenvironment. An ideal agent to perturb the tumor acidity is the introduction of
intravenous or intraperitoneal glucose. Investigators have shown that the
administration of glucose leads to transient acidosis in the tumor microenvironment*' 41.
The decreased pH from hyperglycemia is due to a number of mechanisms including
increased blood viscosity in the tortuous tumor vasculature42 ,43 and acidic byproducts of
glycolysis due to increased metabolic supply".
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Figure V-15 Metabolic acidosis due to intramuscular anesthetics. (a) Experimental protocol for
hyperglycemia experiments with MP-FRIM. (b) Administering glucose intravenously appeared to lower the
pH in the tumor. However, (c) control animals injected with saline exhibited similar dynamics over the
measurement period. (d) In a mouse that expired 20 minutes into the experiment, no change in pH was
observed.
V.6a NC PH BIOSENSORS MEASURE QUALITATIVE CHANGES IN PH DUE TO GLUCOSE
ADMINISTRATION.
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We performed hyperglycemia experiments using the NC pH biosensor and MP-FRIM in
xenograft colorectal adenocarcinoma tumors (LS174T). In the first study, SCID mice
bearing DSC with implanted LS174T were anesthetized with ketamine/xylazine (10:1)
and glucose or saline was administered intravenously. Prior to initiating the study, NC-
biosensor was superfused onto the tumor surface and allowed to diffuse into the tissue.
Multiple locations were imaged every 10 minutes for 90 to 120 minutes (Figure V-15a).
The glucose treated tumors exhibited decreasing pH as indicated by a reduction in the
NC-biosensor emission ratio (Figure V-15b). However, the saline treated tumors also
showed a similar trend to lower pH (Figure V-15c). These results contrasted with a
mouse that expired after introduction of glucose. In this case, the ratio did not change
throughout the experiment (Figure V-15d). According to the pH calibrations in PBS for
this sensor, the pH drop over 90 minutes in treated tumors was 0.2units, consistent with
previous studies in the same tumor model using FRIM with BCECF'.
The acidosis also occurred in the control animals suggesting other mechanisms were
altering the pH. One possibility is in vivo stability of the NC-SNARF construct over time. If
the bound SNARF undergoes photobleaching or the linking PEGs dissociate from the NC,
then FRET will be abolished thereby decreasing the apparent ratio. However, the animal
that was deceased during the experiment did not exhibit a change in emission ratios,
suggesting neither mechanism was at work. Literature on various anesthetics revealed
that metabolic acidosis may occur with their use In particular, ketamine has been
shown to induce metabolic acidosis in a variety of animal models*' 49. Conversely,
inhaled anesthetics like isoflurane have not demonstrated metabolic acidosis50'51. From
this experiment, it was apparent that the NC-biosensor could measure changes in pH,
but also that all such studies should be carried out with inhaled anesthetics to reduce
other potential sources of acidosis.
We repeated the previous hyperglycemia study using the same animal models, but with
anesthesia induced by inhaled isoflurane. In addition, we monitored trends in pH
modulation due to intraperitoneal glucose administration. Both intravenous and
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intraperitoneal routes of glucose administration have demonstrated acidosis in the
tumor microenvironments2. In this case, the NC pH biosensor was coated with DHLA-
PEG, 25% -NH2/75% -OH exhibiting an average hydrodynamic radius of 7-8nm. Our
results, show a statistically significant decrease in pH (lower ratio) over time (P-value:
0.002) after glucose administration in comparison to mice injected with PBS (Figure
V-16). Furthermore, the rate of change in pH is significantly different between both
groups (P-value: 0.016). Differences in starting ratios between the two groups are likely
due to the heterogeneity in pH found in the tumor microenvironment 3. Quantitative
assessment was not possible because the ratios measured in vivo differing from those in
a PBS calibration.
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Figure V-16 Acidosis of the tumor microenvironment due to hyperglycemia. (a) In tumors treated with
glucose administered intraperitoneally, the pH was qualitatively reduced in comparison to control animals
treated with saline. Each line represents the mean of 5-6 different tumor regions in one animal. (b). The
change over time of the NC-biosensor (slope) was significant between the two groups (P-value: 0.016. N =
3 for both groups.
The same experiment was repeated a second time with NC-biosensors that could be
directly microinjected into the tumor interstitium. Nanocrystals passivated with 20%
amino-PEG/80% methoxy-PEG were utilized in the synthesis of a new NC-SNARF
construct. As shown in Section V.4, the methoxy-PEGylated NCs demonstrated excellent
in vivo tissue penetration. When injected directly into tumors, these NC-biosensors
distributed throughout the tumor tissue within 15 minutes (Figure V-17a). Again treated
tumors exhibited acidosis in the microenvironment as demonstrated by a decreasing
NC-biosensor emission ratio (Figure V-17b). By correcting the emission from different
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depths for scattering using an exponential factor, the average ratio was shown not to
change with depth in the tumor. The glucose and saline treated groups were found to
be statistically different over the course of the experiment (P - value: 0.001). The in vivo
ratio values were found to be lower than those determined by a PBS calibration (Figure
V-14). However, if only the change in ratio is taken into account, a linear fit to the
calibration data can be used to qualitatively estimate the pH drop. For the ~0.02 drop in
SNARF emission fractional ratio for this study, a pH drop of ~0.6 units is estimated. This
is within the range found in previous studies40,4 2,43,5 4.
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Figure V-17 In vivo pH sensing during hyperglycemia using methoxy-PEG NC-biosensors. (a) Maximum
intensity projection of tumor vessels (blue) highlighted by Cascade blue 500K dextran and NC-biosensor
(green/red). (b) Acidosis in tumors treated by glucose (green) versus those injected with PBS (blue).
SNARF fraction ratio means at two different depth regions (50-100 and 100-150ptm) are shown to nearly
overlap during the course of the experiment. N = 4 for each group. (c) and (d) Spatial correlation of the
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NC-biosensor ratios with the nearest tumor vessel. Glucose treated animals (red) exhibit a drop in pH of
the distance, while those treated with saline (blue) do not. Scale bar - 100ptm.
MP-FRIM coupled with angiography permitted spatial correlation of the measured ratio
with distance from the nearest tumor vessel (Figure V-17c and d). In both groups, a
substantial pH gradient from the vessel wall was not found. This contrasts with previous
studies which demonstrated pH drops up to 0.4 units away from the vessel wall 53.
However, in those experiments profiles were collected from only single vessels and the
method did not allow true three-dimensional measurements unlike MP-FRIM.
Interestingly, the glucose treated animals did show a drop in pH at every distance from
the vessel wall over the course of the study, although a gradient was never observed.
Using the combination of MPM angiography and MP-FRIM with the NC-biosensor, these
changes in ratio over time can be observed in the context of the vasculature in three
dimensions (Errorl Reference source not found.). Using colormaps to represent the
ratio, the heterogeneous response over time of a glucose treated tumor is observable
even in a single slice from the three-dimensional image stack. Generally, the control
animals maintained similar ratio distributions throughout the experiment as expected
from the stable mean ratio values.
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Figure V-18 MP-FRIM ratiometric images with the tumor vasculature imaged by MPM. The vasculature
(red) was semi-automatically traced in three-dimensions and the resulting cast was overlaid with the
ratiometric images. Here a representative slice from a single region of a glucose and saline treated tumor
are shown over the course of the study. Higher ratios are represented by warmer colors. Scale bar -
500im.
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Figure V-19 NC-CXR control construct demonstrates no ratiometric change with pH alteration by
glucose administration. (a) Representative example of an LS174T tumor containing diffused NC-
Rhodamine construct imaged by multiphoton microscopy. The tumor blood vessels are highlighted by
cascade-blue dextran-500k, while the NC construct is green. Scale Bar - 100 ptm. (b) The photon counts in
both the red (CXR) and green (NC) channels are shown for the image in a. The normalized ratio
(red:red+green channels) is also shown on the right-hand axis. No change in ratio is observed after
glucose is administered at time 0.
V.6b NC-BIOSENSORS ARE UNAFFECTED IN VIVO BY TISSUE OPTICAL PROPERTIES
To address the effects of in vivo tissue optical properties on our ratiometric sensing
measurements, we synthesized control NC-constructs that were insensitive to pH and
repeated the glucose modulation experiment. The control NC-biosensors consisted of a
pH-insensitive carboxy-rhodamine dye attached to the nanocrystal. This is a similar
construct to that used to demonstrate the two-photon antenna (Figure V-5). We applied
the constructs in vivo to both LS174T and murine mammary carcinoma (MCaIV) tumors
during hyperglycemia. In all of our animals, we found little deviation in control construct
ratio over the 90 minutes (Fig. 5). These important studies illustrate the robustness of
the NC-biosensor construct within the in vivo tumor microenvironment. Further, the
constant ratio observed indicates that the measured ratio is not affected by differential
scattering or absorption of the two fluorescent components. The emission spectra of
the NC-CXR control construct are very similar in wavelength to that of the NC-SNARF pH
biosensor. Therefore, ratios determined from the NC pH sensor should also be just as
robust as the control construct.
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V.7 Summary
In this Chapter, I have presented the results of a collaborative effort to develop a FRET-
based semiconductor nanocrystal biosensor for in vivo measurements of pH in tumors.
The particular focus has been on implementing these novel NC-biosensors under two-
photon excitation with multiphoton fluorescence ratiometric imaging. This technique
allows for three-dimensional imaging up to depths of 400-500p.m in murine tumor
models. The application of FRET with NCs under two-photon excitation was confirmed
for both pH sensitive and control constructs. The ability to employ a NC as a two-photon
antenna was demonstrated; confirming that excitation in the nonlinear regime occurs
through the NC due to its large two-photon absorption cross-section. Through a
collaborative process, the design of the NC constructs evolved to materials with
improved in vivo biocompatibility and negligible non-specific binding. Multiple protocols
for calibrating a NC-SNARF pH biosensor were presented and compared. Later
generations of the NC-SNARF construct design limited interactions with the local
environment reducing differences between the in vitro and ex vivo calibrations.
Application of the NC-SNARF pH biosensor to the tumor microenvironment
demonstrated qualitative measurement of acidosis due to hyperglycemia in a number of
experiments. The ability of MP-FRIM coupled with the NC-biosensor was shown to
permit correlation of the ratiometric pH measurements with the local tumor
vasculature. The basic design of the latest generation NC-biosensor was demonstrated
to be robust in vivo and ratiometric measurements were shown to be independent of
tissue optical properties. Future work will focus on vascular delivery of the NC-biosensor
and more stable calibrations.
V.8 Additional Materials and Methods
V.8a ANIMAL MODELS
Dorsal skinfold chambers (DSC) were prepared on 8-10 week old male SCID mice using
previously described methods55. After recovery, a small piece of tumor (~1 mm
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diameter) either from a human colorectal adenocarcinoma tumor (LS174T) or murine
mammary adenocarcinoma (MCaIV) obtained from a serially passaged subcutaneous in
vivo source from the same murine background was implanted in the center of the
chamber. At 1 - 2 weeks time the tumor in the chamber is of appropriate size for
experiments (~ 4 mm diameter). Animals were anesthetized with either
Ketamine/Xylene(10/1 mg/ml) or Isoflurane (1% in medical grade air) for all
experiments. All animal work was approved by the MGH institutional review board on
animal care.
V.8b IN VIVo BIOCOMPATIBILITY STUDIES
For NC construct extravasation studies with PEGylated nanocrystals, cascade blue ~500
kDa dextran (10 mg/mL) was tail-vein injected. After 20 minutes, 0.2 mL of 10%
aminoPEG/90% hydroxyPEG 555 nm emitting NCs were intravenously administered. Five
data points in the tumor were taken starting 30 minutes post-injection of the NCs.
Emission spectra were integrated for 2.5 seconds on the multispectral MPM (Error!
Reference source not found.).
The intravascular biocompatibility experiments with dendrimer and PEGylated NC
constructs were performed in male SCID mice bearing DSC implanted with an HT1080
human fibrosarcoma tumor. Studies were initiated on tumors at least 4mm in diameter
by enface measurement. NC constructs were co-injected into the tail-vein with cascade
blue 500kDa dextran (10mg/ml). Randomly selected regions of the tumor and normal
tissue were imaged using multiphoton microscopy. Nanocrystal construct emission
ranged from 530-580nm, so a 540/100 bandpass emission filter was used for
fluorescence collection.
Comparison of NC constructs with different terminated PEGs was performed in SCID
mice bearing DSC implanted with either LS174T or MCalV tumors. Experiments were
initiated after the tumors reached ~4mm in diameter by enface measurement. NC
constructs were delivered to the tumor through either superfusion onto the tumor
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surface or direct microinjection into the tumor at depths of 200im. Randomly selected
regions of the tumor were imaged using multiphoton microscopy.
For all samples administered to in vivo tumors, solutions of NC constructs were diluted
to at least 2x106 M in PBS and filtered with a 0.2ptm syringe filter (Acrodisc 13mm
0.2ptm HT Tuffryn Membrane, Pall Corp., East Hills, NY).
V.8c IN VITRO CALIBRATION MEASUREMENTS
NC-biosensors were diluted in appropriate standard pH phosphate buffers for pH 5.8-8.
Potassium phosphate buffered solutions with 4% by weight BSA were prepared with
continued adjustments in pH due to the buffering capacity of the albumin. pH was
confirmed using an electrode pH meter (Acumet AB15, Fisher Scientific, Pittsburgh, PA).
Single photon steady-state fluorescence measurements were obtained in a 1 cm
pathlength cuvette from a custom-built fluorometer (Photon Technology Instruments,
Inc. West Suffix, UK) installed with a photomultiplier tube (Hamamatsu R928) and a 150
W Xe excitation lamp. Size measurements were obtained using a dynamic light scatterer
(DynaPro Titan, ProteinSolutions). Samples were filtered through a 0.2pim syringe filter
and microcentrifuged to remove large particulates before measurements were taken at
25 *C. For multispectral MPM and MP-FRIM calibrations, aqueous samples were diluted
to at least 0.5x10 6M in PBS and placed in deep well microscope slides (1527-006, VWR
International, LLC, West Chester, PA). All calibration measurements were performed at
37 0C. Spectral analysis and image processing were performed with custom-code
prepared in Matlab (Mathworks, Inc., Natick, MA).
V.8d Ex Vivo TUMOR TISSUE CALIBRATION
A subcutaneously grown LS174T tumor from a single SCID mouse is removed and thin
slices (~1mm) are obtained from it using surgical blades. These slices are equilibrated for
1 hour in PBS buffers across the physiologic range (pH 5.8 to 8.0). After equilibration,
the NC-biosensor is added to the slices at a concentration of 50-100 pM. Following the
addition of NC-biosensor, the slices are placed in individual deep well microscope slides
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for each pH calibration point. The samples are set aside for 15 minutes at 25-37 *C to
permit diffusion into the tumor slices. To obtain a calibration curve, four random fields
of view are taken in each tumor slice at depths from 0 to 400 pm with 5pm steps using
MP-FRIM. Fluorescent emission from the NC and dye are collected by employing a
585nm longpass dichroic filter to split the signal into two PMTs with a 535/40nm and
635/40nm broadband filter, respectively. A ratiometric signal for each pH was obtained
by post-process filtering of the images with a 3X3 pixel Gaussian filter and taking the
ratio of the dye channel (635/40) to the NC channel (535/40) at each depth.
V.8e Ex Vivo CALIBRATION IN TUMOR CELL SLURRY
Subcutaneously grown LS174T tumors in SCID mice are removed at a size of 5-6mm in
diameter and homogenized. 1% trypsin is added to the homogenate in Hanks' balanced
salt solution (HBSS) and mixed for 5 minutes. Then the mixture is centrifuged at 1200
rpm for 5 minutes. After removal of the supernatant, the pellet is resuspended in HBSS.
For pH calibration, the cell free suspension is centrifuged again followed by removal of
the HBSS and addition of PBS buffers (pH 5.6 - 8.0) containing the NC-biosensor. The
mixture is then added to separate deep well microscope slides and MP-FRIM performed
as described above.
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Figure V-20 Differences In tissue scattering with depth for the NC and SNARF emission channels over
the course of a hyperglycemia experiment.
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V.8f IN Vivo HYPERGLYCEMIA EXPERIMENTS
The NC-biosensor was applied either by superfusion onto the tumor or direct
intratumoral injection at 200 pm depths. To highlight the tumor vasculature, cascade-
blue dextran-500k was intravenously injected into each animal. For each tumor, 5-6
locations were randomly selected and imaged by MP-FRIM immediately prior to
intraperitoneal or intravenous injection of a 300pl bolus of 6mg/kg glucose in PBS. Over
90 minutes, each location was imaged every ten minutes. Ratios of the pH-sensitive dye
(SNARF) emission (red channel) to the 540nm emission of the nanocrystal (green
channel) were determined for each location using custom algorithms prepared in
Matlab (Mathworks, Natick, MA). Briefly, the field of view was normalized for uneven
excitation using standardized solutions. Secondly, the difference in tissue scattering
(Figure V-20) for the red and green fluorescent emissions was corrected by fitting to a
single exponential function. A threshold was then applied to each 12-bit image to
remove low (<200) and high (4095) values that could be artifacts or were too low in
signal to noise ratio. A semi-automated vascular tracing algorithm56 ,5 7 was then applied
to create a three-dimensional mask of the tumor vasculature. These areas and also
regions of extravasated angiographic contrast were then masked out of the images.
Finally, the ratio of the dye to NC channel was taken to create the final ratiometric
images. Correlation with the tumor vasculature was performed by created distance
maps with respect to the traced vasculature. Using the distance map, each pixel from
the ratiometric image within an averaging window (10pm) centered at a given distance
was determined to obtain the distance profile.
V.8g STATISTICAL ANALYSIS
Data are presented as mean ± standard error of the mean (SEM). Significant differences
between groups were assessed by a multivariate repeated measures ANOVA accounting
for response to treatment over time (Systat, Systat Software, Inc., Chicago, IL).
Individual timepoints were compared using a two sample Student's t-Test. P < 0.05 was
considered statistically significant for all comparisons.
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VI. Three-dimensional microscopy of
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optical frequency domain imaging
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CHAPTER 6
VI.1 Introduction and Motivation:
This Chapter introduces novel techniques using optical frequency domain imaging
(OFDI), a coherent microscopy, to non-invasively probe the tumor microenvironment.
The work presented here is the result of collaboration between Professors Ben Vakoc
and Brett Bouma of the Wellman Laboratories for Photomedicine and the Steele Lab for
Tumor Biology. The instrumentation and data collection algorithms were pioneered by
the Wellman labs, while the animal models and biological questions were developed
and proposed by the Steele Lab. Integrating the two biomedical areas of expertise
fostered the joint development and implementation of unique methods using intravital
OFDI to image both microanatomy and function in solid tumors.
The application of multiphoton microscopy' 2 (MPM) to the study of solid tumor biology
in vivo has elucidated pathways and mechanisms of cancer progression and has led to
new therapeutic strategies3. Current high-resolution intravital imaging techniques,
however, can be used to visualize tumor microstructure and vascular morphology only
superficially (300-400 pm depth) and only over volumetric regions that are a fraction of
the total tumor volume in small animal models. Additionally, longitudinal imaging is
often limited in frequency due to the accumulation of exogenous contrast agents.
Consequently, nearly a decade after the introduction of MPM to tumor biology,
significant gaps remain in our understanding of critical aspects of tumor biology
including the vascularization of tumors, the multifaceted interactions between tissues
and vessels within the heterogeneous tumor mass, and the response of blood vessels,
lymphatic vessels and cancer cells to therapy. Filling these gaps will require
complementing existing MPM techniques with new methods for probing the
microenvironment over wider-fields and broader timescales.
Through the adoption of time-of-flight techniques to perform depth sectioning, optical
coherence tomography4 (OCT) alleviates the requirement for high numerical aperture
optics, thereby simplifying wide-field imaging. Through the integration of Doppler
detection principles, OCT can also circumvent the need for exogenous labels to identify
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vasculature. However, attempts to apply OCT to high-resolution three-dimensional
vascular imaging have been hampered by poor sensitivity in the Doppler-based
approaches techniques employed to achieve vascular contrasts9 . Additionally, methods
for characterizing biological parameters of tumor microenvironment and structure have
not been developed for OCT and existing angiographic OCT systems have not achieved
both high sensitivity and the rapid imaging speeds required for large-volume vascular
morphometry.
Here, we overcome these limitations through the development of new methods and
instrumentation building on a second generation OCT technology termed optical
frequency domain imaging 0. We apply these newly advanced techniques to a range of
tumor models in vivo and demonstrate the ability of OFDI to perform 1) high-resolution,
wide-field, and deep imaging of tumor vasculature, 2) morphological and fractal
characterization of vascular networks, 3) frequent and prolonged monitoring of vascular
network dynamics, 4) contrast-free functional lymphangiography, and 5)
characterization of tissue viability. Further, we demonstrate the application of these
capabilities to reveal the responses of murine tumor models in vivo to vascular-targeted
and cellular-targeted therapies.
VI.2 Novel OFDI Instrumentation and Methods
We used a newly developed OFDI instrument to characterize the tumor
microenvironment across multiple tumor models and at multiple sites in mice. The OFDI
instrument scanned a focused laser beam onto the sample to acquire the reflected light
signal as a function of wavelength and time at each transverse location. From this
recorded signal, the static and dynamic scattering properties of the tissue in three-
dimensions were derived (Figure VI-1). Imaging was performed over fields ranging from
20-100 mm2, and to a depth of approximately 1.5 mm for vascular signals and up to 2.5
mm for structural signals. The optical signals reflected from the sample were recorded
and processed offline to extract images and quantitative data describing several
biological parameters (see Methods and Materials).
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Figure VI-1 Principles of in vivo multiparametric imaging with optical frequency domain imaging (OFDI).
(a) An optical beam is focused into the tissue. The light reflected across all depths is interfered with a
reference beam and that interference signal is recorded as a function of light wavelength from 1,220 nm
to 1,360 nm. The amplitude and phase of the reflected light as a function of wavelength is used to localize
the reflected signal as a function of depth. At a given depth, the amplitude and phase of the reflected
signal as a function of time is used to derive the optical scattering properties and thereby the tissue
structure and function. (b) The depth-projected vasculature within the first 2 mm of mouse brain bearing
a xenotransplanted U87 human glioblastoma multiforme tumor imaged with OFDI. Depth is denoted by
color: yellow (superficial) to red (deep). Scale bar - 500 rm.
VI.3 Wide-field three-dimensional angiography
The microvasculature of solid tumors plays a critical role in both progression and
response to therapy". Multiphoton microscopy is currently the preferred method for
obtaining three-dimensional vascular data in vivo'. With MPM, however, it is nearly
impossible to study central regions of relatively large tumor volumes, and impractical to
image across wide fields in multiple animals and at multiple time points. To detect
vessels in OCT, contrast is derived from the Doppler shift 12-17 induced by the circulating
red blood cells. Using novel implementations of Doppler principles and OFDI1 , we
enabled wide-field angiography with sufficient sensitivity to map smaller vessels,
specificity to discriminate vascular motion from physiological motion, and speed to
perform imaging over wide-fields. Three-dimensional angiographic datasets were
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derived from the acquired OFDl signals, and were reduced to en face vascular
projections using color to encode depth (Figure VI-1b).
Figure VI-2 OFDI angiography across tumor types and sites. (a) A human breast cancer cell line (MDA-
MB-361HK) growing in the mammary fat pad window chamber model of a female SCID mouse. Large
avascular regions are notable in the vascular image (top) and reflected in the topographically diffuse
tumor microstructure (bottom).(b) Tumor vasculature of a human colorectal adenocarcinoma (LS174T)
implanted in the dorsal skinfold chamber of a SCID mouse (top). Non-viable tissue is evident within the
tumor nodules on cross-section (lighter regions) in the tissue scattering intensity image (bottom).. (c)
Angiography of a subcutaneous orthotopic human breast tumor xenograft (MDA-MD-231BR) imaged by
the skin flap preparation. (d) Limited vasculature of the human soft-tissue sarcoma (HSTS-26T) growing
orthotopically in the dorsal skinfold chamber. (e) Simultaneous vascular and lymphatic imaging of a tumor
and nearby normal tissue in the ear of a nude mouse, a commonly utilized model in the study of tumor-
associated lymphatics. Scale bars - 500 im.
VI.3a NEOPLASTIC AND NORMAL MICRO VASCULA TURE A CROSS TYPES AND SITES
Vascular projections were obtained across multiple tumor types at various sites.
Different tumor types display strikingly different vascular network architecture and
vessel densities. The utility of the OFDI technique allowed imaging in a variety of tumor
models including window chambers (Figure VI-2a,bd) and subcutaneous tumors (Figure
VI-2c and e). Penetration through the higher scattering skin around the subcutaneous
tumors required a lower numerical aperture lens to improve depth penetration, but also
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reduced radial resolution. Light scattering intensity from the tumor tissue also provided
the ability to perceive the tumor vasculature in context of the microanatomy.
Additionally, in vivo vascular networks in normal tissues including the mammary fat pad
and marrow space within the calvarium were imaged with OFDI. The capillary networks
in normal murine skin are readily identifiable (Figure VI-3a). In the murine mammary fat
pad, the significant vascular supply to the areolar region is observable penetrating from
the subcutaneous tissue (Figure VI-3b). OFDI is capable of penetrating through bone,
which minimally scatters incident photons. This permitted the vasculature within the
bone marrow space between the skull surface and meninges to be imaged without the
use of contrast or a window chamber model (Figure VI-3c).
Figure VI-3 OFDI angiography of normal tissues. (a) Vascular and lymphatic networks in normal skin
within the dorsal skinfold chamber window model implanted on a SCID mouse. (b) Normal vasculature of
the mammary fat pad window model implanted around the third mammary gland. The collection of large
vessels near the center of the field are supplying the areola on the underside of the chamber. (c) and (d)
OFDI microscopy of marrow within the murine calvarium revealing vasculature within the marrow space
(c) and corresponding microanatomy depicted in the cross-sectional structural image (d) showing marrow
regions (>) and the central sinus (DC>).
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Figure VI-4 Imaging across tissue microenvironments reveals strikingly different vascular networks.
The murine mammary carcinoma is shown in three different anatomical locations representative of both
primary and metastatic disease. Scale bars - 500 tm.
It has been proposed that the tumor vasculature forms during angiogenesis in response
to both the microstructure and growth factor gradients found in the tumor
microenvironment"-. We used OFDI to image a murine mammary carcinoma (MCaIV)
implanted in orthotopic (mammary fat pad), metastatic (brain), and ectopic (skin) sites.
The tumor exhibits visually different vascular architecture depending on the host tissue
microenvironment (Figure VI-4). The degree of vascularization is strikingly different
between tumors of approximately the same size (~4mm). Interestingly, in this tumor
type, the morphometry of the individual vessels as typified by vascular diameter was
found to be similar. It has been demonstrated that the level of angiogenesis in a variety
of breast cancer models depends on the tumor location in the host 22 . These differences
are possibly due to varying concentrations of vascular growth factors, which have been
shown to modulate the extent of angiogenesis during tumor growth.
VI.3b MONITORING ANGIOGENESIS
The ability to non-invasively image tumor vasculature over wide-fields at significant
depths using OFDI allowed monitoring of angiogenesis over the course of tumor growth
(Figure VI-5). Initially, the tumor implant induces dilation of the capillary network below
followed by sprouting of vascular branches from these dilated vessels upwards into the
tumor mass. This is followed by sprouting from the lateral arteries and arterioles at a
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farther distance from the tumor mass. The differential response of the regions
surrounding the tumor mass over time is due to diffusion gradients of angiogenic factors
produced by both cancer and stromal cells. Seminal studies by Ausprunk et al
demonstrated that the tumor vasculature is entirely reliant on the surrounding host
vasculature and gradients of vascular growth factors24. Further, cancer cells have been
shown to induce the stromal cells within the tumor microenvironment to produce VEGF
and other vascular growth factors2so . As the tumor continues to grow, the interior
vessel within the tumor mass appear to either spread apart or are compressed due to
cancer cell proliferation31 maintaining a relatively small diameter to those at the
margins. The laterally induced vessels cover the margins of the tumor and remain large
and dilated during tumor progression in this model.
Day 0 ' Day 4 ' Day 6
Dav 0 Dav 4 Day 6 Day 8 Day 10
(A)j
(B)
Day 10
Figure VI-5 Angiogenesis in a murine mammary carcinoma model. The incorporation of the capillary bed
and larger arterioles into the tumor vascular network is observable during tumor growth. Inset:
Differences in the morphologies of the vessels in the center of the tumor versus the margins.
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Figure VI-6 Comparison of multiphoton and OFDI angiography. (a) and (d) Wide-field tumor imaging
using MPM required 2 hours (d), while imaging using OFDI required only 10 minutes (a) for an MCalV
tumor implanted in the dorsal skinfold chamber. (b) and (e), Highlighted regions in a and d demonstrate
the enhanced ability of OFDI to visualize deeper vessels and distinguish morphology in regions of vascular
leakage. (c) and (f), Differences in resolution of the techniques showing the greater detail of finer vascular
structures obtainable by MPM. (g-h), The application of automated vascular tracing to registered datasets
of normal brain vasculature acquired with MPM (g) and OFDI (h) allows quantification of the resolution of
0FDI angiography and validation of the morphological measurements obtained from OFDI (i). Scale Bars -
250 pm
VI.3c OFDI COMPLEMENTS MPM IN IMAGING TUMOR VASCULATURE
To compare Doppler OFDI and MPM angiography, tumors were imaged sequentially
with each modality. MPM required the acquisition and subsequent alignment of 30-40
separate three-dimensional image stacks to sample a field of view equivalent to that of
the OFDI instrument. Imaging durations ranged from 2-4 hours for MPM, and 10-20
minutes for Doppler OFDI, depending upon the imaged field. To provide the greatest
depth of penetration for MPM, we utilized a high numerical aperture (20X, 0.95 NA)
objective lens. Faster imaging times could be obtained using lower magnification lenses
at the expense of penetration depth and resolution. Vascular projections derived from
each modality were compared to provide gross perspective of the relative merits and
complementary nature of the two methods (Figure VI-6ad). Whereas MPM excelled at
visualizing the smallest superficial capillaries (Figure VI-6c,f), OFDI was superior in
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discerning vessels deeper within the central regions of the tumor and in regions where
fluorescent tracers extravasated (Figure VI-6b,e). Vessels beyond 1.0 mm in depth were
routinely observed with OFDI while with MPM the maximum penetration depth in the
surveyed tumor models ranged from 250-400 pm. The difference in depth of
penetration for the two methods was most dramatic in regions where superficial diffuse
contrast agent masked underlying vessels in MPM, or where highly scattering necrotic
regions differentially attenuated the shorter wavelength (800 nm) multiphoton
excitation light relative to the longer wavelength (1300 nm) OFDI light. The unique
Doppler acquisition techniques incorporated into the OFDI instrument allowed rapid
visualization of the tumor vasculature inclusive of its connectivity with host vessels,
complementing the higher resolution but relatively superficial MPM angiography.
VOlum Alography Data (Red)
Vascua Nework Cas~t (Green)
Figure VI-7 Vascular tracing and structural correlation. (a) Cross-sectional OFDI angiographic data
showing vessels and shadow artifacts extending below the vessels. (b) Dataset showing bitmap data (red)
after shadow removal and vascular tracing contours (green). (c) Merged enface image of the vascular
dataset (red) and a cast of the traced vessels (green) illustrating the inclusion of all but a few vessels ( )
within the cast. Scale Bar: 250 tm. (d) Microanatomical display showing tumor boundary definition in a
three-dimensional tissue volume. (e) Skeletonized traced vessels differentiated between intratumoral and
extratumoral for the tumor depicted in d. Transverse extent in de: 5 mm (x), 4.4 mm (y).
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VI.4 Morphological and Fractal Characterization of Vascular
Networks
Morphological characterization of blood vessels in tumors provides insight into
32,33resistance to transport, angiogenic mechanisms, and response to therapy . Previous
characterization methods, based on intravital microscopy and MPM angiography,
however, have been limited to small fields-of-view and superficial depths. To extract
quantitative vascular measurements from the OFDI angiograms, we developed a fully
automated three-dimensional vascular tracing and analysis algorithm, optimized
specifically to operate on the OFDI datasets.
VI.4a VASCULAR MORPHOLOGY FROM OFDI ANGIOGRAMS
Briefly, the vascular networks were then manually masked to remove Doppler artifacts
due to Brownian motion in extracellular fluid or noise from airspaces between the
tumor surface and initial image plane. Then the three-dimensional OFDI angiograms
were processed to reduce the effects of shadowing34 due to high backscatter from large
vessels. The shadowing effect can be enhanced in tumors due to increased vascular
hematocrit 35. This can prevent access to deeper vessels, but is mitigated to some extent
through image processing using an exponential filter referenced to the higher signal
vessels (Figure VI-7a and b). Finally, a semi-automated vascular tracing algorithm
reduced three-dimensional OFDI angiograms to networks of interconnected vessel
segments modeled as superellipsoids36'37 (Figure VI-7c). From the centerlines and shape
parameters of these superellipsoids, the trajectories and morphology of vessel
segments were extracted.
To spatially correlate the vascular parameters with the tumor boundaries, the three-
dimensional tumor volume was determined from the OFDI scattering amplitude. The
tumor cells are higher scattering than the surrounding tissue due to the increased
nuclear to cytoplasm ratio38-41. Briefly, the approximate en face center of the tumor was
determined and axial sections across the tumor at regular intervals of 22.50 were
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created (Figure VI-8). The tumor boundary on each section was then manually drawn.
These boundaries were then used by automated algorithms to interpolate a three-
dimensional tumor volume. The vascular casts output from the semi-automated
vascular tracing were then correlated with distance from the tumor boundary. Using
these methods, the intratumoral vasculature could be separately characterized for
morphological parameters (Figure VI-7d and e).
a..5
Figure VI-8 Determination of tumor boundaries and volume in three-dimensional space. (a) Semi-
automated algorithms enabled definition of the tumor boundaries from the differences in scattering
amplitude between the tumor and host tissue. (b) Manual tracing of the tumor boundary on axial slices.
(c) Three-dimensional volume illustrating the differences in tumor scattering.
To evaluate OFDI morphometry, we obtained MPM (Figure VI-6g) and OFDI (Figure
VI-6h) angiograms of the same region of a normal mouse brain in vivo. Previously
established tracing and morphometry techniques" were applied to the MPM data. We
compared vessel diameter measurements of 402 precisely co-registered segments (each
approximately 100 ptm in length) and found a high correlation (r = 0.87) for vessels
larger than 12 pm in diameter (Figure VI-6i). OFDI methods often located and traced
smaller vessels but overestimated the diameter of these capillaries and thus the
correlation of diameter measurements for vessels with diameters under 12 pm as
measured by MPM was low (r = 0.36).
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Figure VI-9 Fractal characterization of tumor vascular networks imaged by OFDI angiography. (a)
Representative example of the sandbox method for determining the fractal dimension of the vasculature
of both normal murine cortex and a human tumor glioblatoma multiforme (U87) tumor implanted in the
murine brain. A natural log of the mean number of occupied voxels within cubes of dimension (L) covering
the three-dimensional network is plotted versus the natural log of the cube dimension. The slope of the
linear portion of the plot determines the fractal dimension. (b) The local slope of the curves in a for each
cube dimension. The fractal dimension is observed from the plateau regions corresponding to the linear
portions in a (2.74 for the U87 tumor and 3.02 for normal brain). (c) Depiction of the minimum path
length for a given three-dimensional vascular network. Here, each path traversed from one face to the
other is projected though the axial dimension with the minimum path length highlighted in red. The
projection of the Pythagorean distance is shown as a dashed blue line. Tortuosity is determined from the
ratio of these two distances. (d) and (e) The three-dimensional skeletonized vascular networks
geometrically characterized in a and b. Each gridline is 250 pim.
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VI.4b THREE-DIMENSIONAL FRACTAL ANALYSIS OF TUMOR VASCULATURE
The ability of OFDI to extract vascular parameters over larger volumes presents new
opportunities for fractal analysis of the network. Fractal analysis has been invoked to
quantify the ability of a vascular network to provide an efficient transport of blood-
borne nutrients, oxygen, or drugs within the tumor32 . The fractal dimension is a
statistical measure of a network indicating how completely that network fills space. In
three-dimensional geometries, an optimal space-filling network has a fractal dimension
of 3; lower fractal dimensions indicate a lesser degree of space filling. A complementary
metric is the tortuosity defined by the ratio of the minimum vascular path between two
points and the geometric distance between those points. As the tortuosity parameter
increases from its minimum value of 1.0, the transport efficiency of the vascular
network decreases.
Using the topology and branching patterns derived from the OFDI datasets, we have
analyzed, for the first time, the three-dimensional fractal dimension of tumor
vasculature in vivo. The fractal dimension was calculated from skeletonized vascular
networks (obtained by the vascular tracing algorithm) using the sandbox method 42
(Figure VI-9a and b). Tortuosity was determined from the ratio of the minimum path
length across the vascular network to the Pythagorean distance measured between the
first and last point of the path (Figure VI-9c). An analysis of the vascular network
depicted in Figure VI-1b yielded a fractal dimension of 2.74 in the tumor region in
agreement with results expected from prior 2D analyses, and 3.02 in a normal region of
the right hemisphere consistent with a fully developed capillary network filling three-
dimensional space42 43 (Figure VI-9d and e).
VI.5 Imaging Vascular Dynamics during Tumor Growth and
Treatment
Vascular responses to anti-angiogenic and anti-vascular therapies occur continuously
over time-scales of hours to days44. With MPM, however, it is impractical to measure
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the dynamic changes over broad fields due to contrast agent accumulation and the time
required for imaging. Using OFDI, we imaged murine mammary carcinoma tumors
(MCalV) implanted in the dorsal skinfold chamber every 4 hours for 48 hours. We
administered either an anti-angiogenic agent (DC101, a blocking monoclonal anti-
vascular endothelial growth factor receptor (VEGFR)-2 antibody) or non-specific rat-IgG
immediately after the initial imaging session. Promptly following administration of
DC101, the mean vessel diameter began to decrease while the tumor volume continued
to expand. These trends continued throughout the 48-hour time course of the study
(Figure VI-10). Timelapse images of vascular responses acquired every 2 hours for 48
hours highlight the unprecedented ability of OFDI angiography to monitor vascular
dynamics over wide fields.
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Figure VI-10 Vascular dynamics of fields and time intervals not accessible with traditional approaches.
(a) Angiography at a 4 hour interval over 48 hours reveals the rapid response in vascular parameters to
VEGFR-2 blockade. Vascular tracing registered to 3D tumor boundaries allows quantification of the
vascular changes within the tumor mass, showing nearly immediate changes to vascular diameter
(bottom). The tumor growth rate of the treated group trends slower than control tumors, but is not
significant over 48 hours. (top). Control: n=4, DC101 n=3. (b) and (c) Vascular network of a treated tumor
at 0 and 48 hours with respect to DC101 administration.
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Figure VI-11 Contrast-free lymphanglography using OFDI. (a) The scattering signal along a single depth
scan within an OFDI image of a murine ear shows the reduced scattering between the upper (2) and lower
(3) boundaries of an patent lymphatic vessel. Scattering within the vessel is similar to background levels
above the upper surface of the ear (1) or below the lower surface (4). (b) and (c), In addition to lymphatic
vessels revealed by traditional cutaneous injection of Evan's blue dye (c), OFDI is able to detect numerous
additional vessels in the normal dorsal skin (b) and resolve the lymphatic valves found between individual
lymphangions (C>). (d) HSTS26T tumor-associated lymphatics are found to be dilated in comparison to
those in normal tissue. (e), Cross-sectional presentations of a lymphatic vessel showing cellular masses
L>) located near the tumor in d. Scale bars - 500 pm.
VI.6 Contrast-Free Lymphangiography
Lymphatic vessels and their associated lymph nodes have been imaged to reveal their
importance in fluid balance (edema), as avenues for cancer cell dissemination and as
prognostic indicators of disease progression45,46. Lymphangiography is typically
performed by directly injecting a visible or fluorescent dye into the tissue, which
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obscures structures near the site of injection and highlights only those lymphatic vessels
draining the region of the injection. Further, the accumulation of dye is a severe
constraint for longitudinal studies.
Lymphatic networks in vivo appear as structures with negligible scattering intensity in
OFDI. The reduced scattering of the lymph relative to surrounding tissue is likely
associated with its hypocellularity (Figure VI-11a). Using these scattering characteristics,
lymphatic vessels were identified, mapped, and segmented in the OFDI datasets. OFDI
images of lymphatic networks in normal mouse skin showed functional lymphatic
vessels highlighted with conventional Evan's blue lymphangiography, as well as
additional functional lymphatic vessels draining other regions of the skin where Evan's
blue injections were not made (Figure VI-llb,c). Lymphatics surrounding tumors were
observed for murine breast cancer (MCaIV) and human sarcoma (HSTS) models (Figure
VI-11d) growing in the dorsal skinfold of mice. OFDI cross-sectional images were helpful
in identifying cellular masses within the lymphatics (Figure VI-11e). Quantitative
measurements of lymphatic vessel diameters with OFDI showed peritumor lymphatic
vessel hyperplasia consistent with previous measurements using fluorescence
microscopy 4 ,47. For the tumor in Figure VI-11c, a significant difference (P-value < 0.05)
was found between the mean diameters of lymphatic vessels in the normal tissue (40 ±
3 jim; >2mm from tumor) and those in the peritumoral region (81 ± 4 pm; <2mm from
tumor). By eliminating the need for exogenous contrast agents, OFDI allowed the
monitoring of functional lymphatic vessels throughout tumor progression (Figure VI-12).
Importantly, OFDI lymphangiography can be performed simultaneously with OFDI
angiography; the two techniques differ only in the methods for post-processing of the
OFDI data. This is demonstrated in a subcutaneous model in the murine ear48 used to
study lymphatic metastasis (Figure VI-2e)
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Figure VI-12 Longitudinal tracking of lymphatics using OFDI. Changes in lymphatic vessel diameters are
evident over 4 days during tumor (MCalV) progression.
VI.7 Imaging Tissue Viability
Currently available intravital microscopy techniques do not allow measurements of
tissue viability in tumors. As a result, cell-targeted therapies are traditionally studied
through assessment of tumor growth delay and histological examinations. These
techniques, however, have their inherent limitations. Through the dependence of tissue
scattering on cellular structures49, it is possible to differentiate necrotic/apoptotic
regions within a tumor from viable regions in three-dimensions using OFDI. Higher
scattering regions within tumors correlate with necrotic/apoptotic regions defined by
corresponding hematoxylin and eosin staining (Figure VI-13a). Longitudinal imaging of
tumor progression in MCalV tumors revealed the growth of necrotic/apoptotic regions
(Figure VI-13b). During tumor progression, viable areas were limited to ~65 pLm from the
vessel wall. The fraction of necrotic/apoptotic tissue increased (from ~24% to ~46%)
while the vascular volume fraction remained relatively constant (Figure VI-13c). The
unique capability of OFDI to longitudinally image tissue viability and to spatially co-
register this information with tumor vasculature opens new possibilities for the
evaluation of existing therapeutic approaches and the rational design of therapeutic
regimens.
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Figure VI-13 Imaging tissue viability. (a) Comparison of standard hematoxylin and eosin staining (top)
with OFDI (middle) reveals association of tissue necrosis with highly scattering regions. Viable and necrotic
regions within the same tumor highlighted by color gradients indicating scattering intensity (lower). (b)
Scattering properties correlated with the microvasculature during tumor progression illustrate increasing
regions of unviable tissue with viable areas constrained to regions within ~65 prm of the vessels. (c)
Quantitative analysis of tissue viability and vascular regions in vivo revealed an increasing fraction of
necrotic/apoptotic tissue. Scale bars a: 500 ptm; b: 1.0 mm.
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VI.8 Multiparametric Monitoring of Therapeutic Response
To demonstrate the application of OFDI to the study of tumor response to therapy, we
monitored changes induced by vascular or cellular targeted therapy. OFDI allows
multiple parameters in the tumor microenvironment to be probed simultaneously
during treatment. Assessment of changes in the microenvironment with OFDI may
provide a means to screen for new anti-cancer agents or design more efficacious
therapeutic regimens for translation to the clinic.
Day -1 Day 1 Day 3 Day 5 Day 7 Day 9
Figure VI-14 Antianglogenic response to VEGF-R2 blockade imaged by OFDI. Both digital camera images
and OFDI angiograms are shown for a DC101 treated and control animal bearing MCaIV tumors. The top
panel is a representative example of the treated group. Loss of dilated vasculature in the host tissue bed
is notable at Day 1 after treatment. By Day 9 there is very limited intratumoral vasculature and what
exists is small in diameter and density. This is apparent even in the digital camera images by lack of
redness due to lower blood volume. The lower panel is an example of the control group treated with Rat
IgG. In this untreated tumor, the host vascular bed remains dilated and large tortuous blood vessels form
within the tumor mass. The increased blood volume is apparent in the digital camera images. Each image
is approximately 3 X 3 mm. The Doppler OFDI images are maximum intensity projections over a depth of
~500 ptm.
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VI.8a ANTIANGIOGENIC THERAPY: VEGF-R2 BLOCKADE
In the first set of experiments, mice with murine mammary carcinoma tumors were
imaged every other day up to 9 days during treatment with VEGFR-2 blocking
monoclonal antibody DC101. Control animals had the same tumor preparation but
received non-specific rat IgG. Our preliminary imaging studies using OFDI with this
model found high inter-animal variability in the tumor angiogenesis following
implantation and prior to therapy. We therefore used OFDI to normalize the starting
point of longitudinal studies for each mouse; we imaged every two days post-
implantation and defined starting points for each animal based on the status of the
vascular network and the tumor volume (Figure VI-14). OFDI measurements of pre-
treatment and control mean vessel diameters in 11 total tumors were consistent with
previously published results using MPM44 (55.8 ± 3.4 pm versus 49.8 ± 5.1 pim
respectively). OFDI angiograms, acquired at day 5, consistently demonstrated a more
dense and chaotic vascular network in the control group relative to the treated group
(Figure VI-15a). We found a reduction in both mean intratumor vessel length (P-value:
0.001) and diameter (P-value: 0.029) with DC101 treatment, which is consistent with
those obtained in the previous study44 (Figure VI-15b). To assess intratumoral spatial
differences in response to anti-angiogenic therapy, we correlated morphological
parameters of all traced vessel segments with distance from the tumor boundary. The
mean vascular volume in the control group within 200 pm of the boundary was found to
dramatically increase with tumor growth, while DC101 treatment restrained vascular
volume in this region (Figure VI-16). At day 7, the mean tumor volume within the
treated group was 25% of that of the control group (Figure VI-15b) The VEGFR-2
blockade induced a less defined response on fractal parameters compared with
morphological parameters of the vasculature over this timecourse (Figure VI-15b). The
fractal dimensions of both treatment and control groups reached plateaus (2.54 ± 0.04
and 2.60 ± 0.01, respectively) at day 3, and the mean tortuosity in the treated group was
slightly lower than that of the control group at the end of the study.
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Figure VI-15 Therapeutic response to VEGFR-2 blockade characterized by OFDI. (a) Representative
control and treated tumors 5 days after initiation of therapy showing strikingly different vascular
morphologies. The lymphatic vascular networks are also identifiable (blue) for both tumors. (b)
Quantification of tumor volume and vascular geometry and morphology in response to treatment. DC101
treated tumors exhibited a growth delay over the course of this study (P-value: 0.060). Both total vascular
length (P-value: 0.001) and mean intratumoral vessel diameter (P-value: 0.029) significantly decreased
over time for treated tumors. Geometrical properties of the tumor vasculature, i.e., the fractal dimension
and tortuosity, showed a less distinct response between groups. Control N=5, Treated N=6. Scale bars 500
pm. Statistically significant differences (P-value <0.05) at given time points are denoted by asterisks.
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Figure VI-16 DC101 treatment restrains intratumoral vascular growth near tumor margin. The mean
vascular volume spatially correlated with the tumor boundaries across all animals reveals a region of
specific increase within 200 pm of the tumor margin in control animals that is restricted in animals
treated by anti-angiogenic therapy. (Control N=5, Treated N=6).
VI.8b CYTOTOXIC THERAPY: DIPHTHERIA TOXIN
In the second set of experiments, we applied OFDI to investigate direct targeting of
tumor cells. Diphtheria toxin accumulates in human cells, halting protein synthesis and
eventually inducing apoptosis, but does not affect murine cells31,50. Therefore, in mouse
xenograft models, diphtheria toxin can be used to model a cytotoxic treatment that is
not confounded by direct damage to vascular endothelial cells that can result from
chemo- and radiotherapy. When we administered diphtheria toxin into mice bearing a
human colorectal adenocarcinoma xenograft (LS174T) grown in the dorsal skin chamber,
apoptosis was evident within two days through associated changes in tumor scattering
properties (Figure VI-17a). During the first 24 hours, the tumor volume remained
approximately constant (Figure VI-17b). After 24 hours, widespread necrotic/apoptotic
regions within the volume of the treated tumors were observed and the mean tumor
volume began to decrease rapidly in response. After 48 hours, the intratumor vessel
length rapidly decreased, presumably due to the down-regulation or depletion of tumor
cell-derived angiogenic growth factors (Figure VI-17b).
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Figure VI-17 Directed cytotoxic therapy and multiparametric analysis by OFDI. (a) Images of tissue
scattering immediately prior to and two days following administration of diphtheria toxin or saline to mice
bearing human tumor xenografts (LS174T) in dorsal skinfold chambers. Apoptosis induced by diphtheria
toxin is manifest as increased tissue scattering relative to control animals. (b) Quantification of the
response to diphtheria toxin administration. Top: A reduction in tumor volume was apparent 48 hours
after administration, reaching 10% of the original volume after 8 days. Middle: The tissue scattering within
the tumor relative to day 0 showed a statistically significant increase in treated animals 48 hours after
administration and a maximum after 5 days. Bottom: The vascular length within the treated tumors
dropped continuously after administration of the toxin likely due to down regulation of tumor-cell derived
growth and survival factors. Scale bars 500 ptm. Statistically significant differences (P-value < 0.05) at given
time points are denoted by asterisks.
In a separate experiment with only a single tumor, the administration of diphtheria
toxin was followed by tumor regrowth after an initial response (Figure VI-18). During
the first 24 hours, the tumor volume remained constant while the tumor vascular
volume fraction (WF) decreased, presumably due to the down-regulation or depletion
of tumor cell-derived growth factors. After 24 hours, necrotic/apoptotic regions within
the volume of the tumor were observed and the tumor volume began to decrease. In
the same time period, the VVF reversed its previous trend and rapidly increased.
Previous studies have suggested that the increasing VVF following targeted tumor cell
killing by diphtheria toxin in xenograft tumors is due to a reduction of solid stress caused
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by cellular compression31. At +120 hours, the tumor volume and VVF reached measured
extremes and necrotic/apoptotic regions were observed nearly throughout the tumor
with only small regions possessing viable tumor cells (Figure VI-18c,d). After the VVF
peak, the tumor mass began to recover. Due to physicochemical barriers to
macromolecular diffusion in the tumor microenvironment51, the toxin was likely unable
to reach a subsection of the tumor leaving viable tumor cells that, coupled with the
improved perfusion, led to relapse.
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Figure VI-18 Quantification of the response of an LS174T tumor implanted in the dorsal skinfold
chamber to a single diphtheria toxin administration. (a). The initial 24-hours (left) show a marked
decrease in vascular volume fraction (VVF) and increase in tumor tissue scattering due to cellular
apoptosis, while tumor volume remains constant. The following 72 hours find these trends reversing as
tumor volume decreases, while VVF and tissue scattering reach maximal values. At the lowest tumor
volume, compression of the vasculature by tumor cells is at a minimum allowing maximal VVF (-+). It is
after this time that increasing viable tissue is observed through decreasing tissue scattering leading to
regrowth of the tumor mass. (b-e) Images of tissue scattering at timepoints given in a (-+). Color
gradients illustrate the tissue viability ranging from blue (viable, low scattering) to yellow/red
(unviable/apoptotic, high scattering). White arrows indicate regions of potentially viable cells located at
the tumor base. Scale bars 500 ptm.
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VI.9 Discussion
The application of automated vessel tracing algorithms to OFDI angiography permitted
in vivo quantitative morphological and geometrical characterization of three-
dimensional vascular networks over relatively large volumes, and, in some models, over
entire tumors. Although the spatial resolution of OFDI is inferior to that of MPM, our
results indicate that OFDI can provide accurate quantitative data for vessels as small as
12 pm in diameter. OFDI bridges a gap between subcellular resolution optical
microscopies such as MPM and techniques such as Doppler ultrasonography, magnetic
resonance imaging, and micro-computed tomography (CT), which can penetrate deeper
into tissue but are limited to resolutions above ~50 pm. Further, our results illustrate
the utility of the technique for studying anti-angiogenic agents by demonstrating that
VEGFR-2 blockade decreased intratumoral diameter and vascular length, consistent with
previous studies44. Through fractal analysis, the effect of anti-angiogenic therapy on
vascular density and transport efficiency, which have profound implications in the
design of therapeutic regimens, can be studied. We note that since OFDI angiography
requires flow for contrast, it can only detect perfused vessels.
Repeated angiographic imaging over brief intervals is limited with current technologies
by both the need to administer intravenous contrast and interference of contrast
leakage by permeable blood vessels. Many important vascular dynamics ranging from
alterations in cerebral blood flow in cognition, to sprouting or intussusception during
angiogenesis, to the effects of vascular disruptive agents or anti-angiogenic agents occur
on time scales of short duration11,2. Our results show frequent angiographic imaging
over extended periods in the context of therapeutic intervention is possible using OFDI.
This method may therefore have utility in the screening of vascular-targeted agents in
the development of cancer therapies.
The ability to perform tracer-free lymphangiography of functional lymphatic networks
with OFDI is a critical advance in the field. In addition to quantitatively measuring
functional peritumoral lymphatics, the ability of OFDI to image lymphatic networks may
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have clinical application, e.g., in monitoring the functionality of lymphatic networks in
lymphedema, particularly in breast cancer patients after axillary dissection and
radiation. In such applications, the development of methods to quantify lymph flow with
this technology would further its diagnostic capability.
Combining the vascular and structural signatures of OFDI, we performed
multiparametric imaging during cytotoxic treatment of a solid tumor. OFDI revealed
both the direct and indirect effects of tumor cell death through the assessment of
viability and tumor vasculature, respectively. The higher optical scattering of non-viable
tissue is presumably due to an increased number of scatterers from dispersed cellular
components. Because both apoptosis and necrosis increase cellular particles in the
interstitial space, OFDI is unable to differentiate the two mechanisms of cell death. The
structural OFDI signal also allowed delineation of the tumor boundaries providing a
means to non-invasively measure tumor growth delay during treatment and spatially
correlate the vasculature into intratumoral and peritumoral regions.
The deep penetration and wide-field, high-resolution imaging of three-dimensional
tissue volumes enabled by OFDI presents a powerful new tool for the study of solid
tumors and other diseases that complements MPM and is likely to become as widely
used.
VI.1O Summary
Through the development of novel techniques, instrumentation and algorithms, we
have demonstrated the unique capabilities of OFDI to image in vivo the
microenvironment of model tumors rapidly and persistently over time without requiring
exogenous contrast agents. These capabilities provide a new tool to probe the dynamics
of tumor growth and response to therapy. The wide field of view, deep imaging
penetration, and high speed of OFDI relative to MPM provide experimental advantages
as well as a biologically important capability to probe substantially more of the tumor
volume.
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Figure VI-19 OFDI instrumentation. The optical frequency domain imaging system uses a swept-
wavelength laser source comprising a semiconductor optical amplifier (SOA) as the gain element Inside a
fiber ring cavity. The swept filter is based on a polygon mirror (Uncoln Laser). The laser output is split by a
10%/90% coupler to the reference arm/sample arm. The sample arm light is directed to the microscope
with an optical circulator (), while the reference arm light is directed to a fixed reflector. An acousto-optic
frequency shifter (FS) at 25 MHz offsets to coherence range from DC. A free-space polarization-diverse
and balanced optical demodulation circuit comprising broadband beam splitters (BBS) and polarization
beam splitters (PBS) generates four optical signals coupled to multimode fiber (MMF). These fibers relay
the optical signals to two balanced receivers (Rx, New Focus), outputting two electrical signals. A two-
channel 100 MS/s digitizer (Signatec) is used to acquire these signals and transfers this data directly to a
RAID storage array. Approximately 10% of this data is processed in real-time on the CPU to provide image
feedback. A single master clock is used to lock the polygon driver, frequency shifter, and data acquisition
board to achieve high phase sensitivity.
VI11 Materials and Methods
VI.11a OFDJ SYSTEM
OFDI provides high resolution imaging of the elastic light scattering properties of a
sample in three dimensions1. Beam focusing provides transverse (xy) discrimination of
signals. Interferometric measurements of optical delay gate signals across the axial (z)
dimension. The measurements first sample in parallel the interference signal between
light scattered at all detectable depths and an external reference beam as a function of
wavelength. Subsequent Fourier analysis of this interference signal across wavelength
separates the combined signals across all depths into a depth-resolved scattering
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profile. To measure interference signals across wavelength, a wavelength-swept laser
source with an instantaneous narrow linewidth (<0.17 nm) is used (Figure VI-19). This
laser source used a semiconductor optical amplifier (Covega Corp., Jessup, MD) as a
broadband gain medium in combination with a polygon scanner as a scanned
wavelength filter (Lincoln Laser Corp., Phoenix, AZ). Wavelengths sampled continuously
a 140 nm window centered at 1300 nm, resulting in a depth resolution of 6 mm in
tissue. Depth scans (A-lines) were acquired at a rate of 50 kHz. Through inclusion of an
acousto-optic frequency shifter (Brimrose Corp., Sparks, MD), a 5.8 mm scan range was
achieved2. A polarization diverse optical demodulator generated an optical interference
signal for each of two orthogonal polarization states, preventing artifacts due to
polarization signal fading. The interference signals were digitized using a two-channel
100 MHz acquisition board (Signatec, Inc., Newport Beach, CA), and were continuously
archived to a high-speed hard-drive storage array. Real-time display of structural and
vascular images at approximately 10% of the acquisition rate allowed monitoring of the
imaging sessions and interactive definition of the imaging field. Transverse sampling
patterns were developed to achieve rapid scanning across large volumes while
simultaneously matching the Doppler detection range to the empirically determined
optimal motion sensitivity. Data was acquired along the x-dimension at either a 5.0 pm
pitch across a transverse field of 5.0 mm or a 7.62 pLm pitch across a 7.8 mm transverse
field, both at 16.3 frames per second. Each frame comprised 3072 A-lines that were
combined in post-processing to provide 1024 structural and Doppler image lines. Data
was collected in the y-dimension at a 0.56 pm pitch naively, and integrated in post-
processing to yield a reduced dataset with isotropic sampling in the x-y dimensions of
5.0 pm/7.62 pm. Scanning along the y-dimension utilized physical translation of the
animal at 9 pm/sec. The scanned field along this dimension was limited only by the
chamber window aperture. Data along the depth dimension was acquired natively at a
4.1 pm pitch (in tissue) and signal was acquired over the first 1.5 mm to 2.5 mm in
tissue, depending on scattering levels.
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Figure VI-20 Signal processing algorithms and quantitative analysis. Using the raw spatiotemporal
reflectance data from OFDI, all of the angiographic, lymphanglographic and microanatomical images, as
well as the biological metrics, are obtained through a series of processes represented here.
VI.11b OFDI SIGNAL AND IMAGE PROCESSING AND QUANTIFICATION.
Processed images and quantitative data describing microanatomy, blood and lymphatic
vascular networks, and tissue viability in tumors were derived from a single raw data
format using a series of core processing routines followed by parameter specific
algorithms. These methods and algorithms are described here and summarized in a
flowchart format (Figure VI-20).
Core Processing Routines. The OFDI system recorded the interference signal across
wavelength (A) between a reference beam and an optical probe beam directed at a
particular transverse locations of the sample (x,y) and at a particular timepoints (t).
From this raw data, the optical scattering (complex parameter including amplitude and
phase) as a function of (x,y,z,t) was generated as described above. This data was spaced
at either a 5 pm or 7.62 pm pitch in the x dimension and at a 0.56 pm pitch in the y
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dimension. The same locations were resampled at 9 ms time intervals. This dataset
described the scattering properties of a specific spatial location at multiple timepoints.
From the complex scattering dataset, a set of three further datasets were derived that
highlight specific properties of the scattering signal and formed the basis for subsequent
processing (custom code written in programming language C). These datasets are
described as follows:
(i) Microarchitecture: The magnitude of the scattering signals were averaged across
time and the y-dimension to produce a time-independent three-dimensional magnitude
scattering dataset with isotropic pitch in the (x,y) dimensions. This dataset was saved in
log-scale to an 8-bit file (microarch.tif). This dataset was used to reveal the
microanatomical features of the tissue.
(ii) Phase Variation: The scattering signals at the sample transverse locations were
compared across time to produce phase differences from (-n,n) at the native spatial
pitch (5.0/7.62 ptm x 0.56 ptm x 4.1 pim). Each phase difference was weighted by the
magnitude of the average signal from that point. The circular variances (from 0 to 1) of
these amplitude-weighted phase-difference datasets over 50 ptm depth windows were
calculated at each point in three-dimensional space. A three-dimensional angiographic
dataset was then obtained by combining (median) appropriate sample counts in the y-
dimension to yield isotropic pitch in the transverse dimensions. The data was saved to
an 8-bit dataset (phasevar.tif). The use of the amplitude-weighted circular variance over
this limited depth window both minimized phase decorrelation and optical noise
artifacts by amplitude weighting the phase-differences and reduced artifacts due to
background motion resulting from respiration, muscular contractions, and
environmental instabilities. This dataset was used to reveal the vascular regions in the
tissue.
(iii) Phase Variation Weight: The magnitude of the scattered signals that were used
to derive the phase variation signal was calculated at the native spatial pitch, and then
combined in the y-dimension (mean) to yield isotropic pitch in the transverse
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dimensions. The data was saved to an 8-bit dataset (phaseweight.tif). This dataset was
used to weight the phase variation signal and discriminate between vascular regions and
low-signal regions.
These datasets formed the basis for further analysis yielding images and quantitative
data for specific biological parameters as is described in the following sections. Unless
otherwise noted, the parameter specific processing was performed in Matlab (The
Mathworks, Natick, MA).
VI. 11 c THREE-DIMENSIONAL TUMOR VOLUME AND BOUNDARY CALCULATION.
For tumor volume calculations, an en face projected image was calculated by averaging
the signals from 160 pm to 240 pm in depth from the microarchitectural dataset
(microarch.tif). The location of the tumor center in (x,y) was recorded manually from
this image. Using this location and the microarchitectural dataset (microarch.tif), a
series of 8 cross-sectional images was generated through the tumor center at equally
spaced angular increments, i.e., along the meridian planes through the tumor center
defined by 0/180*, 22.5/202.5*, 45/225*, 67.5/247*, 90/2700, 112.5/292.5*, 135/3150,
and 157.5/337.50. To improve contrast in these images, the scattering signal was
integrated over 80 pm in the transverse dimension perpendicular to the plane of each
cross-sectional image. The tumor boundaries were manually segmented in these images
using lmageJ (ImageJ 1.39, open source NIH software,
http://rsb.info.nih.gov/ii/index.html). From the tumor boundaries in the 8 meridian
planes, the tumor boundaries in three-dimensional Cartesian space were calculated by
interpolation yielding a tumor mask defining the intratumoral volume and extratumoral
volume within the three datasets (microarch.tif, phasevar.tif, phaseweight.tif). The
tumor volume was calculated from this mask and the known pitch of these datasets.
VI. 11 d NORMALIZED SCA TTERING/VIABILITY.
The mean scattering intensity within tumors grown in window models was derived from
the set of 8 cross-sectional images after normalizing for scattering intensity across
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depth. In these eight cross-sectional images, the location of the backside Dermis was
identified using ImageJ. The scattering signal intensity of this layer was used to derive
the average scattering attenuation with depth for every depth scan within each cross-
sectional image. Normalized cross-sectional images were generated by applying a
uniform signal gain across depth that compensated the derived attenuation. From these
normalized cross-sectional images and the tumor mask, the average scattering within
the tumor volume was calculated.
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Figure VI-21 Method for determining viable/necrotic fractions with FD. (a) The mean scattering
amplitude is determined for each distance from the nearest vessel wall for each timepoint. A threshold
value is selected from the inflection point (red arrow) on each curve to determine tissue fractions. (b). The
cutoff scattering amplitude is also used to determine the mean distance from the vessels for both necrotic
(green) and viable (blue) tissue.
VI.lle QUANTIFICATION OF VIABLE FRACTION.
To assess the viable fraction, depth-matched 20-40 Iim en face projections of both the
phase variation (phaseva r.tif) and microarchitectura I (microarch-tif) dlatasets were
manually selected. The tumor margins were manually identified from the scattering
differences in the microarchitectural dataset and a mask was created to restrict further
analysis to the tumor region. Using the phase variation dataset, the vascular signal was
identified by thresholding the image to create a binary mask highlighting the vascular
network (Figure VI-21). A vascular distance map (distance of each pixel in the
intravascular space to the nearest vessel) was then determined using a 2-dimensional
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Euclidean distance transform in Matlab. The mean scattering index for distances from 0-
1000 pm were determined using the distance map and the pixel values in the
microarchitectural datasets. Plots of mean scattering index versus distance from nearest
vessel revealed sigmoid shaped curves. For each timepoint, the scattering index at the
inflection point was selected as the threshold value to differentiate viable from non-
viable tissue in the microarchitectural dataset and determine the area in pixels of each
region in the intravascular space. For each timepoint, the tissue fractions of vascular,
viable, and necrotic/apoptotic regions were then determined from the area in pixels of
each over the total pixel area of the tumor. Additionally, the mean distance of each pixel
region (viable or necrotic/apoptotic) to the nearest vessel was determined using the
distance map and thresholded pixels from the microarchitectural dataset. To visually
illustrate the different regions of viable tissue in the tumor, a colormap was selected
and adjusted so that the threshold scattering index for each timepoint was indexed to
the green region of the colormap (blue/light blue indicating viable and yellow/red
indicating non-viable).
VI.11f ANIMAL MODELS.
Dorsal skinfold chambers and mammary fat pad windows were prepared in SCID mice as
previously described5 3-55. The appropriate tumor type was then implanted in the center
of the chamber 2-3 days after the initial surgery. The murine mammary adenocarcinoma
(MCaIV), human colorectal adenocarcinoma (LS174T), and human soft tissue sarcoma
(HSTS26T) were transplanted from subcutaneous tumors grown in isogenic mice. The
human mammary adenocarcinoma (MDA-MB-361HK) was implanted as a single cell
suspension of ~3x10 6 cells in 30 pl of Hank's Buffered Salt Solution (HBSS). Cranial
windows were prepared in nude mice as previously described 55 and either human
glioblastoma multiforme (U87) tumor tissue was implanted 400 pm deep in the
posterior cortex or MCalV tissue was implanted in the leptomeninges of the left
hemisphere. Tumors were generally allowed to grow for 2 weeks to a size of 4 mm in
diameter by en face measurement depending on experimental protocol. Animals were
281
CHAPTER 6
anesthetized using either Ketamine/Xylene(10/1 mg/ml) or Isoflurane (1% in 100%
oxygen), as indicated for each specific experiment. All animal work was approved by the
by the MGH Institutional Animal Care and Use Committee.
VI.11g ANTI-ANGIOGENIC THERAPY: VEGF-R2 BLOCKADE.
DC101 (ImClone Systems Inc., New York, NY) or nonspecific rat IgG were administered
intraperitoneally at 40mg/kg as prescribed in previous studies". Mice were imaged
every 2 days beginning 5 or 6 days after tumor implantation. Therapeutic initiation was
determined through monitoring of tumor growth by both visual inspection and OFDI
angiography. Animals were selected for the study based on the criteria that 1) the
tumor diameter was approximately 4 mm in diameter by en face measurement 2) the
entire margin of the tumor was functionally vascularized and 3) the animal was in good
health. Treatment group assignment was made randomly and masked during the
duration of therapy to remove bias. Three treatments at three-day intervals were given
(defined as day 0, 3, 6), and imaging was performed through day 9. Tumor growth delay
was calculated from measurements of tumor volume by OFDI microanatomy
measurements.
VI.11h CYTOTOXIC THERAPY.
Diphtheria toxin (Sigma-Aldrich Co., St. Louis, MO) was administered intraperitoneally at
30 pig/kg as previously described31 . For control animals, a similar volume of saline was
injected intraperitoneally. Male SCID mice bearing human colorectal adenocarcinoma
tumors in the DSC were treated once and monitored over 10 days. During the initial 24
hours, OFDI multiparametric measurements were made every 12 hours followed by
measurements every other day as described in the Supplementary Methods.
VI. 11i PROLONGED TIME-LAPSE IMAGING.
Imaging was performed under gas anesthesia (1% Isoflurane in oxygen) every 4 hours
for 48 total hours in mice bearing MCaIV murine mammary carcinoma tumors in the
DSC. Each imaging session was 5-10 minutes in duration, between which the
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experimental animal was returned to its cage. DC101 or non-specific Rat IgG (40 mg/kg
i.p.) was administered once after the first imaging session. To generate the shorter
interval time-lapse video, a separate SCID mouse bearing MCaIV in the DSC was imaged
every 2 hours for 48 total hours. DC101 was administered (40 mg/kg i.p.) once 8 hours
after the first imaging session. The resulting angiographic images for each timepoint
were manually cropped and aligned using Adobe Photoshop (Adobe Systems Inc., San
Jose, CA) and imageJ to generate the time-lapse video.
VL11j QUANTITATIVE ANGIOGRAPHY.
Vascular quantification was performed through automated vessel tracing. To condition
the vascular dataset for tracing, the following steps were performed:
(i) If necessary, a mask file was generated manually (ImageJ) that delineates the
vascular signatures in the phase variation dataset (phasevar.tif) from artifacts associated
with low-signal intensities in the air or Brownian motion in the fluid above the non-
planar tissue surface.
(ii) Doppler techniques suffer from artifacts due to forward scattering of red blood
cells that result in signal shadows extending below the deepest extent of a vessel. For
large vessels with high local hematocrit, shadowing can extend to nearly all of the lower
depths. These artifacts frustrate the automated three-dimensional analysis of vascular
networks. To reduce this shadowing, we further processed the angiographic datasets by
applying a step down exponential filter. Working from the surface of the tissue
downward, the magnitudes of the vascular signal (phasevar.tif) of all points below the
current point were attenuated according to the magnitude of the current point. A
deshadowed dataset (phasevarnoshadow.tif) was generated as the output. A result of
this technique is that small vessels underneath very large vessels were obscured and not
traced.
After shadow removal, an automated three-dimensional vessel tracing algorithm was
applied to the deshadowed datasets (phasevarnoshadow.tif) (Figure VI-7). The tracing
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algorithm was developed and adapted for the OFDI images from a model previously
applied to angiographic images from multiphoton microscopy 36,37. Briefly, the model
traverses the vascular network with cylindroidal superellipsoids fit to the vessel
boundaries by minimizing region-based statistics using a likelihood ratio test to
differentiate between noise and other artifacts. In addition to providing the three-
dimensional geometry of vessels segmented by the superellipsoids, the model defines
vessel centerlines, intersections, and branches. Novel seeding algorithms were
developed for the OFDI datasets to provide robust initial guesses for vascular regions
without the requirement of segmentation procedures.
Prior to commencement of the vascular tracing algorithm, homomorphic filtering was
applied to each deshadowed phase variation dataset. Homomorphic filtering consisted
of first convolving a low-pass Gaussian filter across each transverse (XY) slice of the
deshadowed datasets to lower the background signal. The intensity in the resultant
image was then homogenized at both the low and high ends of the intensity spectrum
to increase contrast. To remove any remaining specular noise resulting from the filtering
process, a median filter was applied to each transverse slice of the three-dimensional
OFDI dataset.
For each superellipsoid describing a "vascular segment", the parameters output from
the tracing algorithm provided a centroid, major, minor and longitudinal axes and
quaternary rotation parameters defining the rotation of the axes from image space to
fitting space. Vessels were defined by the fitting algorithm as a series of vascular
segments between intersections, branching points or dead ends. The model fit to each
vascular segment was performed in unitary space rotated from the actual image space
so that all superellipsoid axes rested on the axes defining Cartesian coordinates of this
space. To obtain quantitative measures in image space, the superellipsoid axes were
rotated back into image space and the magnitudes in microns of each axis were
determined by the pixel dimensions in three-dimensional space.
284
CHAPTER 6
Due to the shadow removal processing, vessel morphology in the xz or yz planes were
altered in some cases. Therefore, morphological measurements were always made as
projections onto the xy plane. The two shortest superellipsoid axes were used for the
projection onto the xy plane. To determine the length of each vascular segment, the
distances between adjacent centroids (as defined by the tracing algorithm) were
determined. Vascular diameter for a given set of segments (i.e. intratumoral) was
determined by weighting the xy-projected diameter for each segment by its length.
Vascular length of a given volume of tissue was simply the sum of the length of all
vascular segments in that region. Vascular volume was determined by calculating the
area containing the segment centroid and then multiplying by the segment length and
summing over all segments of interest.
Three-dimensional image casts or skeletons of the vascular networks were obtained
from the parameters output by the vascular tracing algorithm using Matlab.
Visualization was obtained using either Volocity (Improvision, Inc, Waltham, MA) or
OsiriX (The OsiriX Foundation, Open-Source Software).
VI.11k FRACTAL ANALYSIS
The fractal dimension was calculated using the sandbox method42 adjusted for the voxel
size anisotropy in three-dimensions. Skeletonized vascular networks were obtained
using the vessel parameters defined by the vascular tracing algorithm. A three-
dimensional rectangular region of the image volume was selected for geometrical
analysis. For analysis of tumor vascular networks, the rectangular region of largest size
was selected that was within the tumor boundary. A point near the center of the
structure was randomly selected and surrounded by cubes of increasing dimension
through multiple iterations. The mean number of occupied voxels within each cube of a
particular length scale was determined by averaging over all selected voxels. The linear
slope of the log-log plot of mean occupied voxels versus cube dimension defined the
fractal dimension (Figure VI-9). The minimum path length was found by determining the
minimum length between occupied voxels on each pair of opposite faces in the
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skeletonized vascular network defined above. Tortuosity was calculated by taking the
ratio of the minimum path length to the Pythagorean distance measured between the
first and last point of the path.
VI.111 VISUA LIZA TION.
The generation of combined blood and lymphatic vascular projections required
segmentation of the lymphatic networks from the surrounding tissue. The lymphatic
networks were semi-automatically segmented by the manual selection of points within
lymphangions followed by the expansion of these points using a three-dimensional
region growing algorithm. The resulting segmented lymphatic network described the
interluminal volume of the identified lymphatic vessels in three-dimensional space
registered to the vascular datset (phasevar.tif).
Reduction of the three-dimensional vascular (blood and/or lymph) datasets to a single
en face image utilized a customized volume up rendering technique. The vascular
dataset (phasevar.tif) was three-dimensional median filtered with a kernel size of
(3x3x3). The blood vessel signals in this filtered dataset were then colorized according
to their depth. Within the segmented lymphatic network image, lymph vessels were
colored blue. These datasets were then merged if rendering both blood and lymph
vessels. Finally, the vascular (blood) or merged (blood and lymph) dataset were reduced
to an en face presentation using volume up rendering techniques56 wherein each pixel is
assigned an opacity and more superficial features are layered over deeper structures.
The opacity of each pixel was calculated as a product of the vascular signal magnitude
(phasevar.tif) and the signal weight of that vascular signal (phasevarweight.tif).
VI. 11 m QUANTITATIVE LYMPHANGIOGRAPHY.
Lymphatic vessels are identified through the diminished scattering signal within the
microarchitectural dataset (microarch.tif) from the intraluminal lymph, likely attributed
to hypocellularity and lower protein concentration. The distinct network topology and
vessel characteristics coupled with the correspondence of these ascattering structures
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with Evan's blue lymphangiography (Figure VI-11) confirm their identification as
lymphatic vessels. Presentations of the lymphatic networks were generated by manual
selection of the lymphatic bed depth within the microarchitectural dataset
(microarch.tif) at a series of transverse locations. A curved but continuous depth plane
through the lymphatic bed was defined by first interpolating the location of the
lymphatic bed across all transverse points using three-dimensional cubic interpolation
through Delaunay triangulation, and then smoothing this curve through application of a
two-dimensional Gaussian filter of kernel size of 250 pm. Minimum intensity projections
across depth over regions within +/-50 pm of the lymphatic bed were then generated to
reveal the network in a two-dimensional image (Figure VI-11). The maximum diameter
of lymphangions (lymphatic vessel segments) were measured in the XY plane with
imageJ software.
Evan's Blue lymphangiography was performed by injecting 10 pl of 4% Evan's Blue into
the tissue and observing nearby lymphatic vessels with a dissecting scope.
VI.11n MULTIPHOTON MICROSCOPY AND REGISTRATION.
Multiphoton imaging was performed with a custom-modified confocal laser scanning
microscope (Olympus 300; Optical Analysis Corp., Center Valley, PA) using a broadband
femtosecond source (High Performance MaiTai, SpectraPhysics, Mountain View, CA).
Angiographic contrast was achieved through intravenous administration of 200 d of 8
mg/ml fluorescein isothiocyanate dextran 2M molecular weight (FITC-Dex 2M, Sigma-
Aldrich, St. Louis, MO) in phosphate buffered saline. Image stacks were taken at 800nm
excitation (~60 mW at sample surface) with depths ranging to 500 pm depending on
animal model and tumor type. To image tumors or organs (brain) over wide-fields,
collections of mosaic images were taken in raster pattern using a motorized stage
(H101, Prior Scientific, Inc., Rockland, MA) and customized automation software
(LabView, National Instruments, Austin, TX). Mosaic stacks were assembled using
ImageJ (NIH, Bethesda, MD) and Matlab (MathWorks, Natick, MA). Registration
between MPM and OFDI of the same sample was conducted by denoting imaging
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regions on the window coverglass by histological markers and manually comparing the
locations of large vessels. All multiphoton imaging studies were performed with a 20X
magnification, 0.95NA water immersion objective (Olympus XLUMPlanFI, 1-UB965,
Optical Anaylsis, Center Valley, PA) with estimated 1/e2 radii of 0.27plm radially and
1.14 im axially.
VL110 STATISTICAL ANALYSIS.
Data are presented as mean ± standard error of the mean (SEM). Significant differences
between groups were determined by a multivariate repeated measures ANOVA
accounting for response to treatment over time (Systat, Systat Software, Inc., Chicago,
IL). For quantitative metrics calculated by the vascular tracing algorithm, such as
vascular diameters, significant differences at each time-point were determined by a
two-sample Student's t-test. For tumor growth, statistical differences at each time-point
were determined by the non-parametric Mann-Whitney test. Statistical differences at
given time-points are denoted on the plots by asterisks. p-value 0.05 was considered
statistically significant for all comparisons. The multiphoton and OFDI measurements of
vessel diameters (Figure VI-6i) were compared using the Pearson product-moment
correlation.
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VII.1 Introduction:
Understanding the effects of disease progression and therapy on the tumor
microenvironment is critical for elucidating the pathophysiologic mechanisms that
underlie clinical prognosis and designing more efficacious combinatorial therapeutic
regimens. While clinical imaging modalities and mechanical sensors exist to probe the
anatomical, functional and metabolic aspects of the tumor microenvironment, they all
lack high-resolution capabilities (< 50pm) and many are indirect measures of these
parameters. The focus of this thesis has been to develop and apply new minimally
invasive microscopic tools to study the tumor microenvironment in preclinical tumor
models.
Principle characteristics of the tumor microenvironment are the metabolic parameters
of oxygen tension (P02) and pH. Solid tumors are often found to be hypoxic and acidic;
both determinants of metastatic progression, clinical prognosis, gene expression,
angiogenesis, and therapeutic response. In Chapters 3 and 4, I developed and applied a
new microscopic method for quantifying P02 by combining the techniques of
phosphorescence quenching and multiphoton microscopy. This method, multiphoton
phosphorescence quenching microscopy (MP-PQM), was fully characterized (Chapter 3)
and used to successfully study P02 during tumor progression and in response to
targeted therapy with either antiangiogenic agents or trastuzumab (Chapter 4). The
significant outcomes from these experiments were 1) characterizing preclinical tumor
models with respect to progression, 2) methods for correlating tumor microvascular
parameters with oxygenation including metabolic consumption, 3) a new model for
tissue oxygenation based on a simple parameter describing vascular structure and 4) an
understanding that antiangiogenic therapy should be titrated to potentially "normalize"
the metabolic microenvironment for improved therapeutic response.
In collaboration with investigators in the MIT Chemistry department, a novel biosensor
for pH was developed and implemented under multiphoton excitation to perform high-
resolution mapping of pH (Chapter 5). This sensor combined the attractive
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photophysical and stability properties of luminescent semiconductor nanocrystals (NCs,
quantum dots) with fluorescent dye molecules sensitive to pH. Using the principles of
F6rster resonance energy transfer (FRET), this construct enabled reversible internally
referenced ratiometric measurements of pH using multiphoton multispectral and
fluorescence ratiometric imaging (MP-FRIM). Critical advancements presented in this
work were 1) the application of nanocrystals as two-photon antennas even for dyes with
substantial two-photon action cross-sections, 2) biocompatible coatings for nanoscale
materials that exhibit minimal physical interactions with the tissue (and tumor)
microenvironment components, 3) techniques for calibrating pH sensors in
environments mimicking the tumor microenvironment and 4) methodology for
qualitatively measuring pH changes in the tumor microenvironment and correlating with
the vasculature using MP-FRIM and NC biosensors for pH.
In addition to the metabolic parameters defining the tumor microenvironment, the
structural and cellular components including the tumor vasculature, peritumoral
lymphatics, and microanatomic features all influence tumor progression and response
to therapy. Furthermore, the ability to probe these aspects dynamically and over wide
fields on short (minutes) and long (days-weeks) timescales with microscopic resolution
has profound implications in the study of tumor biology and drug development. The
coherent microscopy optical frequency domain imaging (OFDI) enabled the
simultaneous investigation of the tumor microenvironment with these characteristics
(Chapter 6). Through a collaboration with scientists in the Wellman Laboratories for
Photomedicine, we developed and implemented new techniques and methods for OFDI
to non-invasively probe the tumor vasculature, lymphatics and cellular
microenvironment. Importantly, we demonstrated 1) the capability to perform non-
invasive three-dimensional imaging and morphometric and geometric characterization
of tumor microvasculature without the need for angiographic contrast agents, 2)
identification of tumor-associated lymphatics based entirely on their optical scattering
signal, 3) in vivo histological assessment of tumor necrosis and apoptosis and 4)
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multiparametric monitoring of vascular and cellular targeted therapies in preclinical
tumor models.
VII.2 Optimizing and Advancing MP-PQM
While the technique of MP-PQM was proven successful (Chapter 3) and effective in
quantifying in vivo P02 in the tumor microenvironment, many aspects could be
improved to increase signal to noise and therefore measurement time. The methods
proposed in this Thesis employ time-domain lifetime measurements using an electro-
optic modulator (EOM) for impulse selection. The use of any optics in the path of a
pulsed mode-locked laser induces group delay dispersion which increases the temporal
duration of the pulse'. In the case of EOMs or especially acousto-optic modulators, the
laser pulse duration is increased due to significant group delay dispersion. In
multiphoton excitation, the fluorescent emission is inversely proportional to the laser
pulse duration2. Longer pulses decrease the peak power in the focal volume reducing
the excitation rate of MPM. Through a process termed "pulse shaping", the excitation
laser pulsed can be pre-chirped to counteract the effects of optics in the laser path3
Numerous methods exist to perform pulse compression in this fashion including prism
pairs4, diffraction grating pairs5, and adaptive optics6 .
Secondary to pulse shaping is the repetition rate of the pulse laser. Typically 80MHz
Ti:Sapphire lasers are used in MPM because the temporal separation between pulses is
longer than the luminescent lifetime of most fluorophores. However, luminophores with
longer lifetimes may be more efficient at lower repetition rates. In fact, many studies
using phosphorescence with nonlinear excitation employed lasers in the kilohertz
range . However, these lasers typically also have longer (nanosecond versus
femtosecond) pulse durations. Therefore, little or no improvement may be observed
with this pulsed laser source given very similar duty cycles (pulse duration x repetition
rate).
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The original concept behind the development of MP-PQM was its adaptability to
existing MPM setups. However, pulse shaping may dramatically increase
phosphorescence of the PO2 sensor, a phosphorescent porphyrin, which has a reduced
two-photon action cross-section compared to commonly used fluorophores. Another
possibility, which will be explored in the next section, is the development of oxygen
sensors with improved two-photon action cross-section. Other investigators have
developed phosphorescent porphyrins with two-photon antennas for improved
quantum yield under two-photon excitation7'9 . However, these probes have not been
fully characterized for in vivo application. If adaptations to MP-PQM or improved two-
photon oxygen sensors are developed, the measurement time may be significantly
reduced. MP-PQM may therefore someday be applied in a beam scanning fashion
analogous to normal MPM function instead of stationary beam photon counting. This
would permit imaging of P0 2 over wider fields and increased sampling rate.
VII.3 New NC-Biosensor Constructs and Designs
The novel nanocrystal biosensor design introduced in Chapter 5 is adaptable to other
sensing strategies. Two additional sensing schemes not introduced in Chapter 5 are 1)
protease sensing through cleavage of a peptide linking abrogating FRET 2) binding of an
analyte altered the F6rster distance (R0) and therefore the FRET efficiency. The designs
reported in Chapter 5 can also be applied to a number of analytes dependent only on
the dye selected. Fluorescent dyes exist that are sensitive to biologically important ions
including calcium, magnesium, and sodium 0 . These chemosensors change their
fluorescence emission intensity dependent on the concentration of a specific ion in
solution. As there is no change in absorption spectrum, the nanocrystal emission acts as
a two-photon antenna and internal reference as demonstrated in Chapter 5. As such,
the photophysical properties of the construct are determine entirely by the nanocrystal
abrogating any differences observed between single or two-photon direct excitation of
the dye molecule.
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The NC biosensor construct employed in the fashion of a two-photon antenna would
also improve the excitation rate of the oxygen sensors utilized in Chapters 3 and 4. In
collaboration with the Bawendi and Nocera groups at MIT, initial experiments have
been performed providing evidence to support this hypothesis. A Pd-porphyrin (Pd-
meso-tetra(4-carboxyphenyl) porphyrin; Oxyphor RO, Oxygen Enterprises, Ltd.,
Philadelphia, PA) coupled to a nanocrystal emitting at an absorption maxima for the
porphyrin does demonstrate response to oxygen (Figure VII-1). Similar to pH, the NC
emission is again unresponsive to the local environment, particularly oxygen, regardless
of the solvent used. This probe could be applied in a ratiometric fashion or lifetime
measurements could be performed to quantify oxygen. In fact, given the broad
excitation spectrum of the NC and high quantum yield, a sensor designed with
maximum FRET efficiency could be employed for frequency domain lifetime
measurements. Here, the duty cycle of the experiment would be vastly improved
compared to the time-domain, speeding up the in vivo measurement time. However, as
seen in Chapter 5, again the issue is delivering the probes to the tumor
microenvironment.
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Figure VII-1 Nanocrystal biosensor for oxygen. A NC construct containing a bound Pd-porphyrin
demonstrated response to changes in oxygen in both dimethylformamide (a) and aqueous solution (b).
The NC emission was unaffected by pO2 in either situation.
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The issue of transporting NC biosensors directly to the tumor microenvironment may be
resolved by direct targeting. Coupling NCs to antibodies or peptides against molecular
markers found in the tumor microenvironment may improve both delivery and
retention for long-term studies. It has been demonstrated that conjugation of
antibodies or peptides to fluorescent nanocrystals is possible for
immunohistochemistry", cellular labeling' 2' 4 and in vivo cancer cell 15 and vascular
targeting16 . The majority of these studies have been performed ex vivo or the in vivo
results were not microscopic (whole-body imaging) or hindered by aggregation in the
vasculature. Our collaborators have recently demonstrated targeted NC constructs with
limited non-specific binding to cells17 . These constructs had an attached dye molecule
(CXR) and still exhibited FRET during cell labeling.
Figure VII-2 In vivo imaging of NC-immunoconstructs, fibroblast-like stromal cells, and collagen matrix
in a sarcoma tumor model. (a) GFP-positive stromal cells interacting with the collagen matrix in integrin
P1 labeled areas (yellow arrows). GFP negative cells positive for P1 interacting with the collagen matrix
(light blue arrows). (b) Integrin P1 is also expressed near the tumor vasculature; (yellow arrows) -
colocalization of integrin P1 immunostaining and GFP-negative endothelial cells. Red - NC-
immunoconstructs; Green - VEGF-GFP host cells. Blue- signal from Collagen 1. Scale Bars - 50pLm.
I have investigated in vivo targeting in the murine tumor models using NCs bound to
antibodies against integrin p1. These were prepared with the "Quantum Dot Antibody
Conjugation Kit" available from Molecular Probes. Briefly, reduced antibodies with free
sulfhydryls exposed are attached to PEGylated NCs with terminal maleimide groups. In
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the DSC chamber of a VEGF-GFP mouse18 bearing a human soft tissue sarcoma
xenograft, this construct demonstrated labeling of stromal cells colocalized with second
harmonic signal generated from collagen (Figure VIl-2). Further optimization of the NC
construct design for size and charge introduces the ability to perform targeted sensing.
Further, the narrow emission spectra and broad two-photon excitation spectra would
allow for multiplexed phenotyping of cells in the tumor microenvironment 9. It is
apparent that luminescent semiconductor nanocrystals possess many possibilities for
studying in vivo cancer biology as both sensing and imaging agents.
VII.4 Future Directions of OFDI in Cancer Biology
The interaction of light with tissue contains much information about structure and
dynamic processes. In Chapter 6, the coherent microscopy technique of optical
frequency domain imaging was shown to provide quantitative three-dimensional images
of in vivo tumor vasculature, lymphatic vessels, tissue viability and microanatomy over
wide fields of view. There is much still to be advanced using this technology both in
methodology and assessment of additional anatomical and functional parameters of the
tumor microenvironment. These include measuring blood flow, vascular permeability,
tumor transport properties, edema, and cell metabolism. The application of
multiparametric OFDI to a number of in vivo tissues was demonstrated in Chapter 6.
However, additional aspects of the tumor microenvironment may still be uncovered
including in vivo staging of tumorigenesis and lymphatic metastasis.
Given the ability to non-invasively determine the morphometry and three-dimensional
geometry of tumor vascular networks, the next logical step is to develop methods that
probe the function of the vascular network. Others have demonstrated an ability to
qualitatively measure blood flow perfusion using Doppler methodologies and OCT2O-n.
Quantitative velocity measurements with OCT require either standard vessel geometries
(straight tube)23 or specially designed probes to measure multiple components of the
velocity vector24. At minimum, the angle of the sample beam with the vessel of interest
needs to be known to determine the velocity. If the beam is directly perpendicular to
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the flow vector, no measurement is possible. With our collaborators at the Wellman
Laboratories, we have proposed three methods for in vivo quantitation of flow
velocities.
1.) Calibrate the temporal modulation of the reflectance signature with known flow
velocities and apply to in vivo measurements.
2.) Either incorporate a second sample beam at a different angle of incidence for
simultaneous measurements or rotate the subject to obtain measurements from
another angle. Additional angles of incidence with the velocity vector will permit
direct calculation of velocity magnitude.
3.) Use the geometrical information obtained from semi-automated vascular tracing
of the three-dimensional tumor microvasculature to determine the incidence
angle of the sample beam along a discriminated length of vessel. An average
velocity along the vessel length could then be calculated. This is computationally
more intensive, but attemptable with the current OFDI systems.
Beyond flow, quantitative assessment of other parameters of vascular function may be
accessible by OFDI. Spectroscopic OFDI has been shown to differentiate between
scatterers of different sizes based on Mie theory25. Mie theory predicts that particles
scatter light with a wavelength around the spherical dimension of the particle. Using
angle-resolved OFDI, which removes the speckle (coherent noise)26 27 by averaging over
different reflectance angles of the backscattered photons, the microarchitecture of
tissue in the murine models is better defined28 (Figure VII-3). Further, measurements of
tissue scattering are found to be more accurate; enabling the discrimination of particles
of different size. We hypothesize that angular-resolved OFDI will be able to quantify
vascular permeability and interstitial transport in the tumor microenvironment. We
theorize that intravascular administration of optical scatterers (gold nanoparticles,
carbon nanotubes, etc) on the order of the wavelengths of light used to probe the tissue
(1230-1370nm) or possibly smaller will extravasate from the vasculature and be
detectable by OFDI.
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Figure VII-3 Angle-resolved OFDI of normal murine skin In the DSC. (a) Ordinary OFDI with speckle noise
apparent. (b) Same tissue with angular averaging reduces speckle and reveals additional microstructure.
Time-resolved measurements of dynamic changes in tissue scattering coupled with
Doppler OFDI imaging of the tumor vasculature may provide measurements of single
vessel permeabilities as well as diffusion from the intravascular space through the
interstitium. A possible secondary effect of intravenous injection of optical scatterers
would be enhances sensitivity of vessels with lower perfusion. However, the
"shadowing" noise observed with larger vessels and high hematocrit may be enhanced
by this technique. Although the effect of rotating the sample frame discussed above (#1
and 2) may reduce the shadowing effect.
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Figure VII-4 Higher Doppler background signal observed in a human glioblastoma xenograft. (a) Enface
projection demonstrates a demarcation between the intratumoral Doppler signal and the rest of the
cortical tissue. Signal amplitudes are inverted in this image. (b) Axial section of the tumor vasculature
from angiographic OFDI. (c) Minimum projection of the Doppler dataset potentially indicating edema.
Scale Bar - 1mm.
Doppler OFDI is capable of detecting the movement of scattering interfaces anywhere in
the tissue. While the highest sensitivity and signal is obtained from fluid flow in the
blood vessels, any other processes that change over time may be observable. When we
viewed the minimum intensity projection of the Doppler OFDI datasets, we observed
that the tumor tissue exhibited a higher Doppler background than the surrounding
tissue (Figure ViI-4). Others have observed that tumor spheroids29 and individual cells30
modulate the reflectance of light based on metabolic activity in living cells. It is possible
that Doppler OFDI is differentiating the tumor based on the higher metabolic activity of
the cancer cells. However, preliminary results of Doppler OFDI in formalin-fixed samples
from tumors implanted in the DSC reveal similar properties of the tumor to those seen
in Figure VII-4.
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Figure VIl-5 In vivo microarchitecture and perfusion of murine mammary ducts imaged by OFDI. Top:
Reflectance signature from the mammary fat pad of a female mouse reveals the normal globular ductal
structure. Bottom: Doppler OFDI signal showing fluid motion in the globules and within the mammary
ducts. Scale Bar - 500pm.
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It is possible that OFDI is detecting the Brownian motion of particulate matter in the
extracellular fluid. In the case of a tumor, the extracellular fluid, particularly at the
margins, may be increased due to the high interstitial pressure and absence of
lymphatics. In this case, OFDI may be detecting edema in the tumor microenvironment
an important pathophysiology found in tumors. Edema can have profound clinical
implications particularly for brain tumors where additional pressure on the adjacent
normal tissue can induce damage or neurological sequelae. Interestingly, edema is a
common finding in the mouse model shown in Figure VII-4, further supporting the
possibility that it is edema.
In Chapter 6, we demonstrated the application of OFDI to numerous animal models
including neoplastic and normal tissues. These results are only a cursory summary of
what is possible with OFDI. We showed that, in some cases, cellular structures are
observable in the peritumoral lymphatics. This suggests that OFDI may be used to study
lymphatic metastasis in preclinical models. We also demonstrated the ability of OFDI to
perform multiparametric assessment of treatment response, but this would also be
applicable to studying any facet of tumor biology. One important aspect of cancer
biology that has not been well studied in an in vivo environment in the same animal is
progression of disease from the earliest signs of dysplasia to end-stage metastatic
disease. Using spontaneous murine mammary tumor models, such as the MMTV-PyMT
mice32,33, it may be possible to non-invasively study tumor progression using all the
methods demonstrated in Chapter 6. In a preliminary study, I found that the normal
mammary fat pad architecture including mammary ducts is detectable by OFDI (Figure
VI-5). With OFDI and these models, we may be able to illuminate the disease process of
cancer through progression and treatment.
VII.5 Concluding Statements
My dissertation has focused on the development of new minimally invasive techniques
to study the in vivo tumor microenvironment during progression and response to
treatment. These tools have demonstrated advancements in multiphoton microscopy,
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semiconductor nanocrystal technology and coherent microscopy. Utmost has been the
development of new methods using these technologies to perform multiparametric
analysis of solid tumors. As this final Chapter illustrated many directions in further
developing and applying these technologies are possible. Each -new step in advancing
our understanding of the tumor microenvironment may help develop new methods and
drugs for treating cancer.
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